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ABSTRACT 
Genetic and epigenetic alterations as well as viruses such as Epstein Barr virus (EBV) 
contribute towards the development of immunodeficiency lymphoproliferative disorders 
(IDLDs). We investigated 66, 25 and 58 cases of post-transplant lymphoproliferative 
disorders (PTLDs), HIV-B-cell lymphoma (HIV-BCL) and immunocompetent diffuse large 
B-cell lymphoma (iDLBCL) respectively. Immunohistochemical analysis was used to assess 
the prevalence of different T-cell subsets, NK cells and plasmacytoid dendritic cells (PDCs) 
in the microenvironment of these disorders. We used in-situ hybridization to assess the EBV 
status, fluorescent in-situ hybridization to evaluate common lymphoma-associated gene 
rearrangements and PCR to determine B- and T-cell clonality, the methylation status of 
DAP-kinase and SHP1 genes and to identify EBV-genotypes. Our results showed that: 1) 
EBV is frequently seen in IDLDs with type-A being more prevalent in PTLDs, whilst both 
types are equally prevalent in HIV-BCLs. Among HIV-BCL, cases associated with type-B-
EBV had been HIV- positive for a significantly longer duration compared to those with 
type-A, 2) Characteristic lymphoma-associated gene rearrangements, apart from c-MYC 
which showed a significant difference among different groups, are very rare among IDLDs, 
3) Aberrant hypermethylation of DAP-k and SHP1 genes is a frequent finding in aggressive 
BCL and is an early event in the pathogenesis of PTLD, 4) B-PTLDs have significantly 
higher numbers of CD123- and BDCA-2-positive PDCs as compared to other groups and 
the numbers are higher in early lesions of PTLD than in the more established lesions, 5) 
Cases of post-transplant DLBCL have significantly higher numbers of different T cell 
subsets including regulatory T-cells and NK cells than iDLBCL, and finally 6) Monoclonal 
T-cell populations, which seem to arise mainly from CD8-positive T-cells, occur frequently 
in B-PTLDs and they co-exist with the monoclonal B-cell population. 
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Chapter 1 
INTRODUCTION 
1.1 GENERAL INTRODUCTION  
Lymphoproliferative disorders in immune deficient states are a group of diseases that range 
from benign polyclonal to malignant monoclonal lymphoid proliferations. They develop as a 
consequence of immunosuppression. Immunodeficiency settings may be of congenital, 
infectious or therapeutic origin. Post-transplant lymphoproliferative disorders (PTLDs) and 
HIV-related lymphomas are well-known examples of these disorders. PTLDs are similar to 
other immunodeficiency-related lymphomas in some aspects: both are derived from B-cells 
with preferential presentation as non-Hodgkin lymphoma versus Hodgkin lymphoma, they 
usually originate in extranodal sites, they rarely affect skin, they behave aggressively and 
they frequently harbour the EBV genome 
1
. Whilst most are high-grade B-cell non Hodgkin 
lymphomas (NHLs), a few are classical Hodgkin lymphomas. Rare cases have also been 
shown to be either of T-cell or NK-cell lineages 
2;3
. T-cell neoplasms constitute 10% to 15% 
of all PTLDs and about 75% of T- cell PTLDs have been shown to be negative for EBV and 
to behave more aggressively 
3-7
. With regard to PTLDs, the abnormal B-cells in solid organ 
transplant recipients originate usually from those of the recipient, while in recipients of bone 
marrow transplant they are of donor origin 
8;9
.  Cases arising from B-cells of the recipients 
carry IG variable (IGV) gene somatic hypermutations pointing to a germinal centre (GC) or 
post-GC B-cell origin 
10;11
. 
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1.2 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS 
1.2.1 Frequency of occurrence and risk factors 
Patients who undergo organ transplantation are at a 28-49 fold increased risk of developing 
a lymphoproliferative disorder than non-immune-compromised patients 
12
. 
The occurrence of PTLD varies between different studies, but the overall frequency is less 
than 2% in transplant recipients 
13
. It differs according to many factors such as: 
 
I. The age of the patient: children are more prone to developing PTLDs as they are usually 
naïve for Epstein Barr Virus (EBV) infection 
14;15
.  
II. The organ transplanted: the frequency of PTLD differs according to the type of organ 
transplanted. The highest being in small bowel transplants with up to 30% of patients 
being affected, while the frequency of PTLD in patients with transplantation of other 
organs is 9.4% following combined heart and lung transplantation, 1.8-7.9% in lung, 2-5% 
in heart, 2-5% in liver, 2.1% in pancreas, and 1% following renal transplantation 
9;13;16-21
. 
The lowest risk however, follows bone marrow transplantation, where less than 1% of 
recipients suffer from PTLD 
9
. The high frequency observed following lung and intestine 
transplantation can be explained by the fact that these patients require more 
immunosuppressive drugs 
22;23
. Table 1-1 shows the frequency of PTLDs in transplant 
recipients.  
III. Type and dosage regimen of immunosuppressive drugs: It has been reported that the risk of 
developing PTLD increases with the use of certain drugs such as tacrolimus and OKT3, 
especially when they are combined 
24
. Despite the fact that immunosuppressive drugs are 
an established risk factor, it is still not well-understood whether the risk is due to the 
cumulative dose or peak levels of immunosuppressive drugs. The cumulative dose, 
however, is more likely to be the incriminating factor 
25;26
.  
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Table 1-1 Frequency of PTLD in different types of transplants 
Organ 
transplanted 
Reported risk of developing 
(PTLD)% and references 
Kidney 1% 
17
 
Liver 2-5% 
18
 
Heart 2-5% 
19
 
Lung 1.8-7.9% 
16
 
Heart-lung 9.4%
20
 
Small bowel up to 30% 
13
 
Pancreas 2.1% 
21
 
Bone marrow ‹1% 9 
 
 
IV. The pre-transplant EBV sero-status: EBV-naive recipients, being incapable of initiating an 
EBV-specific cytotoxic T-lymphocyte (CTC) response, are more liable to develop PTLD 
27;28
.  
Of these situations, non-exposure to EBV before transplantation remains the most 
important predisposing factor 
28
.  
 
V. Florid follicular hyperplasia (FFH) of tonsils or adenoids in post-transplant patients has 
been postulated to be a precursor lesion of PTLD 
29
. Histopathological evaluation of 
tonsillectomy specimens in the post-transplant setting has been reported to provide a useful 
tool for early diagnosis of PTLD 
30
. 
 
1.2.2 Onset  
PTLDs are classified as either early onset lesions which develop within one year, or late 
onset lesions, which develop more than one year post-transplantation 
31;32
. 
 
  
 
 
 
  
21 
 
1.2.3 Clinical presentation 
The clinical manifestations vary from non-specific symptoms in the form of fever, sweats, 
malaise, weight loss and features of primary EBV infection in some patients, to a sudden 
enlargement of tonsils, lymph nodes, or other extranodal lymphoid organs. Other organs 
such as the central nervous system, bone marrow, spleen, lung, small intestine, liver and 
kidney may also be affected 
33
. The frequencies of extranodal organ involvement are 
summarised in Table 1-2. 
 
 
Table 1-2  Extranodal involvement in PTLD 
TABLE 3Organ Frequency References 
Gastrointestinal tract 20%–25% 
17;34-37
 
Lung 15% - 20% 
Liver 30% - 50% 
Kidney 10% - 20% 
CNS 10% 
Transplanted organ 15% - 20% 
Skin A few case reports 
 
 
 
 
1.2.4 Pathological features and classification of PTLDS: 
The classification of PTLDs is currently based on the WHO classification of lymphoid 
neoplasms 
38
. Table 1-3. Three main pathologic subsets / stages of evolution are recognised. 
The identification of similar cytogenetic alterations and clonal relationship between 
polymorphic-PTLD (pPTLD) and monomorphic-PTLD (mPTLD) support a precursor-
product relationship between some pPTLD and mPTLD as well as supporting the hypothesis 
that PTLD progress along a continuum from polyclonal early lesions to monoclonal mPTLD 
29;38;39
. 
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Table 1-3 Categories of post-transplant lymphoproliferative disorders 
38
  
1- Early lesions 
a. Reactive plasmacytic hyperplasia 
b. Infectious mononucleosis-like lesions.  
2- Polymorphic PTLD 
3- Monomorphic PTLD 
(classified according to lymphoma they resemble) 
B-cell neoplasms 
a. Diffuse large B-cell lymphoma (DLBCL) 
b. Burkitt lymphoma 
c. Plasma cell myeloma.  
d. Plasmacytoma-like lesions    
e. Others*  
 T-cell neoplasms 
a. Peripheral T-cell lymphoma not otherwise specified. 
b. Hepatosplenic T-cell lymphoma 
c. Others*  
4- Classical Hodgkin lymphoma-type PTLD 
(*) indolent small B-cell lymphomas developing in transplant recipient are not included among the PTLD. 
 
 
Early lesions form one end of the spectrum of PTLD, and mostly develop within one year 
post-transplantation. These include two morphological types: plasma cell hyperplasia and 
infectious mononucleosis-like lesions. Early lesions more frequently involve tonsils, 
adenoids or lymph nodes than true extranodal sites.  They do not invade or disturb the 
architecture of the affected tissue 
38
. Plasmacytic hyperplasia shows numerous polytypic 
plasma cells and occasional immunoblasts. IM-like lesions show marked paracortical 
expansion by a cellular infiltrate composed of numerous immunoblasts and a mixed 
population of T-cells and plasma cells. These lesions often show spontaneous regression or 
regress following reduction in immunosuppression
38
. Immunoblasts in IM-like lesions 
frequently harbour EBV and express EBV-encoded RNA (EBER) or EBV-LMP-1 
40
. Early 
lesions rarely harbour clonal cytogenetic changes 
29;41
.  
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Polymorphic PTLD (pPTLDs) affect nodal and extranodal tissues, and show loss of tissue 
architecture and necrosis.  pPTLDs are composed of a mixed population of immunoblasts, 
plasma cells, intermediate-sized lymphoid cells (incorporating a full range of B-cell 
morphology and differentiation), as well as occasional Hodgkin Reed-Sternberg-like cells 
42
. 
The B-cells are usually monotypic but may be polytypic. Nonetheless, a clonal pattern of 
IgH or episomal EBV genome is observed 
43-45
. The majority of the lesions exhibit EBV 
latency type II or III (expressing EBER and EBV-LMP-1 with variable expression of EBV-
EBNA2 and other viral antigens). A variable proportion of cases show regression in 
response to reduction in immunosuppression while others cases may progress and require 
chemotherapy 
38
.  
 
Monomorphic PTLD (mPTLD) can be either of B-cell or T-cell lineage, and resemble the 
typical types of non Hodgkin lymphomas (NHLs) seen in immunocompetent patients, and 
are usually monoclonal. They disturb the tissue architecture and spread to other organs. 
They are classified according to the WHO classification of lymphomas in 
immunocompetent patients. Monomorphic B-PTLDs show features of different 
morphologic variants of DLBCL in immunocompetent patients (iDLBCL (immunoblastic, 
centroblastic or anaplastic), Burkitt lymphoma or plasmablastic lymphoma. Almost all cases 
display a clonal pattern of IGH rearrangement, and EBV-positive cases show an episomal 
EBV genome. mPTLDs can be EBV-negative, these tend to be more aggressive, and only 
rarely respond to a reduction in immunosuppression 
46-48
. In addition, genetic alterations of 
3q27, 8q24.1, and 14q32 have been described in monomorphic B-PTLDs 
41
.  
 
Most PTLDs are associated with EBV, but nonetheless, a significant minority (42% reported 
in one study) are EBV-negative, including 53% of the mPTLD cases 
11;46;47
. There is a 
debate as to whether EBV-negative PTLDs are in fact incidental lymphomas developing in 
transplant patients, or true PTLDs that can regress following reduction of the 
immunosuppression 
49
. It has to be noted that the lack of identifiable EBV, based on EBER 
or LMP-1 staining, does not necessarily imply that EBV-DNA is absent in all of these cases, 
or that EBV did not play a role in the pathogenesis of the EBV-negative lymphoid 
proliferations 
50
.  It has been suggested that EBV-negative PTLD may develop as a result of 
„hit and run‟ oncogenesis as do EBV- negative sporadic BL and classical Hodgkin 
lymphoma (cHL) 
50-52
. Chronic antigenic stimulation on the background of 
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immunosuppression is thought to play an essential role in the pathogenesis of EBV-negative 
PTLD, although a few cases have been shown to be associated with viruses other than EBV, 
such as HHV8 (some of these cases belong to the primary effusion lymphoma (PEL) 
category) 
53;54
. 
 
Plasmablastic lymphomas (PL), which were originally described in HIV-infected people 
affecting the oral cavity, may occur as a post-transplant lymphoproliferative disorder 
55;56
. 
They have also been described in extra-oral sites and in immunocompetent patients 
57;58
. 
Nearly 60-75% of cases of PL are EBV-associated 
59
. 
 
The histological features of HL-type PTLD are similar to mixed cellularity or lymphocyte-
depleted subtypes. The infiltrate is composed of scattered large pleomorphic mono and 
binucleated Hodgkin/Reed-Sternberg giant cells in a background of small lymphocytes, B-
immunoblasts intermingled with histiocytes, plasma cells, a few eosinophils and 
neutrophils. The neoplastic cells are usually CD30
+
, CD15
+
, EBER
+
 , CD45
-
, OCT-2
-
/BOB1
-
 
38
.  Clinicopathologic features of major types of PTLD are summarized in Table 
1-5. 
 
1.2.5 Ontogenic relationships  
Mature B-cells in various lymphoid compartments such as naive B-cells, germinal centre 
(GC)  B-cells and post-GC B-cells, can be distinguished based on genotypic and phenotypic 
markers 
11;60
. B-cell neoplasms, positive for immunoglobulin variable gene (IgV) somatic 
hypermutations (SHMs), are of either GC or post-GC B-cell origin. SHM is a physiological 
process that occurs in the GC and involves deletion, insertion or single-base substitution in 
the variable region of the immunoglobulin heavy chain (IgH) gene, subsequent to exposure 
to an antigen 
61;62
.   
 
SHM of IgHV genes is seen in about 90% of mB-PTLDs, indicating that malignant 
transformation occurs in GC B-cells and their descendants both in EBV-positive and EBV-
negative mPTLDs 
63
. The majority of B-cell lymphomas developing in the context of either 
primary immunosuppression or secondary immunosuppression in both AIDS patients and in 
immunocompetent hosts usually originate from GC B-cells. Unmutated IgHV , however, is 
present in 10% of PT-DLBCLs and refers to a pre-GC B cell origin 
11;60
. Based on three 
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phenotypic markers of histogenesis (BCL6, MUM1, and CD138), three B-cell PTLD 
subsets can be recognised Table 1-4& Figure 1-1. 
 
BCL6 protein expression is seen in GC B-cells whereas MUM1/IRF4 is expressed from 
late-GC B-cells to their subsequent differentiation into plasma cells. MUM1/IRF4 , 
therefore, is considered to be a marker of transition from BCL6-positive B-cells to CD138-
expressing immunoblast and plasma cells 
64-66
. On the other hand, CD138, a marker of post-
GC differentiation, is expressed by post-follicular immunoblasts and plasma cells as well as 
pre-terminal B-cells 
67;68
. Under normal circumstances, Expression of BCL6 and MUM1 are 
mutually exclusive. However, both may be expressed in the same cell, a finding that is 
thought to be due to abnormal retention of BCL6 expression 
69-71
. It has been reported that 
most mB-PTLDs are of the late GC/early post-GC type, with only a minority being GC or 
post-GC types 11;72.  
 
Table 1-4  PTLDs classification based on three histogenetic markers 
11;72
 
 BCL6 MUM1 CD138 PTLD morphology 
1- B-cells exhibiting GC 
reaction 
+ +/- - mPTLD (DLBCL, 
centroblastic) 
BL 
2- B-cell undergone GC 
reaction but not terminally 
differentiated 
- + - pPTLD (65%) 
m-PTLD (DLBCL, 
immunoblastic) (30%) 
3- B-cell, post GC and 
pre-terminally 
differentiated  
- + + pPTLD (35%) 
mPTLD (DLBCL,  
immunoblastic) (60%) 
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Figure 1-1 An illustration showing molecular histogenesis of PTLD. 
Adapted from Capello et al, 
72
. 
p PTLD
DLBCL, immunoblastic
pPTLD
DLBCL, immunoblastic
Burkitt / Burkitt-like 
lymphoma
DLBCL, centroblastic
BCL-6+/MUM1-/CD138- BCL-6-/MUM1+/CD138- BCL-6-/MUM1+/CD138+
GC B-cells Memory B-cellsVirgin B-cells
MUM1 CD138
BCL-6
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Table 1-5  Clinicopathologic features of major types of post-transplant lymphoproliferative disorder 
38
. 
 Early lesions (plasmacytic 
hyperplasia and infectious 
mononucleosis-like) 
Polymorphic PTLD Monomorphic PTLD 
 Clinical features: 
 
a) Age 
 
b) Organ involved 
 
c) Regression 
 
 
Children and young adults 
 
Tonsils or lymph nodes 
 
Usually regress either with minimal 
reduction of immunosuppressive drugs 
or spontaneously 
 
 
All age groups 
 
Lymph nodes, GIT, lung or allograft. 
 
Some cases regress, others progress 
 
 
All age groups 
 
Lymph node, any extranodal site, 
including bone marrow. 
Very rare. Most cases progress rapidly 
 Histopathological features 
a) Tissue architecture 
 
b) Nature of infiltrate 
 
 
 
 
c) Atypia 
d) Necrosis 
 
 
No or partial effacement 
 
Comprised mainly of plasma cells and 
lymphoplasmacytoid cells in 
plasmacytic hyperplasia, and 
immunoblasts and plasmablasts in 
infectious mononucleosis-like lesion 
Absent 
Absent  
 
 
Nearly complete effacement 
 
Composed of a mixture of plasma cells, 
small lymphocytes, and large activated 
cells 
 
 
Present/absent in large cells 
Variable 
 
 
Complete effacement 
 
Monotonous, similar to that of usual 
type B –cell NHL 
 
 
 
Present 
Present (geographic) 
 Molecular features 
a) Ig gene 
 
b) EBV 
c) Structural alterations of 
oncogenes and TSG. 
 
Polyclonal in most cases 
 
Usually non-clonal 
Usually absent 
 
Usually monoclonal; may be oligo or 
polyclonal 
Clonal 
Usually absent 
 
Monoclonal 
 
Clonal 
Usually present 
Ig = immunoglobulin, EBV = Epstein-Barr virus, PTLD = post-transplant lymphoproliferative disorder, NHL= Non-Hodgkin lymphoma, TSG=tumour suppressor gene.
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1.2.6 Aetiology and pathogenesis: 
1.2.6.1 Viral infection 
1.2.6.1.1 Epstein Barr Virus (EBV): 
 EBV is an oncogenic double-stranded DNA virus that infects and persists in memory B-
cells. It has the ability to immortalize B-lymphocytes and causes them to eventually undergo 
uncontrolled lymphoproliferation 
73
. Cell mediated immunity (CMI), stimulated by cytotoxic 
T-lymphocytes (CTC), is essential in the destruction of EBV-infected cells during the 
primary infection and in reactivation. In patients with defective CMI, the T-cells may fail to 
control the multiplication of EBV-infected cells 
43;73
.   
Pathogenesis: 
Two phases of EBV infection have been recognised. The lytic phase is characterised by the 
expression of all EBV proteins and active viral replication, leading eventually to cell death 
and the release of virions. The latency phase involves the infection of lymphoid B-cells via 
their CD21 receptors, resulting in the formation of EBV episomes and the expression of a 
limited number of viral proteins 
73
. This results in persistence of the virus in the lymphoid 
cells and their progeny without distruction of infected cell. LMP-1 and LMP-2 viral proteins 
are believed to act as oncogenes, allowing B-cells to escape cell death and proliferate 
autonomously 
73
.  
 
There are three different latency patterns that correspond to the differentiation stages of B 
cells. These patterns are thought to play a major role in protecting EBV-infected cells from 
immunosurveillance 
74-76
. EBV-infected naive B cells expressing all latent antigens are said 
to have “type III latency”. Infected naive B cells enter the germinal centre where they 
multiply and form clones. They express EBNA1, LMP-1, and LMP-2, and this is known as 
“type II latency” 75. The infected GC cells then differentiate into memory B cells which are 
resting and long lived cells. EBV, therefore, can persist for a long time without needing to 
express any of the viral antigens (“type 0 latency”, perhaps, LMP-2A and EBER are 
expressed) 
73
. However, some only express EBNA-1 and 2 as well as small non-coding 
Epstein Barr RNAs (EBERS) and are said to have “type I latency” 77;78. EBV latency patterns 
in selected EBV-driven lymphoproliferative disorders are shown in Table 1-6. Protein 
products of latent EBV-encoded genes, their locations and functions are shown in       Figure 
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1-2. All EBV latent proteins are located in the nucleus, except LMP-1 and LMP-2, which are 
located on the membrane and in the cytoplasm. 
 
There are several lines of evidence that implicate EBV in the pathogenesis of PTLD:  
a) The monoclonality of EBV in many cases of monomorphic PTLD suggests that the virus 
is present from an early phase of clonal expansion 
11
.  
b) The association of all cases of early PTLD and about 95% of post-transplant Hodgkin 
lymphoma with EBV 
79
.  
c) Some of the EBV genes which are expressed during the latency phase can cause B cell 
transformation 
80;81
.  
d) The presence of large number of EBV infected-B-cells in tissues and blood of post 
transplant patients who later develop PTLD 
82;83
.  
e) Regression of tumour size in response to autologous EBV-specific cytotoxic T-cells 84.    
Although EBV plays an important role in driving the proliferation of EBV-infected B cells, it 
is widely perceived that it is not solely responsible for the „neoplastic‟ state. Accumulation of 
different aberrations in proto-oncogenes and suppressor genes, and hypermethylation of 
suppressor genes are integral parts of the pathogenesis 
72
.   
 
 
Table 1-6    EBV latency patterns in some selected lymphoproliferative disorders 
85
 
EBV latency programs Disease 
Type I  Burkitt lymphoma 
Type II  Hodgkin lymphoma 
 B-PTLD 
 EBV-positive DLBCL of the elderly 
 Primary effusion lymphoma* 
Type III   B-PTLD 
 EBV-positive DLBCL of the elderly  
 Primary CNS lymphoma* 
(*) HIV-associated lymphomas 
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      Figure 1-2: Protein products of latent EBV-encoded genes, their locations and functions 
EBV-
encoded 
gene 
Protein product 
localisation 
Protein function 
 
EBNA1 is required for the replication of the viral DNA and 
its distribution to the daughter proliferating cells 
86
. EBNA1 is 
not presented by MHC class I molecule so cytotoxic T cells 
are unable to recognize EBV-positive B cells that express 
only EBNA1 
87
. 
EBNA2 is the first viral protein to be expressed in vitro after 
infection of B cells. It plays a crucial role in cellular 
transformation and regulates many cellular and viral genes, 
such as LMP-1 and LMP-2A 
73
. 
EBNA3 may play a role in alteration of the B-cell homing 
process 
75
. 
LMP-1 is considered to be the main transforming protein of 
EBV and the major effector of viral-induced cellular changes. 
It inhibits apoptosis by activating NF-κB pathways, leading to 
upregulated expression of BCL2 and other target genes 
88
. 
This signalling pathway mimics that of CD40, which has a 
central role in the differentiation and activation of B-cells 
89
. 
LMP-2 sequesters tyrosine kinase from the BCR, thereby 
hindering EBV-infected cells from entering the lytic cycle, 
resulting in the inhibition of BCR signalling 
90
.  It also can 
mimic the BCR, thereby copying the survival signals for B 
cells, normally supplied by BCR 
91
. 
EBER1 & 2 appear to have no role in the EBV-induced 
transformation of B-lymphocytes. However, because of their 
abundant expression they are a useful aid in the detection of 
the virus.  They can induce the secretion of IL-10, which 
suppresses cytotoxic T cells and stimulates growth of infected 
B cells 
92
.  EBERs are thought to mediate resistance of EBV
+ 
Burkitt lymphoma cells to interferon-α 93. 
* Small nuclear RNAs without protein product  
 
 
 
 
EBNA-1
EBNA-3
EBER 1 & 2
LMP-2
LMP-1
EBNA-2
Nucleus
Nucleus
Nucleus
Membrane
Membrane
*Nucleus
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1.2.6.1.2 Human Herpes Virus-8 (HHV-8):  
HHV-8 is a gamma-herpes virus that, like EBV, infects B-cells and acquires an episomal 
configuration in the nucleus and results in a state of latency 
94
. In the post-transplant setting, 
it has only been detected in cases of primary effusion lymphoma 
54;95
. In a recently published 
study, KSHV/HHV-8 was found to be consistently absent in PTLD 
96
.  
 
1.2.6.2 Molecular alteration of cellular genes 
1.2.6.2.1 Microsatellite instability 
Lymphomas developing in immunocompetent patients are often characterised by relative 
genomic stability. In contrast, a small subset of PTLD is associated with microsatellite 
instability, which results from defects in DNA mismatch repair mechanisms 
97
. These cases 
show mutations involving multiple genes, including BAX and CASPASE5 (pro-apoptotic 
factors) and RAD50 (a DNA repair gene). This phenomenon has been described as “mutator 
phenotype”. These mutations in different genes might result in the formation of new antigens 
on the tumour cell surface 
72
. 
1.2.6.2.2 Aberrant somatic hypermutation (ASHM) 
B-cells in the GC are subjected to a physiological phenomenon known as “somatic 
hypermutation” (SHM), which involves the introduction of single nucleotide substitution into 
their IgV genes 
62;98
. It involves not only the IgH gene but also non-immunoglobulin genes 
such as BCL6 and Fas/CD95. In more than 50% of DLBCLs, SHMs can also affect some 
proto-oncogenes such as PAX5, PIM-1, RhoH/TTF and c-MYC-gene, which are involved in 
the pathogenesis of lymphoid neoplasms 
99
. At the molecular level, mutations involving the 
PAX5, PIM-1, RhoH/TTF and c-MYC genes recapitulate physiological SHMs. However, they 
occur at an insignificant level in normal GC B-cells, suggesting a malfunction of the SHM 
process is associated with lymphoid malignancies. This phenomenon has been referred to as 
“aberrant somatic hypermutation” (ASHM)  99.  
 
PAX5 is located on chromosome 9q13 and it encodes a B-cell-specific activation protein that 
is expressed in B cells from the progenitor to the mature B-cell stage. It is required for a 
lymphoid progenitor to commit to the B-cell pathway 
100
. PIM-1 encodes a serine-threonine 
kinase and is rarely involved in chromosomal translocation of DLBCL. RhoH/TTF encodes a 
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small GTP-binding protein and is occasionally a target for chromosomal translocations in 
lymphomas 
101
. Approximately 30% of mPTLDs, especially DLBCLs, and a proportion of 
HIV-B-cell lymphomas (HIV-BCLs) display mutations in multiple genes: a finding that 
implicates ASHM in the pathogenesis of PTLD 
39;99;102;103
. There are two mechanisms by 
which ASHM may alter the function of PIM-1, PAX5, RhoH/TTF and c-MYC: deregulation 
of gene expression because of mutations around the 5´ regulatory sequences of the genes, or 
structural and / or biochemical alteration at the protein level because of mutation-induced 
mis-translation of the gene 
72;103
. 
 
1.2.6.2.3 Other genetic alterations: 
a- BCL6 gene:  
The BCL6 gene, cloned in 1993, is located on chromosome 3q27, and encodes a 
transcriptional repressor 
104
. Although it is necessary for GC memory B-cell development, its 
down-regulation is essential for terminal differentiation of B-cells 
105
.  BCL6 rearrangement 
is very rarely seen in PTLDs although it is the target of SHM in approximately 50% of 
PTLDs 
29;41
. On the other hand, BCL6 
11;106
. Mutations of BCL6 most commonly target the 
DNA sequence close to the promoter region where the chromosomal breaks at 3q27 usually 
occur 
72
.  
 
b- c-MYC gene:  
c-MYC gene is located on chromosome 8q24 and contains three exons, two of which encode a 
functional protein 
107
. Chromosomal translocation results in deregulation of c-MYC through 
two pathways: translocated c-MYC (to the IGH gene) is brought under the control of 
regulatory sequences of the IGH gene; and via mutations that take place in the 5´ regulatory 
regions of c-MYC, which are thought to regulate their sensitivity to cellular factors and in turn 
regulate c-MYC expression 
72
. Most post-transplant Burkitt lymphomas (PT-BL), similar to 
HIV-BL and BL developing in immunocompetent patients (iBL), display chromosomal 
breaks at 8q24 involving the c-MYC oncogene 
29;41;44;108;109
.   
c- BCL2 gene:  
BCL2 gene, an anti-apoptotic gene, is located on chromosome 18q21 
110
. Although the BCL2 
locus on 18q21 has been documented to display amplification in a proportion of PTLDs, 
rearrangement of BCL2 is a very rare event in PTLDs 
29;111
.  
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d- P53 gene:  
The P53 gene is a tumour suppressor gene located on 17p13.1 and is mutated or deleted in a 
small proportion of mPTLDs (DLBCL) 
44
. Mutated P53 fails to trans-activate its target genes 
and to down-regulate the expression of P21. The latter is a cyclin–dependant kinase inhibitor 
which neutralises the activity of cyclin E 
72
. 
 
e- IGH gene:  
This is located on 14q32 and breakpoints involving the gene are detected in 52 % cases of 
iDLBCL 
112
. On the other hand, a few cases of PTLD and rarely, florid follicular hyperplasia 
in post-transplant setting are positive for chromosomal breaks on 14q32 
29
. 
 
f- PAX5 gene:  
PAX5 is the target of t(9;14)(p13;q32) as well as ASHM in DLBCL and in mPTLD (DLBCL) 
102;113;114
. A proportion of PTLDs have been reported to have PAX5 gene amplification 
115
. 
 
g- Other chromosomal changes:  
Comparative genomic hybridisation (CGH) analysis of PTLDs highlights some genetic 
changes similar to those occurring in the lymphoma of immunocompetent patients: for 
example gains of 3q27, 7q, 8q24, 12q, 12p, 18q21, 21q and losses of 1p, 6q, 9p and 17p13. In 
addition, PTLDs show a gain of 5p and losses of 4q, 17q and Xp that are not common in 
other lymphomas 
111;115-117
.  It has been demonstrated that post-transplant-DLBCLs (PT-
DLBCLs), with a frequency similar to iDLBCLs, show gains of chromosomes 5p and 11p. 
Moreover, deletions of 12p, 4p, 4q, 12q, 17p and 18q are frequently seen in PT-DLBCLs 
115
.  
The finding that iDLBCLs and a proportion of PTLDs (especially PT-DLBCLs) share some 
histogenetic and pathogenetic pathways is reinforced by the presence of recurrent 
chromosomal aberrations common to both PTLDs and iDLBCLs 
72
. It has been also reported 
that PT-DLBCLs harbour recurrent lesions, though at a lower frequency, similar to those in 
iDLBCLs. In addition, recurrent deletions on 11q25 and gains on 6q25.3 were observed in 
PT-BLs 
115
. There is usually a discrepancy between the reduction in DNA copy number and 
loss of heterozygosity (LOH). Whilst DNA loss with no LOH is common in iDLBCLs, LOH 
with no reduction in copy number is common in PTLDs 
118;119
. Rinaldi et al 
120
, using high-
density genome wide SNP-based arrays reported similar genomic complexity among PT-
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DLBCLs, HIV-DLBCLs and iDLBCLs. Nonetheless, PT-DLBCLs displayed a genomic 
profile with distinctive features.  
 
“Fragile sites” are regions with marked genomic instability, present throughout the genome, 
that are often the sites of DNA breakage in malignant tumours and in cells exposed to 
specific chemical agents 
121;122
. PT-DLBCLs have been described to have frequent interstitial 
deletions at 1p32.2, 2p16.1, 3p14.2, 4p14, 14q13.2, 20p12.3 and 20q13.32. Some of these 
deletions involve fragile sites such as FRA1B, FRA2E and FRA3B. Del(2p16.1) (FRA2E) is 
the most common aberration in PT-DLBCLs and the involvement is significantly higher than 
in iDLBCLs 
120
. The absence of del(13q14.3) in PT-DLBCLs, a lesion that is also reported in 
HIV-DLBCLs,  is the most significant difference between PT-DLBCLs and iDLBCLs 
120;123
. 
Lack of copy neutral LOH at 6p (HLA-DR locus) is a frequent occurrence in PT-DLBCL 
120
. 
 
Craig et al 
124
 used Affymetrix HU133A GeneChips to show that EBV-positive mPTLDs 
over-express several interferon-induced genes compared with EBV-negative mPTLDs. 
Furthermore, EBV-negative PTLDs overexpress genes containing elements of B-cell receptor 
signalling pathways and a group of proliferation-related genes. In other words, EBV-negative 
PTLDs lacked viral-associated changes, suggesting that they are biologically distinct from 
EBV-positive PTLDs and are more similar to iDLBCL. Conversely, there is a published 
study which did not find distinguishing patterns between EBV+ and EBV- cases 
39
. 
 
When compared with EBV-negative PT-DLBCLs, EBV-positive PT-DLBCLs have been 
described as having less recurrent lesions. However, del(2p16.1) is common in both EBV-
negative and positive PT-DLBCLs. PT-, HIV- and i-DLBCLs have a similar frequency of 
recurrent gains of 1q, 11q and of chromosome 7, in addition to losses at 17p (TP53) 
120
. 
 
Some viruses such as EBV, HBV, HHV-8 and HPV have been shown to incorporate 
themselves into the host genome, mainly at fragile sites, resulting in local genomic instability 
at the insertion sites 
125-127
. It has been postulated that the increased breakage at fragile sites 
in HIV-DLBCLs could point to a role of viruses in the pathogenesis 
123
. Similarly, 
iatrogenically immunosuppressed post-transplant patients are more susceptible to a wide 
range of viruses which could integrate into the genome, particularly at fragile sites 
120
. The 
dissimilar pattern of breakage at fragile sites reported in PT-DLBCLs and HIV-DLBCLs 
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might be due to different integration sites of the various viruses 
120;128
. PT-DLBCLs have IgV 
mutational status and gene expression profiles similar to post-GC B-cells 
38;39;72
. Nonetheless, 
iDLBCLs of post-GC phenotype display genetic lesions that are different from PT-DLBCLs 
120;129;130
. This confirms the finding of genetic heterogeneity between PT-DLBCLs and other 
types of DLBCLs sharing comparable immunophenotypic profiles 
123
.  
 
1.2.6.2.4 Epigenetic alteration (DNA hypermethylation).  
Within the regulatory regions of many genes there are CpG islands that typically display a 
low level of methylation. The activity of tumour suppressor genes can be inhibited as a result 
of hypermethylation of cytosine residues in these islands. Hypermethylation is an epigenetic 
phenomenon that alters the gene activity without changing its base sequences and is 
accomplished through DNA methyl transferase enzyme 
131
. Aberrant hypermethylation (AH) 
is a mechanism for tumour suppressor gene silencing that is an alternative to deletion and/or 
mutation. Aberrant hypermethylation (AH) of the promoter regions of a number of 
lymphoma-related suppressor genes has been implicated in the pathogenesis of 
lymphoproliferative disorders in post-transplant setting 
132
.  
 
a) Hypermethylation of death-associated protein kinase (DAP-k):  
DAP-k is a serine-threonine kinase and plays an important role in apoptosis triggered by 
TNFα, INFγ and the FAS ligand. About 75% of mPTLDs display DAP-k hypermethylation 
133;133
 
b) Hypermethylation of O6-methylguanine-DNA methyl-transferase (MGMT):  
MGMT is one of the DNA repair genes that serve to protect against DNA damage. Its 
repression through AH predisposes to malignancy by causing genomic instability and point 
mutation of P53 and RAS genes 
134
. MGMT is methylated in nearly 75% and 93% pPTLDs 
and mPTLDs respectively 
132
.  
c) Hypermethylation of P73:  
P73 is a tumour suppressor gene that bears some functional and structural resemblance to 
P53. It plays a role in cell cycle regulation and apoptosis and is hypermethylated in about 
20% mPTLDs 
132
.   
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d) Hypermethylation of P16:  
P16 is a tumour suppressor gene located on chromosome 9p21. It hinders the G1-S cell cycle 
transition by inhibiting the phosphorylation of Retinoblastoma protein 
135
. A fraction of 
follicular lymphomas harbour hypermethylation of P16. Lymphomas with a high 
proliferation rate are more frequently associated with P16 methylation 
136
. It has been 
reported that 27-56% of DLBCLs show AH of P16 
137;138
. Martin et al 
139
, described down-
regulation of P16/INK4a in subsets of mPTLDs (DLBCLs) that had an aggressive course but 
were not associated with EBV. There is a rare case report of an EBV-positive mPTLD 
(plasmablastic type) that showed P16 hypermethylation 
140
.  
e) Hypermethylation of SHP1 gene.  
The SHP1 gene is located on chromosome 12p13, and it encodes SHP1 protein. SHP1 is a 68 
kDa, cytoplasmic protein tyrosine phosphatase (PTP) 
141
. It is expressed in hematopoietic 
cells and it potentiates its negative effect on cell cycle regulation by inhibiting the 
JAKs/STATs pathway. In B-lymphocytes, therefore, it inhibits proliferation and its 
deficiency through AH results in overgrowth 
142;143
.  
 It has been suggested that hypermethylation of SHP1 gene might play a role in the 
pathogenesis of multiple myeloma by activating the JAK2/STAT pathway 
144
. AH of SHP1 
gene is reported in various lymphoma types including iDLBCLs, being observed in 80% of 
cases 
138
. Cerri et al, 
145
 reported frequent SHP1 methylation in IDLDs: Amongst PTLDs, 
SHP1 methylation was detected in 76% of the cases, including 76.5% of the PT-DLBCLs, 
75% of the pPTLDs, 66% of the PT-BLs and in one PT-myeloma. Amongst HIV-B-cell 
lymphoma, it was reported in 57% of HIV-DLBCLs, 17.6% of HIV-BLs and 80% of HIV-
PELs.   
 
1.2.6.3 Antigen stimulation 
Antigen stimulation plays an important role in the pathogenesis of immunodeficiency-
associated lymphomas. This stems from the molecular features of the IGV genes in B-cell 
lymphomas 
146;147
. Under normal circumstances B-cells express the B-cell receptor (BCR), 
the loss of which, through the acquisition of mutations, results in apoptosis 
10;11;148
. It has 
been demonstrated that EBV through expression of LMP2A which simulates a BCR, protects 
BCR-lacking GC B-cells from death, leading to lymphoma development 
10;148;149
. There are a 
few reports of the existence of EBV-negative PTLDs that lack expression of sIg, pointing to 
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the possibility of as yet unidentified genetic mechanisms that may rescue EBV-negative, 
BCR-lacking lymphocytes 
39;63
. Although the role of antigen stimulation is evident in HIV-
NHL pathogenesis, it is a less obvious pathogenetic mechanism in PTLDs 
11;72
.  
 
 
 
 
1.3 HIV-RELATED LYMPHOMAS 
1.3.1 Introduction 
AIDS patients, being immunosuppressed, are at about a  hundred times higher risk of 
developing non-Hodgkin lymphomas (NHL) than the general population 
150
. There has been a 
steady increase in the incidence of AIDS-related NHLs since the beginning of the AIDS 
epidemic. Furthermore, in 1985 NHLs were recognized by the Centers for Disease Control as 
an AIDS-defining condition 
151
. It is said that because HIV-NHLs are frequently late 
complications of AIDS, their incidence will continue to show a steady rise with the increase 
in life expectancy of patients infected with HIV 
152
. Following the introduction of 
combination antiretroviral therapy (cART) in 1996, there has been a more pronounced 
decline in the incidence of Kaposi‟s sarcoma (KS) than that of NHL. NHL, therefore, has 
become the most frequent (the incidence is more than halved in patients on cART) AIDS-
defining event in recent years 
153
. 
 
HIV-lymphomas develop secondary to a combination of immune-suppression by HIV, co-
infection with EBV and /or HHV-8, in a small number of cases due to chronic antigen 
stimulation of B-cells and accumulated genetic alterations 
154-156
. Sabaawy et al, 
157
 reported a 
benign lymphoproliferative lesion and a DLBCL that developed from a common clone in an 
HIV-infected patient. They recommended that HIV-positive patients with a reactive 
lymphoproliferative lesion should be tested for clonal disease and undergo regular monitoring 
at both the clinical and molecular level, for transformation to frank clonal lesions.   
 
Despite the fact that all HIV-NHLs share a number of similarities such as an origin from B-
cells, aggressive clinical course, and a predilection for extranodal sites, they have been shown 
to exhibit obvious clinico-morphologic heterogeneity 
158
. 
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In the latest WHO proposal, HIV-related lymphomas are classified into three subsets: 
lymphomas also occurring in non-immunocompromised patients, lymphomas that 
specifically occur in HIV-patients and lymphomas that also occur in the background of other 
immunosuppressive states 
159
.Table 1-7. 
 
Table 1-7  Categories of HIV-associated lymphomas 
159
 
2- 1) Lymphomas also occurring in non-immunocompromised patients 
a. Burkitt lymphoma (classic, or with plasmacytoid differentiation) 
b. Diffuse large B-cell lymphoma (centroblastic, immunoblastic) 
c. Extranodal marginal zone B-cell lymphoma of mucosa associated 
lymphoid tissue type (MALT lymphoma) (rare). 
d. Peripheral T-cell lymphoma. 
e. Classical Hodgkin lymphoma. 
3- 2) Lymphomas occurring more specifically in HIV+ patients 
a. Primary effusion lymphoma 
b. Plasmablastic lymphoma of the oral cavity. 
4- 3) Lymphomas also occurring in other immunodeficiency states 
                  Polymorphic B-cell lymphoma (PTLD-like). 
 
1.3.2 Aetiology and pathogenesis  
The pathogenesis of HIV-NHL is a complex multistep process with different phases as in 
PTLD. The genetic events involved in the pathogenesis include activation of cellular proto-
oncogenes (mainly through translocations), inactivation of tumour suppressor genes, chronic 
antigenic stimulation or participation of oncogenic viruses such as EBV and HHV8 
160-163
. 
The initial step is to render that patient immunocompromised, while the main event is lack of 
immunosurveillance and chronic antigen stimulation, which results in poly/oligo-clonal B-
cell hyperstimulation and hyperplasia, leading to persistent generalised lymphadenopathy 
151;164
. There is a close association between the low numbers of CD4+ T cells in the 
peripheral blood of HIV-infected patients and the increased risk of HIV-NHL development. 
This highlights the role of disrupted immunosurveillance in the pathogenesis of these 
disorders 
165
. Despite the fact that this association is particularly evident in HIV-DLBCL and 
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HIV-PCNSL, HIV-BL may develop on the background of a more intact immune function 
151
. 
It has been shown that B-cells in different compartments of the germinal centre give rise to 
different entities of AIDS-related lymphomas 
166
 Figure 1-3. The clonal accumulation of 
genetic aberrations within the neoplastic cells together with chronic B-cell stimulation and 
hyperplasia not only drives the initiation of HIV-NHL clones but also enhances their 
progressive proliferation 
151
. The findings that nearly 50% of HIV-related lymphomas contain 
HIV-positive macrophages and that macrophages facilitate the progression of lymphomas 
shed some light on the possible role of macrophages in the pathogenesis of HIV-related 
lymphomas 
167
. 
 
 
 
 
 
 
 
 
Figure 1-3 Molecular histogenesis of HIV-related NHLs. 
Adapted from Carbone and Carbone & Gloghini 
161;166
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1.3.2.1 Viral infection 
1.3.2.1.1 EBV 
EBV has been shown to be involved in the pathogenesis of HIV-NHL 
151;168
. EBV is found in 
30-80% of HIV-DLBCLs,  ~ 75% of plasmablastic lymphomas and 30% of HIV-BLs 
59;169;170
. In addition, EBV is seen in all cases of AIDS-PCNSL and in approximately 90% of 
PEL 
171-173
. EBV is also present in 80-100 % of classical Hodgkin lymphoma developing in 
the context of HIV infection 
174
. The pattern of expression of EBNA-2 and LMP-1 varies 
amongst HIV-NHLs with HIV-BL cases characteristically lacking the expression of both 
antigens; approximately 50% of HIV-DLBCL express LMP-1 and some rare cases of HIV-
DLBCL express EBNA-2 
175;176
.  
1.3.2.1.2 HHV-8 
HHV-8, which was first identified as a causative agent of AIDS-related Kaposi sarcoma, is 
implicated in the pathogenesis of two lymphoproliferative disorders seen in AIDS patients: 
multicentric Castleman‟s disease (MCD) and AIDS-PEL. In addition, both HHV-8 and EBV 
play a distinctive role in the pathogenesis of PEL 
177-179
.  
HHV-8 has been also described as a causative agent of DLBCL arising in the context of 
MCD and of germinotropic lymphoproliferative disorder occurring in HIV-seronegative 
patients 
180;181
. HHV-8 can be detected by the polymerase chain reaction 
171;182
. However, 
KSHV/HHV-8 is best identified in paraffin-embedded tissue sections using a highly sensitive 
and specific monoclonal antibody against HHV-8 latent nuclear antigen-1
166;183;184
. 
 
1.3.2.2 Genetic alterations 
c-MYC 
Both HIV-BL and iBL have chromosomal translocations affecting 8q24, where the c-MYC 
proto-oncogene is located 
185
. Activation of c-MYC occurs in all HIV-BLs though c-MYC is 
not activated in majority of HIV-DLBCLs. The most common translocation affecting c-MYC 
gene is t(8;14)(q24;q32) in which the c-MYC gene, as a result of translocation, is brought 
under the influence of IgH, resulting in its deregulation 
151
. There is a partner protein (p107) 
which under normal circumstances inhibits the transactivation properties of c-MYC. It is also 
known that c-MYC is frequently mutated within the region of exon 2, causing a lack of 
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response of the mutated allele to the suppressor effect of p107 and the subsequent activation 
of c-MYC 
186;187
. 
 
BCL6 
The BCL6 gene rearrangement is seen in approximately 40% of iDLBCLs, in only a fraction 
of HIV-DLBCLs, but not in HIV-BL or PEL 
188-190
. The significantly lower frequency of 
BCL6 rearrangements in HIV-related lymphomas supports the notion that these two groups of 
neoplasms have different pathogenetic mechanisms. BCL6 can also be altered through 
mutations that affect its 5‟ non-coding region. BCL6 mutations have been described in about 
65% of iDLBCLs, 50% of follicular lymphomas, 66% of HIV-BLs and HIV-DLBCLs, but in 
only 20% of PEL 
189;191
. The BCL6 protein is expressed in all HIV-BL cases and in 
approximately 50% of HIV-DLBCLs. Expression of BCL6 protein and EBV-LMP-1 among 
the latter is mutually exclusive 
160;192
. Mutation of BCL6 5‟ regulatory regions is considered a 
marker of the transition of B-cells through the GC, and BCL6 protein expression is a marker 
of the GC origin of a given B-cell lymphoma 
66;191
. 
 
P53 
Silencing of the P53 tumour suppressor gene, (the most common gene involved in human 
cancer), usually results from a mutation of one allele and the deletion of the other allele, 
although biallelic mutation or biallelic deletion may occur in a small fraction of cases. P53 
mutation is seen in 30% of non-HIV-BL cases, in iDLBCL transformed from a previous 
follicular phase, and in 60% of HIV-BL cases. P53 mutation is absent amongst HIV-DLBCLs 
and HIV-PEL 
151;169
. The higher frequency seen in HIV-BL compared with non-HIV-BL 
might be related to the immune deficiency of HIV-infected patients 
160;169
. The lack of P53 
mutation and BCL2 gene rearrangement among HIV-DLBCLs, points to a de novo origin of 
HIV-DLBCL 
151
.   
 
Aberrant somatic hypermutation(ASHM)  
ASHM of at least one of the PIM-1, PAX5, RhoH/TTF, and c-MYC genes has been reported 
in 55%, 36 %, 67% and 25% of AIDS-DLBCLs, -BLs, -PELs, and –PCNSLs respectively. In 
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addition, 33% of AIDS-DLBCLs, 18 % of AIDS-BLs and 25 % of AIDS-PCNSLs have 
ASHM in more than one gene 
103
. 
Aberrant hypermethylation: 
 Aberrant hypermethylation of SHP1 genes plays a role in the pathogenesis of HIV-
associated lymphoma 
145
. 
1.3.2.3 Antigen stimulation:  
As previously mentioned,  the role of antigen stimulation is evident in HIV-NHL 
pathogenesis, though it is a less obvious pathogenetic mechanism in PTLDs 
11;72
 
 
1.3.3 Sites of involvement 
HIV- associated lymphomas frequently involve extranodal sites, especially the GIT, the CNS, 
the liver and the bone marrow. Unusual sites of involvement include the oral cavity, the jaw 
and body cavities. About one third of patients present with lymph node involvement
193
. 
 
1.3.4 Histological types 
1.3.4.1 Burkitt lymphoma 
BLs comprise 30% of all HIV-related lymphomas and are characterised histologically by a 
diffuse proliferation of monomorphous medium-sized cells with scant cytoplasm and round 
nuclei displaying multiple nucleoli, a starry-sky pattern resulting from many scattered 
tangible-body macrophages and abundant mitoses. BL has a typical immunophenotype; 
strong Ig expression, expression of B-cell antigens and germinal centre (GC) markers, 
absence of BCL2 expression, and a near 100% Ki-67 expression. However, about 20% or less 
cases show very weak and heterogeneous expression of BCL2 and rare cases can be CD10 
negative. Furthermore, nearly one-third of cases with a molecular signature of BL have <95% 
Ki-67 expression (rare cases <90% proliferation). Typically BL harbours MYC-IGH 
translocation - t(8;14)(q24;q32), and less commonly the translocation partner of the MYC 
gene is one of the light chain genes (22q11 or 2p12). However, up to 10% of BL lack 
demonstrable MYC-translocation. Typically, MYC-IG translocation occurs as the sole 
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abnormality (MYC-simple karyotype) in BL. EBV-positive cases are EBER positive but do 
not express LMP-1 
185;194;195
. 
Prior to the current WHO classification (2008), a proportion of HIV-BL would be classified 
as atypical BLs. These were cases resembling conventional BL except the cells were more 
variable in size and shape and the nuclei may have more prominent nucleoli 
196
. 
Cytogenetically, the cells have a rearrangement of the c-MYC gene t(8;14)(q24;q32) or one of 
its variants 
161
. Many of these cases represent true BL. However, a proportion of them 
represent what is currently described as B-cell lymphoma, unclassifiable with features 
intermediate between DLBCL and BL which has an extremely poor prognosis. The cell size 
is usually medium or slightly larger. The tumour cells show variation in cell, nuclear and 
nucleolar size. The immunophenotype is variable with a higher proportion of cases 
expressing BCL2. Although MYC-IG translocation occurs in a proportion of DLBCL/BL, the 
more characteristic feature is presence of MYC translocation with non-IG partners. 
Furthermore, cases of DLBCL/BL with MYC translocation also carry additional 
chromosomal translocations or other cytogenetic abnormalities (MYC-complex karyotype), 
and it includes cases of the so-called double-hit lymphomas (cases with MYC and BCL2 
translocations or MYC and BCL6 translocations). On array CGH the MYC-complex karyotype 
is characterised by 6 or more abnormalities in addition to MYC translocation 
185;197-201
. The 
proportion of HIV-NHL that would correspond to DLBCL/BL category is currently not 
known. A proportion of BL have plasmacytoid differentiation/features and these are thought 
to be almost exclusively restricted to patients with AIDS. They comprise medium-sized cells 
with ample basophilic cytoplasm and eccentric nuclei with a prominent central nucleolus 
202
. 
BLs are also associated with the inactivation of P53 (in 50-60% of patients) and EBV 
infection (in 30-50% of cases). In addition, ASHM involving the PIM-1, PAX5, RhoH/TTFa 
and BCL6 genes seem to play a role in the pathogenesis 
166
. 
 
Capello et al 
123
, using high-density, genome wide, SNP-based microarray analysis, have 
shown that, in contrast to HIV-DLBCLs and iDLBCLs, HIV-BLs are relatively stable 
genomically. Lower genomic complexity has been reported in lymphomas arising in patients 
following organ transplantation and in immunocompetent individuals 
115;199
. Therefore, lower 
genomic complexity has been suggested to be a feature of BL, independent of the 
individual‟s immune status 123.  
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1.3.4.2 Diffuse large B-cell lymphoma (DLBCL) 
In the more recent literature, DLBCLs even those arising in the HIV setting, are classified as 
GC (59%) and non-GC subsets (41%) 
170
.  However, HIV-DLBCLs in the earlier literature 
are mostly classified as centroblastic and immunoblastic subsets.  
DLBCL with centroblastic features 
DLBCL with centroblastic features arises on the background of mild immunodeficiency. It 
comprises about 25% of HIV-related lymphomas and shows a diffuse cellular infiltrate 
composed of centroblasts admixed with a few immunoblasts. The tumour cells express CD20 
and sometimes CD10 or CD30 or both 
194;196;203
.  
DLBCL with centroblastic features is associated with translocations and mutations involving 
the BCL6 proto-oncogene and it comprises 20% of HIV-related lymphoma 
194
. On a 
molecular histogenetic basis, it has been shown that this type of lymphoma has a 
BCL6
+
/CD138
-
, LMP-1
-
 phenotype 
166
. 
DLBCL with immunoblastic features 
DLBCL with immunoblastic features arises, in contrast to DLBCLs with centroblastic 
morphology, in patients with marked immunodeficiency. They constitute about 10% of HIV-
related lymphomas and are composed of immunoblasts having ample basophilic cytoplasm, 
usually with plasmacytoid differentiation & round or oval nuclei containing a single 
centrally-located nucleolus. The cells are BCL6
-
/CD138
+
/LMP-1
+
 
166
 and in addition, some 
cells may express CD30 
194
.  
DLBCL with immunoblastic features shows a strong association with EBV, and as LMP-1 is 
expressed in many cases, EBV possibly plays a crucial role in its pathogenesis 
155
. DLBCLs 
with immunoblastic features express p27/KIP1, a cell cycle inhibitor, despite their high 
proliferative rate. The EBV-LMP-1 expressed in these cells is thought to stimulate cell 
growth and maintain cell cycle progression, despite p27/KIP1 expression. Usually, p27/KIP1 
(a nuclear phosphoprotein of the KIP family of CDK inhibitors) is expressed in non-dividing 
but not in proliferating lymphoid cells. Furthermore, an inverse relationship between 
p27/KIP1 expression and cell proliferation exists in normal lymphoid tissue and in most types 
of immunocompetent NHLs 
161;204
.  
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Fragile sites are regions with marked genomic instability present throughout the genome. 
They are often found where DNA breaks in malignant tumours and in cells exposed to 
specific chemical agents. Interstitial deletions affecting genes overlapping these fragile sites 
have been reported more frequently in HIV-DLBCLs than in iDLBCLs 
121-123
. Of the fragile 
site-associated genes those that are more frequently involved in deletions in HIV-NHL are 
Fragile Histidine Triade (FHIT) (FRA3B), WW domain-containing Oxidoreductases 
(WWOX)(FRA16D), Deleted in Colon Cancer (DCC)(FRA18B) and Parkinson disease 
(PARPK2) (FRA6E), with FHIT (FRA3B) deletion being the most common aberration 
123
. 
These genes are also silenced through gene methylation in HIV-NHL, with FHIT and WWOX 
tumour suppressor genes frequently being affected in a proportion of human cancers 
including hematolymphoid neoplasms 
123;205;206
. Some viruses such as EBV, HBV, HHV8 
and HPV have been shown to incorporate into the host genome, preferentially at the fragile 
sites, resulting in local genomic instability at the insertion sites 
125-127
. Therefore, a higher 
frequency of fragile site instability in HIV-DLBCLs compared to iDLBCLs might denote a 
role for viral infections in the pathogenesis 
163
. In addition, it has been suggested that viruses 
can induce transformation through a direct effect, rather than expressing viral transforming 
proteins 
123
.   
More than 15% of HIV-DLBCLs show gains of 1q, 2p, 11q, and 12p as well as losses of 17p 
and LOH of 17q 
123
. In addition, gain of 19p13.2 and loss of 16q23.1 have been described as 
a novel genetic alteration in HIV-DLBCL 
207
. Amongst HIV-DLBCLs, EBV-positive cases 
have been shown to display a lower genomic complexity than EBV-negative cases. This 
could be attributable to a direct EBV transforming effect that can act as a surrogate for 
additional genetic aberrations 
123;208;209
. 
 
1.3.4.3 Primary effusion lymphoma (PEL) 
Primary effusion lymphoma (PEL), is a rare type of non-Hodgkin lymphoma that arises in the 
liquid phase in serous cavities 
171;210
. It is composed of cells that are variable in size and 
shape, have irregular nuclei and exhibit plasmacytoid features. The cells usually express 
CD45, CD138 but lack expression of CD20  About 20% of patients have detectable 
cytoplasmic immunoglobulin 
159;161
.  
HHV-8 is consistently positive and EBV is commonly present in PEL. In addition, there is 
usually a background of severe immunosuppression 
166
. It has been proposed that the 
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replacement of the inherent D-type cyclins with the HHV-8 encoded viral cyclin might help 
the cells to escape p27KIP1-mediated control 
211
.ASHM of the PAX5, RhoH/TTF, c-MYC and 
BCL6 genes is responsible for the pathogenesis in some cases 
103
. Microsatellite instability 
has also been reported in some cases 
95
. PELs are characterised by the high frequency of 
recurrent lesions which either involve a whole chromosome or gains of 2p, 7p, 7q,  whole 7, 
8q, 12p, 12 q, whole 12, 19p, 22q and LOH of 12q 
123;212
. 
 
1.3.4.4 Plasmablastic lymphoma  
Plasmablastic lymphoma (PL) was originally described as a PL of the oral cavity in the HIV 
setting 
213
. However, occurrences in extra-oral sites have been reported including stomach, 
skin, maxillary sinus, nasopharynx, small bowel, anus, lungs, soft tissues, heart and the 
spermatic cord 
214
. Plasmablastic lymphoma is characterised by a diffuse monomorphic 
cellular infiltrate. The cells have ample cytoplasm and eccentric nuclei with a prominent 
single nucleolus. These cases show prominent plasma cell differentiation, and the cells are 
CD20
-
, CD79a
-,
 CD45
-/+
, CD138
+
, MUM1
+
 and EMA
+
. The neoplastic cells usually show 
cytoplasmic light chain restriction. They are most often EBV-associated 
213;215-217
. More 
recently, c-MYC/IgH translocation has been described as the first genetic abnormality 
identified in plasmablastic lymphomas arising in HIV-infected patients 
218-220
. 
 
 
1.3.4.5 Primary CNS lymphoma 
Primary CNS lymphoma affects AIDS-patients with severe immunodeficiency. It is 
composed of cells which exhibit immunoblastic features  and express a B-cell phenotype and 
EBV-LMP-1 
194
. ASHM of RhoH/TTF and c-MYC genes plays a role in the pathogenesis of 
some PCNL cases
103
. Primary CNS lymphoma is characterized by a very few genomic 
aberrations and no recurrent chromosomal lesions 
123
. 
1.3.4.6 HIV-associated pPTLD-like lesions 
These constitute less than 5% of HIV associated lymphomas. They simulate pPTLDs and are 
often EBV-associated 
159
. 
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1.3.4.7 HIV-classical Hodgkin lymphoma (cHL) 
AIDS patients are 5 to 15 times more likely to develop cHL than the general population and the 
neoplasm is usually of the lymphocyte depleted or mixed cellularity subtypes 
221;222
. cHLs 
usually involves the lymph nodes, with a few cases presenting in the bone marrow or at other 
extranodal sites. Whilst most cases are EBV-associated, the less common cases of nodular 
sclerosis subtype are said to be EBV-negative 
222
. Moreover, it has been reported that the risk 
of developing cHL declines significantly with severe immunosuppression. This can be 
explained by the fact that RS cells secrete cytokines that can attract CD4+ T-cells and 
histiocytes. This in turn inhibits apoptosis or stimulates the proliferation of the RS cells. In 
patients with severe immunodeficiency, the RS-cells / RS-cell precursors fail to stimulate the 
CD4+ T-cell infiltration which is essential for their survival 
222
. EBV has been implicated in 
the pathogenesis of HIV-cHL, through the expression of LMP-1, as evidenced by its presence 
in 80-100% of the cases and the presence of clonal viral episome in the neoplastic cells. This 
supports the notion that EBV infection precedes the clonal expansion of the neoplastic cells 
174
.  
 
 
 
1.4 LYMPHOMAS DEVELOPING SECONDARY TO IMMUNOSUPPRESSIVE 
DRUGS. 
Immunosuppression-driven lymphoproliferative disorders occur in patients receiving 
immunosuppressive therapy 
223;224
. Patients receiving long-term methotrexate therapy and/or 
tumour necrosis factor-alpha (TNF-α), like adalimumab, infliximab and entanercept, for 
inflammatory diseases such as rheumatoid arthritis are more likely to develop 
lymphoproliferative disorders 
225;226
. Nearly 40% of methotrexate-related LPD are EBV-
associated. The mechanism that drives the increased risk of EBV-driven lymphomas is not 
well established, but it might be related to an effect of methotrexate on EBV reactivation 
and/or its direct effect 
227
.  
 
Methotrexate-associated lymphoproliferative disorders are very similar to EBV-driven PTLDs, 
and they usually regress with the reduction/withdrawal of methotrexate or the use of rituximab 
1;228
. Cases associated with TNF-α, however, do not regress following discontinuation of the 
drug. Morphologicaly, these lesions have features of DLBCL (35-60%), cHL (12-25%), 
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pPTLD (~15%) and follicular lymphoma (5-10%). BL, MALT lymphoma and peripheral T 
cell lymphoma, unspecified are less common 
225
. Although most of the lymphomas that 
develop following immunosuppressive therapy are non-Hodgkin lymphomas, there are a few 
case reports of methotrexate-induced cHL 
229;230
.  
 
1.5 EBV-POSITIVE DLBCL OF THE ELDERLY 
EBV-positive DLBCL of the elderly is an EBV+ clonal B-cell lymphoid proliferation that 
occurs in elderly (more than 50 years) patients without any known cause of 
immunosuppression or immunodeficiency
231;232
.  
1.5.1 Aetiology/pathogenesis 
It has been suggested that immunological deterioration due to the aging process affects 
patients older than 50 years 
233;234
. Quantitative or qualitative alterations of the T-cell 
population associated with aging, help EBV-infected B cells to evade the immune system and 
proliferate unchecked, resulting in development of EBV-positive DLBCL of the elderly 
235;236
. 
1.5.2 Morphology 
Age-related EBV+ DLBCL initially were morphologically divided into polymorphous and 
large-cell lymphoma subtypes 
237
. Both polymorphic lesions and large cell lymphomas 
include immunoblasts, many large transformed cells and Hodgkin / Reed-Sternberg-like giant 
cells 
231
. However, in the polymorphous subtype, there is a wide range of B-cell maturation 
and a variable reactive component composed of mature lymphocytes, histiocytes, epithelioid 
cells and plasma cells. In the DLBCL subtype, most of the cells appear to be transformed. 
Widespread areas of geographic necrosis can be seen in both subtypes. A variable 
morphology from area to area, pointing to the possibility that stages of evolution between the 
subtypes, sometimes is present. Both subtypes in the current WHO classification are 
classified as DLBCLs 
231
 
1.5.3 Immunophenotype 
EBV+ B-cells are positive for CD20 and/ or CD79a and are light chain restricted. BCL6 and 
CD10 are usually negative, whilst IRF4/MUM1 is commonly positive. Cases with the 
morphology of immunoblastic lymphomas with plasmacytoid features or plasmablastic 
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lymphomas are usually negative for CD20 but positive for cytoplasmic immunoglobulin 
231
.  
In addition, the large cells stain positive for CD30, EBV-LMP1 and EBNA2 in 
approximately 75%, 94%, and 28% of the cases respectively, but are negative for CD15 
237
. 
1.5.4 Genotype 
The detection of clonality of the immunoglobulin genes and EBV in both polymorphic and 
large cell lymphoma subtypes helps to distinguish polymorphous age-related EBV+ DLBCL 
from infectious mononucleosis and EBV+ reactive B-LPD in middle-aged or elderly patients 
237
. 
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1.6 PLASMACYTOID DENDRITIC CELLS (PDCs) 
1.6.1 Introduction 
There is a growing interest in the role played by plasmacytoid dendritic cells (PDCs) in many 
non-neoplastic and neoplastic human diseases. PDCs are potent antigen-presenting cells that 
originate from the hematopoietic stem cells in the bone marrow under the effect of some 
cytokines, principally Flt3L 
238
. PDCs migrate through the blood to lymphoid organs, 
including mucosal-associated lymphoid tissue, lymph nodes, the spleen and the thymus. In 
lymph nodes, they home into the paracortical T-cell areas close to the high endothelial 
venules 
239;240
.  
 
The average lifespan of PDCs in mice is approximately 2 weeks 
241
. PDCs constitute less than 
1% of total peripheral blood mononuclear cells 
242
. IL-3 prolongs the survival of PDCs that 
express high levels of the IL-3 receptor α-chain 243. It has been reported that mice with acute 
viral infections show a rapid transient decrease in the number of PDCs in lymphoid organs, 
which could in part be explained by an altered migration pattern in activated PDCs. Once the 
acute viral infection is resolved, the PDC count increases to normal within a few days 
238
. 
However, in some chronic viral infections such as HIV and Hepatitis B and C, PDCs are 
fewer and are functionally impaired 
238
. 
 
1.6.2 PDCs in viral infections 
PDCs play an important role in fighting viral infections through the expression of toll-like 
receptors (TLRs) 7, 8 & 9. PDCs produce type I interferon (IFN-I), which boosts the 
cytotoxic function of CD8
+
 T cells and NK cells. IL-6 and IL-12 are also produced by PDCs. 
IL-6 and IFN-I help the terminal differentiation of memory B-cells to plasma cells, which in 
turn generates antiviral antibodies, whereas the IL-12 and IFN-I together facilitate the 
production of IFN-γ in CD4+ T cells, CD8+ T-cells and NK cells 244-247.  
 
1.6.3 PDCs in HIV infection: 
PDCs express CD4 (the primary HIV-1 receptor), CXCR4 and CCR5 and in vitro they can be 
infected with the R5 and x4 strains of HIV-1. Whether PDCs can be infected with HIV-1 in 
vivo has been a matter of controversy 
248
. 
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It has been shown that the numbers of PDCs in peripheral blood correlate with CD4 counts 
and/or inversely correlate with viral load 
249
. A correlation has also been observed between 
decreased PDC counts, IFNα production and progression of HIV infection 250;251. It has also 
been reported that PDCs might protect against HIV because increased numbers of PDCs have 
been found in long-term non-progressors compared with healthy non-infected controls 
252
. 
Furthermore, the level of PDCs in patients who have undergone antiretroviral therapy is 
nearly normal. Based on these findings, it is hypothesised that therapeutic trials directed at 
preserving or boosting PDC function and count may be beneficial 
248
.     
Mechanism of depletion of circulating PDC in HIV-infected patient 
It has been postulated that in HIV infections, PDCs activated in peripheral blood redistribute 
to the lymph nodes in a manner similar to the redistribution of PDCs from the peripheral 
blood to the skin in Systemic lupus erythematosus (SLE)
253
. In asymptomatic, untreated HIV
+ 
patients, a reduction in PDC levels in the peripheral blood is accompanied by increased levels 
in lymph nodes 
248
. In chronically infected individuals, PDCs are redistributed to the 
lymphoid tissue and organs, including the spleen. In marked contrast, there are reports of a 
profound reduction of PDCs in the lymph nodes of HIV
+ 
subjects and in the tonsils of HIV-
infected children 
248
. It therefore seems likely that the recruitment of PDCs to the lymph 
nodes of HIV
+ 
patients does not explain the peripheral reduction of these cells, even though 
the lymph node-recruited cells possibly die rapidly 
254;255
. Whether the depletion of PDCs in 
advanced HIV infection could, in part, be due to bone marrow failure needs to be 
investigated. 
 
The link between PDCs and functional impairment in HIV
+ 
individuals has been investigated. 
TLR7/9 agonist failed to up-regulate the expression of maturation markers and CCR7 in 
PDCs obtained from HIV-infected donors 
256
.  Moreover, the defective PDC-mediated NK 
activity in viraemic HIV infection has been largely attributed to an inappropriate response of 
NK cells to INF-α, a response that is required for the optimal PDC-NK cell interaction 257;258. 
HIV gene products have been shown to play a direct role in inhibiting IFN-α. In addition, 
impaired PDC-induced NK cytolytic activity has been attributed to trimeric gp120 
259
. INF-α 
can be produced by cell-free HIV-infected PDCs, in a similar way to many other viruses 
248
. 
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1.6.4 PDCs in the post-transplant scenario: 
In the post-transplant scenario, EBV-stimulated PDCs produce insufficient concentrations of 
IFN-α. Furthermore, the numbers of circulating blood PDC precursors are reduced in renal 
and cardiac transplant recipients. These are thought to play a significant role in the 
development of lymphoproliferative disorders 
260;261
. In addition, EBV-stimulated PDCs 
produce the immunosuppressive cytokine IL-10, thereby allowing the virus-infected B-cells 
to escape immune-recognition 
262
. IL-10 inhibits expression of co-stimulatory molecules, 
which in turn results in inability of monocytes and macrophages to activate T-cells 
263
 . In 
addition, IL-10 suppresses the production of IFN-α and IFN-γ by PDCs, T-cells and NK cells 
Figure 1-4. It also has an inhibitory effect on antigen-specific activation and proliferation 
264;265
.  It has been suggested that serum IL-10 levels could be used as a biomarker for the 
early diagnosis and follow up of EBV-driven PTLD 
83;266
. PDCs can be identified through 
their expression of CD45RA, CD123 (IL-3R), Blood dendritic cell antigen 2 (BDCA2) and 
BDCA-4 
238;267
 . Although PDCs may express granzyme B, they lack perforin expression 
268
. 
 
Ullrich et al, 
269
 investigated the PDC/NK cell interaction in human and murine tumours. 
They found that in the presence of IL-2 (but not IL-3), mouse PDCs stimulate resting NK 
cells in vitro. In humans, freshly isolated CD56
+
, CD3
-
 NK cells incubated with IL-2 and 
added to GEN2.2 (PDC cell line) induced the secretion of TNF- α and IFN-γ and the up-
regulation of TRAIL on NK cells 
269
. The latter effect was associated with lysis of target 
cells. Based on the finding that no interaction could be found in the absence of IL-2, IL-2 was 
thought to play a crucial role in mediating the synergistic effects between PDC and NK cells 
in the absence of either viral stimuli or TLR9
269
. 
 
1.6.5 PDCs and tumours 
It has been suggested that the peri-tumoural infiltration of PDCs in cutaneous melanomas 
may have two functions: immune-regulation and the enhancement of tumour-specific CTC 
responses
270;271
. Moseman et al, 
272
 , using in-vitro experiments, suggested that PDCs have 
the ability to induce CD4
+
, CD25
+ 
Regulatory T cells (Tregs). In addition, PDCs, through the 
activation of Tregs, could have a suppressive effect on the anti-tumor cytotoxic T cell 
response 
273;274
. The observation that a synthetic TLR9 agonist can activate PDCs raises the 
possibility of its use in the treatment of metastatic melanoma
275
. However, on the other hand, 
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in primary localised breast tumours, PDC infiltration correlates with an adverse outcome. 
PDCs, therefore, probably play a multifaceted role in the cancer 
276
.  
 
PDCs have been studied in some malignant neoplasms and it has been shown that their levels 
are increased in squamous cell carcinoma, basal cell carcinoma, and cutaneous T cell 
lymphoma 
242
. PDCs are markedly decreased in number and qualitatively altered in non-
Hodgkin‟s lymphoma compared with reactive lymph nodes 242. However, in some cases of 
classical Hodgkins lymphoma (cHL) there are increased numbers of PDCs present which 
may be attributed to the cytokines released in the microenvironment of cHL 
242
. The 
observation of PDC clusters in tumour samples suggest that PDCs may also play an important 
role in the pathogenesis of cutaneous marginal zone B-cell lymphoma 
277
. 
 
1.6.6 PDCs in non-neoplastic inflammatory conditions 
PDC numbers are considerably increased in lymph nodes involved by various inflammatory 
conditions such as sarcoidosis, infections such as tuberculosis and toxoplasmosis, and 
particularly in Kikuchi-Fujimoto lymphadenopathy and Castleman disease 
242
. PDCs react to 
antigens by releasing IFN-α and they can also induce the expansion of CTCs and CD4+ Th-1 
cells 
277
. It is clear therefore, that mechanisms exist by which PDCs could play a critical role in 
the pathogenesis of these disorders. 
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Figure 1-4 A proposed model of the pathogenesis of EBV infection in the development 
of PTLD in solid organ transplant recipients. 
 (1) EBV infects B-cells and stimulates the production of the IL-10 which inhibits dendritic 
cell, CTC, and NK cell function. IL-10 may be an autocrine factor for EBV-infected B-cell 
proliferation. (2) EBV also interacts with PDCs, which produce IFN-α and IL-10. (3) PDCs 
in turn activate CTCs and NK cells via cell–cell contact (rather than via IFN-α) to produce 
IFN-γ and lyse EBV-infected cells. (4) Following post-transplantation immunosuppression, 
the number of circulating PDCs is reduced, leading to decreased effector cell activation and 
the potential development of uncontrolled B-cell proliferation and thereby 
lymphoproliferative disorder. Adapted from Lim et al, 
278
 
* CTC, cytotoxic lymphocyte; EBV, Epstein - Barr virus; IL-10, interleukin-10; IFN, 
interferon; NK, natural killer cell. 
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1.7 Tumour-infiltrating lymphoid and natural killer (NK) cells 
1.7.1 Role of microenvironment in lymphomagenesis 
The tumour microenvironment is composed of several subtypes of benign cells such as 
lymphocytes, macrophages, myeloid cells, adipocytes, and fibroblasts. The neoplastic cells 
acquire various properties as a result of the surrounding non-tumoural cells 
279
. The tumour 
microenvironment is an important culprit, not only in the development of cancer but also in 
its progression 
280;281
 .The possible relationship between chronic inflammation and the 
development of cancer was first suggested by Virchow in 1863 
282
. The increased risk of 
developing gastric cancer in patients with Helicobacter pylori-associated gastritis, 
hepatocellular carcinoma in patients suffering from hepatitis C viral infection, and colon 
cancer in patients with autoimmune diseases such as ulcerative colitis  support the role of 
inflammation in oncogenesis 
283-286
.   
For many years, the immune system was thought to have an anti-tumour effect. This, 
however, is too simplistic a view. In reality, the interactions between the tumour cells and the 
tumour-immune microenvironment seem to be much more complicated. The complexity of 
interactions stems from the numerous and contradictory reports on the numbers and types of 
tumour infiltrating lymphocytes (TILs) within different malignant tumours, and the 
correlation of these with prognosis. For example, in patients with melanoma, there are reports 
associating greater numbers of TILs with improved prognosis 
287
. In contrast, other reports 
have not found any such association
288
. The lack of TILs in a proportion of primary 
cutaneous melanomas has been suggested to be a predictor of sentinel lymph node metastasis, 
and sentinel lymph node involvement has been described as the most important predictor of 
survival in patients with melanoma 
289
.  
 
1.7.2 T lymphocytes and their subpopulations 
T lymphocytes develop in the bone marrow from their precursors, and then migrate to the 
thymus where they mature. They are the effector cells of cellular and cell-mediated 
immunity. CD3 is a common lineage marker expressed on T lymphocytes. There are two 
main subsets of T cells: a) CD4+ Helper (Th) T cells that recognize peptides presented by 
MHCII, and b) CD8
+
 cytotoxic T cells (CTC) that recognize peptides presented by MHC 
class I (MHCI). Th cells are further subdivided: Th1 cells secrete interferon (IFN)-γ and 
tumour necrosis factor (TNF)-α, Th2 cells secrete interleukin (IL)-4, IL-5 and IL-13, Th17 
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cells secrete IL17, and CD4
+
 T reg cells 
290
.  Similarly, CTC are divided into CTC1, CTC2, 
CTC17, as well as regulatory CD8
+
 cells 
291-293
.  
1.7.2.1 Cytotoxic T lymphocytes (CTC) 
Both CD8
+
 CTC and natural killer (NK) cells play a crucial role in mediating the anti-tumour 
response by directly killing target cells and through the release of IFN-γ 296. There is a cross-
talk between NK cells, CD8
+
 T cells and tissue-resident dendritic cells (DCs). NK cells 
produce IFNγ, which aids the maturation of DCs and regulates the effector function of CD8+ 
T cells. Meanwhile, DCs and activated T cells release cytokines that in turn boost the NK 
cells‟ effector functions 297. 
 
During the early course of HIV-1 infection, numbers of CD8
+
 T cells show a moderate rise, 
which is transient in most cases, followed by a decline in parallel with the depletion of CD4+ 
T cells 
298
. However, persistent elevation of circulating CD8
+
 T cells with visceral 
involvement, mainly salivary glands and lung, in response to HIV-1 infection, has been 
described in certain group of patients 
299
.  CD8
+
 T-cells are thought to play a central role in 
the host defence against primary and chronic phases of HIV infection. The CD8
+
 T-cell 
response against HIV is accomplished through two main mechanisms; a cytotoxic T-cell 
response and non-cytolytic suppression of HIV
300;301
. An oligoclonal expansion of CD8
+
 T-
cells with restricted TCR Vβ repertoire is seen in adults with acute and chronic HIV infection 
301;302
. A strong CD8
+
 T cell response that is characterised by the proliferation of oligoclonal 
populations of CD8
+
 T-cells can be driven by HIV or/and EBV. These clonal expansions can 
be very large  and may persist with specific clones dominating 
301;303-305
.  Normal elderly 
individuals, HIV-infected infants and some HIV-infected patients with CD8
+ 
lymphocytosis 
have been described as having a monoclonal expansion of T cells 
306-308
.  
The impact of the CD8+ CTCs in the tumour microenvironment to the tumour biology and 
patient behaviour is variable. In prostatic carcinoma, the number of granzyme B+ TILs 
negatively correlates with prognosis 
309-311
. In PTLD, however, high numbers of tumour-
infiltrating CD3
+‏ T-cells and TIA-1‏+ CTC have been reported to be predictors of favourable 
overall survival and progression free survival in PTLD 
312
. This may indicate that the 
antitumour immune response, through microenvironment-infiltrating lymphoid cells, is 
relatively preserved. Richendolla et al‟s conclusion has been reinforced by the finding that 
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CTC can directly kill tumour cells through apoptosis 
313;314
. Treg cells, which may potentially 
oppose such an effect, however, were uniformly low and lacked correlation with outcome 
312
. 
1.7.2.2 T helper cells 
The differentiation of CD4+ T cells into Th1 and Th2 cells is mediated by IL-12 and IL-4 
respectively, whilst the differentiation into Th17 cells is enhanced by both IL-6 and TGF-β. 
Th17 cells produce their effect via the secretion of IL-17A, IL-17F, IL-21 and IL-22  
290;315;316
. CD4+ cells play a role in helping antibody production, initiating and maintaining 
CTC numbers and function, and they also have the ability to exert direct effector activity 
317-
319
. Merlo et al, 
320
, using a mouse model of PTLD, have developed EBV-specific CD4+ T 
cell cultures characterized in vitro by a cytotoxic activity similar to that of CD8
+
 cells. CD4+ 
cells alone in vivo, however, showed reduced efficacy. The positive role of pure CD4+ T cell 
populations in anti-tumour therapy has been mainly attributed to cytokine release and 
recruitment of other effector cells 
321
.  
Th17 cells have been reported in the microenvironment of ovarian, prostatic, and gastric 
tumours, which suggests Th17 cells might be involved in the pathogenesis of these cancers 
322-324
. In prostatic carcinoma, it is thought that Th17 and/or T reg cells (rather than Th2 T 
cells) are involved in the development or progression of prostate cancer 
323
. In hepatocellular 
carcinoma, higher numbers of Th17 cells have a negative impact on prognosis. The 
predominant effects of Th17 cells appear to be through secretion of IL17 
325
.  
In a murine experimental model, it has been shown that expression of cell line-induced IL-17 
promotes angiogenesis, which in turn facilitates tumour growth, IL-17 depletion delays the 
development of chemically-induced papillomas 
326-328
. Furthermore, the knockdown of the 
IL-17 receptor in the 4T1 mouse mammary tumour cell line results in shorter survival of 
tumour cells and slower tumour growth 
329
.     
1.7.2.3 Regulatory T cell lymphocytes (Treg cells) 
Over the past few years, there has been a growing interest in Treg cells, which have come 
under intense investigation in human diseases 
330
. The identification of large numbers of T 
reg cells in the peripheral blood of cancer patients, within the tumour microenvironment or in 
lymph nodes draining tumours reflects their role in cancer-induced immunosuppression 
331-
334
. Treg cells became the focus of interest after a population of CD4
+
 T lymphocytes with 
high levels of CD25 expression capable of preventing autoimmunity in mice was discovered 
335
. Although these CD4
+
, CD25
+
 T reg cells account for only 1-2% of the circulating CD4
+
 T 
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cells in humans, they contribute approximately to 10% of the CD4
+
 T lymphocytes in the 
spleen and lymph nodes of normal (uninfected) mice 
336;337
.  
 
In humans, FOXP3+ cells can be CD25 
high
 or CD25 
low
 
338
. In mice, FOXP3 expression has 
been shown to be restricted only to Treg cells 
339
. In humans, the FOXP3 gene is located on 
Xp11.23. FOXP3 is a forkhead box transcription factor that  is expressed by Treg cells, and it 
serves as the “master regulator” of their development and function 340;341. Treg cells develop 
in the thymus 
342
.  
The impact of the numbers of Treg cells in the tumour microenvironment has been evaluated 
in several tumours. Tzankov et al 
343
 reported that higher numbers of tumour infiltrating 
FOXP3 + cells correlated with longer survival in patients with diffuse large B cell 
lymphomas (DLBCLs), follicular lymphoma, and cHL. On the other hand, increased number 
of TIA-1+ cells (a marker for CTC) together with reduced number of infiltrating FOXP3+ 
cells is associated with shorter survival in patients with classical Hodgkin lymphoma 
344
. The 
number of T regs has been shown to be increased in the B-cell lymphomas as compared to 
reactive lymph nodes or tonsils and this might be due to attraction of Treg cells through 
CCL22 secreted by the malignant cells. FOXP3+ cells may act to suppress the proliferation 
and cytokine production of other T cells and sometimes suppress B-cell lymphoproliferation 
as well 
345. The number of FOXP3+ cells negatively affects patients‟ prognosis in ovarian 
carcinoma 
346
. 
 
 
1.7.2.3.1 Types of regulatory T cells 
Several types of Treg cells have been identified. Among these are naturally occurring T reg 
cells and induced T reg cells. Naturally occurring Treg cells develop in the thymus and are 
exported in a fully functioning state 
347
. Induced Treg cells include; Treg1, Th3, and CD8 
expressing Treg cells. Treg1 cells are derived, under the influence of IL-10, from CD4
+
 T-
lymphocytes and are chronically active in both mice and humans. This subset produces high 
levels of IL-10, low level of IL-2 and no IL-4 and can suppress the proliferation of CD4
+
 T-
lymphocytes in response to antigens. Th3 cells can be generated in vivo after oral 
administration of antigen and produce TGF-β as well as IL-4 and IL-10 348-350. Xystrakis et 
al,
351
 identified a small population of regulatory cells which express CD8 and not CD4.  
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1.7.2.3.2 Functions of regulatory T cells 
It has been shown that Treg cells do not proliferate when stimulated via the TCR but can do 
so when stimulated by IL-2 
352;353
. Fontenot et al, 
338
 demonstrated that, in vivo, IL-2 
signalling is vital for preservation of optimal Treg cell function. When Treg cells undergo 
activation via their TCR, they inhibit the proliferation of CD4
+
 T lymphocytes & CD8
+
 T-
lymphocytes. This is accomplished by inhibiting IL-2 mRNA transcription in CD4+ and 
CD8+ T lymphocytes 
352;354
. With respect to Treg cells produced in the thymus (naturally 
occurring Treg cells), the suppression is mediated, however, via cell-contact rather than 
cytokines 
353;354
. Using a human model of B-cell non Hodgkin lymphoma, it has been 
reported that, in addition to their suppressor effect on the proliferation of CD8
+
 T cells, intra-
tumoural Treg cells have an inhibitory effect on the production and release of perforin and 
granzyme B 
355
. Perforin and granzyme B are necessary for the effector function of CD8+ 
cells and perforin/granzyme pathway has been reported to be crucial for CTC-mediated lysis 
of B-cell lymphoma cells 
356
. It has been suggested that the absence of Treg cells within the 
tumour microenvironment, would enable CTC to eradicate tumour cells 
355
. Furthermore, an 
inverse correlation has also been observed between the number of T reg cells and that of 
CD8
+
 T cells in biopsy specimens from patients with B-cell NHL 
355
.  
 
Treg cells also have the ability to suppress the production of IL-4 and IFN-γ, suggesting that 
FOXP3 may block the transcriptional activator that is required for the transcription of various 
cytokine genes 
357
. 
There are two main mechanisms by which Treg cells could inhibit the function of effector 
cells: cytokine-dependent (involving IL-10 and TGF-β for instance) and cell-cell contact 
dependent (via the perforin/Granzyme B pathway) 
358-361
. Activated CD4+CD25+ Treg cells 
have been shown to kill B-lymphocytes via a cell-contact dependant mechanism, achieved by 
the upregulation of perforin and granzyme B 
362
. Treg cells, through a direct effect on B-
lymphocytes, can also inhibit the production of immunoglobulins 
363
. 
Treg cells can suppress the growth of some tumours in addition to suppressing the anti-
tumour immune response through inhibition of cytokine production by the tumour cells 
364
. 
The latter effect allows the tumour cells to escape the host anti-tumoural T-cell immune 
response. These intratumoural FOXP3+ Treg cells have been shown to inhibit the 
proliferation and cytokine production of CD4
+ 
T cells 
345;365
. 
  
  
60 
 
Numbers of FOXP3‏ positive Treg cells are reported to be low in peripheral blood of solid 
organ transplant recipients on immunosuppressive drugs 
366
. Despite the lack of correlation 
between numbers of tumour-infiltrating Treg cells and clinical outcome, the role of Treg cells 
in the pathogenesis of PTLD cannot be ruled out 
312
.  
 
1.7.2.3.3 Treg cells and HIV infection 
Patients with chronic HIV infection and those with advanced disease in particular have a 
decreased number of circulating Treg cells 
337;367
. It has been suggested, therefore, that a 
direct cytopathic effect of HIV infection is responsible for the progressive loss of Treg cells. 
Patients who displayed strong HIV-specific Treg cell function showed higher CD4:CD8 
ratios and lower levels of plasma viremia than did those individuals with undetectable Treg 
activity 
368
. Based on these findings, it has been postulated that Treg cells play a crucial role 
during HIV infection by regulating immune activation. On the other hand, the finding that the 
tissue-infiltrating Treg cells are increased in HIV infection led to a suggestion that 
recruitment of Treg cells into tissues, and not loss of Treg cells, might explain decreased 
frequency of circulating Treg cells 
369-371
. There are, however, some contrasting reports 
suggesting that Treg cells inhibit HIV-specific immunity, allowing for uncontrolled viral 
replication 
368;372;373
. It has also been suggested that Treg cells receive survival signals from 
HIV 
370
. In addition, CD8+ Treg cells are a very heterogeneous population of cells in terms of 
phenotype and function. They exert a suppressive effect on the immune system, similar to 
that of CD4+ Treg cells. This effect is accomplished through either release of 
immunosuppressive cytokines such as IL-10 and TGF-β or cell-cell dependant contact 
inhibition, and this in turn results in HIV persistence 
374
. 
 
1.7.2.3.4 Treg cells in the tumour microenvironment of EBV-positive malignancies.  
Increased numbers of circulating and microenvironment-resident Treg cells have been 
reported in EBV-positive nasopharyngeal carcinoma and cHL patients 
375
. It has been shown 
that, in EBV-positive cHL, the EBNA1 antigen can up-regulate the expression of the 
chemokine CCL20 in the Reed-Sternberg cells. The chemokine CCL20 in turn can enhance 
the migration of Treg cells to the tumour microenvironment, which can suppress the patient‟s 
immunity against EBV, leading to tumour progression 
376
. It has been suggested that the 
LMP-1 epitope can stimulate the recruitment of HL-infiltrating Treg cells 
375
.  
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1.7.3 CD57 expression on lymphoma microenvironment  
CD57 positive cells account for 10-25% of the peripheral blood cells, which include CD8
+
 T-
cells and CD16
+
/CD56
+
 NK cells. Normal CD8
+
 CD57
+
 T-cells suppress generation of CTC 
cells in response to EBV-transformed lymphoblastoid cells. These cells preferentially 
mediate lectin dependent cytotoxicity 
377;378
. Within the lymphoid tissues CD4
+ 
CD57
+
 T-
cells specifically identify follicular T- helper cells (FTh), which also expresses BCL6, CD10 
and PD-1 and secrete the chemokine CXCL13. These cells are present in normal germinal 
centres and are also the normal lymphoid cell counterpart of neoplastic cells in 
angioimmunoblastic T-cell lymphomas 
379;380
. CD57 expression reflects the inability of 
lymphocytes to undergo new cell division cycles (replicative senescence). It has been 
demonstrated that expression of CD57 on CD4
+
, CD8
+
, and NK cells has a direct correlation 
with the number of cell divisions the cell has been through, and an inverse correlation with 
telomere length 
381
. Under normal circumstances, approximately 16% of CD8
+
 T cells 
express CD57, whilst during chronic immune activation and increasing age the number 
increases 
382;383
.  
CD4
+ 
CD57
+
 T-cells also form an important component of the microenvironment of nodular 
lymphocytic predominant Hodgkin lymphoma and follicular lymphoma. In follicular 
lymphoma cases, infiltration with predominantly CD57+ T cells tends to be associated with a 
significantly higher frequency of adverse manifestations 
384;385
. 
The percentage of CD8
+
 CD57
+
 cells rises in various clinical settings, notably infections that 
are dominantly associated with immune dysfunction; for instance, AIDS, tuberculosis, and 
cytomegalovirus infection 
386
. There are also some non-infectious diseases that show 
increased number of CD57
+
 cells; these include autoimmune lymphoproliferation, 
rheumatoid arthritis, multiple myeloma and common variable immunodeficiency. This 
phenomenon is also seen following hematopoietic stem cell transplantation 
386
.  
1.7.4 NK cells 
NK cells are a distinct type of cytotoxic lymphocytes that do not express either B cell surface 
immunoglobulin or T cell receptor. They play major roles in fighting virally-infected cells 
and tumour cells via direct mechanisms, death receptor mediated apoptosis and antibody-
dependant cellular cytotoxicity through release of cytotoxic granules 
387-389
.  
IFN-γ, produced by NK cells, plays a pivotal role in the induction of Th1 cells and the 
activation of antigen presenting cells 
390;391
.  Using an EBV-infected lymphoblastoid cell line 
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which simulates PTLD, it has been shown that an intact NK-cell mediated killing of EBV-
infected cells is required for the maximum effect of rituximab against PTLD 
392
. It has been 
suggested that the number of circulating viable NK cells might have an impact on the response 
of PTLD to rituximab 
312;393
. Wendel et al, 
393
 using in- vitro experimental models, have shown 
that the accumulation of NK cells within the tumour microenvironment is dependent on IFN-γ 
and the expression of CXCR3 by NK cells. Various types of cancers with high numbers of 
tumour microenvironment-resident NK cells have been shown to correlate with good prognosis 
and improved patients survival 
394;395
.  
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1.8 HYPOTHESES: 
We hypothesized that: 
1- Genetic and epigenetic mechanisms involving evolution and progression of IDLDs are 
distinct from those of lymphomas in immune competent patients.  
2- The microenvironment plays a major role in the pathogenesis of IDLD. 
 
 
 
1.9 OBJECTIVES:  
We aimed to: 
1- Subclassify disease groups in the background of the current understanding of gene 
expression-based classification of lymphomas.  
2- Investigate the viral association and the prevalence of different EBV genotypes among 
B-PTLD and HIV-BCL samples from patients diagnosed in England.  
3- Study rearrangements involving BCL2, BCL3, BCL6, c-MYC, IGH, PAX5, and MALT1 
loci in B-PTLD and HIV-BCL samples. 
4- Study the epigenetic changes (aberrant hypermethylation) involving DAP-kinase, and 
SHP1 genes in these diseases. 
5- Investigate the prevalence of PDCs, Treg cells, different T cells subsets, and NK cells in 
the microenvironment in these diseases. 
6- Define clonal populations with respect to their lineages within PTLDs.  
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Chapter 2 
MATERIALS AND METHODS 
2.1 Selection of cases.  
A total number of 183 cases were collected from 4 different centres. The cases included 89 
PTLDs, 36 HIV-associated lymphomas and 58 iDLBCLs. Ninety two cases were selected 
from the archives of the Hammersmith and Charing Cross Hospitals;10 PTLD, 24 HIV-
lymphomas and 58  iDLBCL, 21 cases were obtained from King‟s College; 16 PTLD and 5 
HIV-BCL; 21 PTLD cases from the Christie Hospital, and 42 PTLD cases from Harfield 
Hospital. Cases with very little or no tissue were excluded from further analysis. DNA was 
extracted from the remaining cases and assessed for integrity using multiplex PCR for control 
genes (BIOMED-1 protocol). Cases with absence of amplifiable DNA products were also 
excluded from subsequent PCR analysis. Seven HIV-cHL cases and 1 PT-HL and 3 cases T-
PTLD were also excluded from further analysis. The H&E slides of cases collected from the 
Hammersmith and Charing Cross Hospitals were retrieved from the archive while H&E 
slides were prepared from cases collected from other hospitals and then examined by 
Professor Naresh to confirm the diagnosis. Then areas of interest were marked to be arrayed 
as tissue cores onto the tissue micro-array blocks (TMA). Ethical approval for the study was 
obtained from the Hammersmith Research Ethics Committee. The proposal was exempt from 
site-specific approval in order to be able to accrue cases from other centres. 
 
2.2 Collection of patient information 
Patients‟ records and clinical data were reviewed retrospectively regarding age, gender, 
organs involved and biopsy site. 
 
2.3 Techniques employed 
The methods employed for this research included: a) Construction of tissue arrays b) 
Immunohistochemistry for analysis of the frequency of T-cell subsets and PDCs in the 
tumour microenvironment, classification of disease groups, detection of EBV-LMP-1 and 
HHV8-LANA-1; c) In-situ hybridization using Bond
TM
 ISH EBER (EBV encoded small 
RNA), κ and λ mRNA probes; d) Fluorescent in-situ hybridisation (FISH) for detection of 
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chromosomal translocations; e) CISH for conversion of the fluorescent signals into 
chromogenic ones; and f) Polymerase chain reaction-based methods were used for evaluating 
EBV-genotypes, clonality assessment (heteroduplex PCR) and methylation status of some 
genes (methylation-specific PCR). 
 
2.3.1 Tissue microarray (TMA) 
2.3.1.1  Manual tissue microarrayer 
The manual tissue arrayer (Beecher Instrument Inc. Sun Prairie, WI 53590) is an instrument 
that allows the researchers to array up to 1000 tissue samples in a single paraffin block. It 
works through two needles: one is used to make a hole in the recipient block and the other is 
used to obtain the tissue core from the donor block.  The array sections in this study were 
used for histological staining, immunohistochemical staining, in situ hybridization, and 
Fluorescent in situ hybridization. The most important advantages of tissue array technology 
include increased capacity and negligible damage to original tissue blocks. 
2.3.1.2 TMA Procedure 
An empty recipient block was placed in the holder and the smaller punch was switched into a 
vertical position which was then pushed downwards and rotated using the handle. The 
pushing pressure was released and the stylet used to empty the punch and the paraffin core 
was discarded. The pre-marked slides were aligned to the donor block and then moved away 
and the larger punch (1 mm) was switched into a vertical position and pushed downward to 
retrieve (free) the tissue cores (1-3 cores according to the tissue size in the block) from the 
corresponding areas of the block. A donor block of a different tissue (liver / placental tissue) 
was used to produce control cores to help identify the samples in the TMA easily. After 
retrieving the tissue core from the sample the punch was pushed downward into the hole 
created by the smaller punch and the larger stylet was used to empty the tissue core. After 
constructing the TMA, its surface was smoothed, to bring the tissue cores to the same level, 
before sectioning could be done. Four, two, and 3 array blocks were constructed for PTLD, 
HIV-related lymphoma and IC-DLBCL cases respectively.  
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2.3.1.3 Tissue sectioning 
Sixty 1µm thick serial sections were cut from each of the constructed microarray blocks 
using a rotatory microtome (Olympus Cut 4060 microtome). The sections were floated on 
distilled water at 37 °C for five minutes. The sections were picked up by labelled slides 
(SuperFrost® Plus) (VWR international) which were then allowed to dry at 37 C overnight. 
These slides were used for all immunohistochemical staining, ISH and FISH. 
 
2.3.2 Haematoxylin and Eosin staining (H&E) 
H&E staining was carried out on the first and the last serially cut slides to allow us to identify 
the different samples and confirm the diagnosis of each one. Briefly, sections were taken 
through 3 changes of xylene, hydrated through 2 changes of absolute alcohol and 1 change of 
70% alcohol and brought to running tap water for 1 min.  Slides were stained with Harris‟ 
Haematoxylin for 30 sec, and washed in running tap water for 3 min.  Slides were 
differentiated in 1% acid alcohol (1% HCL in 70% alcohol) for 5 sec, and again washed in 
running tap water for 3 min. Sections were stained with 1% eosin for 1 min and washed in 
running tap water for 3 min. Finally, sections were dehydrated through graded alcohols, 
cleared in xylene and mounted with DPX 
 
 
2.3.3 Immunohistochemistry (IHC) 
IHC is a method for precise localisation of cellular or tissue antigens using labelled 
antibodies. The antibody binding site can be recognised either by direct labelling of the 
antibody, by using a secondary labelled antibody, or a more sensitive three layer method. 
Tissue sections from TMA blocks prepared as described in section 2.3.1 were used. 
 
2.3.3.1 Procedure 
The detection system of choice was the Super Sensitive™ IHC polymer Detection (Biogenex, 
California, USA) unless otherwise stated. Sources and dilutions of antibodies used and 
different antigen retrieval techniques are shown in Table 2-1 
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The slides were deparaffinised in 3 changes of xylene, rehydrated through graded alcohol and 
brought to water. Endogenous peroxidase was blocked with peroxide block for 15 minutes. 
The slides were brought to tap water then subjected to antigen retrieval as required Table 2-1.  
 
Immunohistochemistry for all antibodies except CD123 and BDCA2 was carried out using 
standard procedures on BOND-MAX automated immunohistochemistry system (Leica 
Microsystems, Newcastle, UK). 
 
Immunohistochemistry for CD123 and BDCA-2 antibodies was carried out manually using 
sequenza rack as discussed below.  Antibodies (CD10, BCL6, MUM1 and CD138) were used 
to classify the lesions according to germinal centre or post germinal centre origin using a 
combination of criteria described 
70;396
. The cases were classified as having GC, activated-GC 
or non-germinal centre phenotypes when they had (CD10
+
, BCL6
+/-
, MUM1
-
 / CD138
-
), 
(CD10
+
, BCL6
+
, MUM1
+
 / CD138
+
), (CD10
-
, BCL6
-/+
, MUM1
+
 / CD138
+
) respectively 
Figure 2-1. Immunostains CD123 & BDCA-2 were used to assess the prevalence of PDCs in 
the tumour microenvironment, while FOXP3, CD3, CD4, CD8, CD56, CD57 and Granzyme 
B were used to assess the prevalence different T-cell subsets and natural killer cells in the 
tumour microenvironment. The rest of antibodies were used to confirm the diagnosis.   
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Figure 2-1: Diagram showing classification of DLBCL into GC, non GC and   activated GC 
subtypes 
70;396
  
 
 
2.3.3.2 Optimisation of CD123 & BDCA-2 antibodies  
These slides were deparaffinised in 3 changes of xylene, rehydrated through graded alcohols 
and brought to water. Endogenous peroxidase was blocked with 0.6 % H2O2 in water for 20 
min. Slides were placed back in water then transferred to a plastic container. Antigen retrieval 
was carried out by microwaving in EDTA at pH 9.0 for 20 min. For BDCA-2, antigen 
retrieval was carried out by microwaving in citrate buffer at pH 6.0 for 20 min initially. After 
cooling and washing in running tap water, slides were then transferred to Sequenza racks. 100 
µl of power block was applied for 10 minutes followed by 100 µl of diluted CD123 primary 
antibody (in dilutions of 1:100, 1:200, and 1:400) and diluted BDCA-2 primary antibody (in 
dilutions of 1:10, 1:20, 1:40, 1:80, 1:160) for 1 hour at room temperature. Slides were then 
rinsed with PBS for 5 min followed by incubation with Super enhancer for 20 min at room 
DLBCL
Positive for CD10
GC subtype
Negative for CD10
Negative for BCL-6 
Non-GC subtypePositive for BCL-6
Negative for MUM-1
GC subtype
Positive for MUM-1
Non-GC subtype
Activated GC subtype
Positive for BCL-6 and MUM-1
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temperature followed by PBS for 5 min and poly-HRP for 30 min. Slides were rinsed with 
PBS before DAB was applied for 4 minutes. Slides were checked using a microscope then 
brought to tap water. Slides were placed in copper sulphate for 2 minutes. Slides were 
counterstained with haematoxylin for 10 sec, dehydrated in graded alcohol, cleared with 
xylene and mounted in Pertex mounting medium. 
 
2.3.3.3 Double immunostaining (FOXP3 was combined with CD4, CD20 or CD25) 
Double immunostaining was carried out for selected cases only. Immunohistochemistry for 
FOXP3 using Bond polymer AP Red detection kit (Leica Microsystems, Newcastle, UK) was 
carried out first, using the Bond immunostainer according to the manufacturer‟s protocol. 
This was followed by CD4, CD20 or CD25 immunostaining using a peroxidase based 
detection system and diaminobenzidine (DAB) as the chromogen. 
 
2.3.3.4 Positive and Negative Control Slides 
For every run of immunostaining, normal human tonsil, reactive lymph node or spleen 
sections were used as positive control slides. Specific positive control slides were used for 
HHV8-LANA1 (Kaposi sarcoma) and EBV-LMP-1 (EBV-positive classical Hodgkin 
lymphoma) immunostains. As a negative control, PBS was used to replace monoclonal 
antibody whereas normal goat serum was used to replace polyclonal antibody. 
 
2.3.3.5 Analysis of Data 
Immunohistochemicaly-stained slides were examined using Olympus BX40 light 
microscope. For CD123, BDCA-2, FOXP3, CD3, CD4, CD8, CD56, CD57, and Granzyme B 
all positive cells were quantified in each of the tissue cores and then expressed as cells per 
mm
2
. In addition to PDC, CD123 was also expressed on some subsets of endothelial cells: a 
finding that has been reported in the literature 
277;397
. IL-3 released by T-lymphocytes has the 
ability to upregulate the expression of its receptor (IL-3 receptor-α chain) on high endothelial 
venule-like vessels in vitro 
398
. However, endothelial cell staining was diffuse and weak, and 
therefore, could be easily excluded from the counting. BDCA-2 staining was more specific 
for PDC. With regards to CD10, BCL6 and MUM1, a 30% cut-off was used.  
 
  
70 
 
Table 2-1 Sources and dilutions of antibodies used 
Antibody Clone  Source 
Clonality 
Retrieval method Dilution 
factor 
Manufactur
er 
BCL2 124 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:200 Dako 
BCL3 1EB Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:100 Novocastra 
BCL6 PG-B6P Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:20 Dako 
BDCA-2 124B3-13 Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:160 Cambridge 
biosciences 
CD3 LN10 Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:50 Novocastra 
CD4 4B12 Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:400 Novocastra 
CD8 1A5 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:50 Novocastra 
CD10 56C6 Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:20 Novocastra 
CD15 C3D-1 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:10 Dako 
CD20 L26 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:250 Dako 
CD25 4C9 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:100 Novocastra 
CD30 Ber-H2 Monoclonal 
Mouse 
20 min Dako retrieval 
solution, pH 6 
1:50 Dako 
CD45 (LCA) 2B11+PD7
/26 
Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:200 Dako 
CD56 
(NCAM) 
1B6 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:100 Novocastra 
CD57 (leu 7) NK1 Monoclonal 
Mouse 
No antigen retrieval  1:50 Novocastra 
CD123 (IL-3 
receptor α) 
7G3 Monoclonal 
Mouse 
20 min, EDTA, pH 9 1:400 BD 
Bioscience 
CD138 M1-15 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:100 Dako 
EBV-LMP-1 CS1-4 
(Cocktail) 
Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:50 Novocastra 
FOXP3 236A/E7 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:200 eBioscience 
Granzyme B 11F1 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:20 Novocastra 
HHV-8-
LANA1 
13B10 Monoclonal 
Mouse 
20 min MW, citrate 
buffer pH 6.0 
1:50 Novocastra 
MUM1 (IRF-
4) 
 M-17 Polyclonal 
Goat 
20 min MW, citrate 
buffer pH 6.0 
1:100 Santa Cruz 
PAX5 C-20 Polyclonal 
Goat 
20 min MW, citrate 
buffer pH 6.0 
1:200 Santa Cruz 
EBV, Epstein-Barr birus; EDTA, ethylene diamene tetraacetic acid, IL-3; interleukin-3, LMP, latent membrane 
protein; Min= minute, MW=microwave, BD Bioscience (Ireland, UK ) Cambridge biosciences (Cambridge CB5 
8LA, UK ); Dako (Carpinteria, California, USA); Novocastra, Newcastle upon Tyne, UK; Santa Cruz (Raleigh, 
North Carolina, USA) 
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2.3.4 In-Situ Hybridization (ISH) 
Tissue sections from TMA blocks prepared as described in section 2.3.1 were used. All 
reagents (Bond
TM
 Polymer Refine Detection kit) and probes used were purchased from 
(Vision Biosystems Newcastle upon Tyne, UK).  
2.3.4.1 Procedure  
mRNA in situ hybridization with EBER, κ and ג probes was carried out using BOND-MAX 
automated in-situ hybridization system (Leica Microsystems, New Castle, UK).  The system 
employs fluorescein-conjugated oligonucleotide probes. Probe hybridization is followed by 
application of anti-Fluorescein antibody and other procedures leading to signal detection as 
suggested by the manufacturer.  
 
The slides were placed in (Bond Max) where they were deparaffinised in dewax, rehydrated 
in alcohol and then washed using (Bond wash solution 10X) which was used after each step. 
The tissue was digested with proteinase-K, for 15 minutes at 37˚C before hybridization to 
allow the probe to penetrate to the target. The slides were hybridized at 37ºC for 2 hours with 
fluorescein-conjugated oligonucleotide probes followed by peroxide block (3% hydrogen 
peroxide) to block endogenous peroxidase. Anti-Fluorescein antibody was added for 15 
minutes followed by post primary polymer penetration enhancer for 8 minutes. This was 
followed by polymer poly-HRP antimouse/rabbit IgG for 8 minutes. Slides were washed 
using (Bond wash solution 10X) before Diaminobenzidine (DAB) was applied for 10 
minutes. Slides were counterstained with haematoxylin for 5 minutes, dehydrated in alcohol, 
cleared with dewax. The slides were then mounted manually in Pertex mounting medium. 
 
2.3.4.2 Positive and negative control slides 
For every run of ISH slides, human tonsil was used as a positive control for κ and λ probes 
and a known EBV-positive classical Hodgkin lymphoma case was used as a positive control 
for the EBER probe. Poly-dT probe against the poly-A tail of mRNA was used to assess 
RNA preservation in the tissue sections. As a negative control, RNA Negative Control Probe 
ASR designed from zebra fish was used. 
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2.3.5 Combined immunohistochemistry and in-situ hybridization (ImmunoISH) 
ISH using the EBER probe and with DAB as the chromogen was performed on paraffin 
sections using the Bond immunostainer according to the manufacturer‟s protocol (as 
described above). This was followed by immunohistochemistry for CD3 using Bond polymer 
AP Red detection kit (Leica Microsystems, Newcastle, UK). 
 
2.3.6 Fluorescent in-situ hybridization (FISH) 
Tissue sections from TMA blocks prepared as described in section 2.3.1 were used. FISH, a 
useful technique that involves the use of labelled DNA probes which hybridize to the target 
sequence of interest, helps identify numerical and structural chromosomal changes, which 
occur in many tumours, in either tissue or cytological preparations 
399
. Of the various FISH 
related techniques, metaphase and interphase FISH are the most commonly used. Metaphase 
FISH use in lymphoma diagnosis is limited by many factors: a) it requires large number of 
cells, b) it needs viable cell suspension, and c) lymphomas with a high mitotic index are more 
likely to yield metaphases. Therefore, interphase FISH is more widely used as it can be 
applied to paraffin sections, air-dried smears and nuclei isolated from fresh or frozen tissue or 
from paraffin embedded material 
400
. Of the main disadvantages of interphase FISH is the 
difficulty experienced in scoring in some situations due to sectioning and overlapping. When 
the breakpoints are widely separated as in cases of Burkitt lymphoma, PCR usually fails to 
detect rearrangements, however since FISH probes are large and can span in excess of 100 
Kb of the genome, it provides an advantage for FISH over PCR for detection of 
translocations 
399
. 
 
 
2.3.6.1 Procedure: 
The slides were deparaffinised, rehydrated then were immersed into pre-treatment solution at 
95˚C for 10 min. For the purpose of probe penetration, the tissue was digested with pepsin on 
heat block at 37˚C for 5 minutes. Slides were then dehydrated and allowed to air dry before 
10 µl of BCL2, BCL3, BCL6, c-MYC, PAX5, MALT1, and IGH, dual-colour split-apart probes 
(Dakocytomation, Denmark) were applied separately to the centre of tissue sections of each 
slide. IGK and IGL split-apart probes were used in cases positive for rearrangement of one of 
the investigated oncogene loci (BCL2, BCL3, BCL6, c-MYC, PAX5 or MALT1), but negative 
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for IGH rearrangement. The slides were then placed in a Spot-light
®
 CISH
TM
 hybridizer 
(Invitrogen, Paisley, United Kingdom) for 5 minutes at 82˚C, for the purpose of denaturation, 
followed by 18 hours incubation at 45˚C for the purpose of hybridization. The slides were 
then incubated in stringency buffer at room temperature for 5 minutes, transferred into fresh 
stringency buffer at 65˚C for 10 minutes (to remove unbound probes), dehydrated in an 
ethanol series and mounted with a DAPI-based mounting medium. The slides were then 
screened using a fluorescent microscope. The cases were scored positive for breakpoints 
when the distance between the red and the green signals was more than the size of a single 
signal. A minimum of 50 nuclei were examined in each core.   
 
2.3.6.2 Interpretation of FISH results:  
The slides were then examined using (Olympus Bx41) fluorescence microscope and 
assessment was carried out, and cases were scored positive when the red and green signals in 
each nucleus were widely separated and negative when the two colours were co-localised or 
fused giving a yellow colour. Then images were captured using (Hamamatsu ORCA-ER) 
digital camera. 
 
2.3.7 Conversion of FISH signals into chromogenic signals (CISH): 
This is a technique that involves conversion of fluorescent signals into chromogenic ones, 
and such signals are usually permanent and can be interpreted using light microscopy. It was 
performed using Dako DuoCISH kit (Dakocytomation, Denmark) to confirm the FISH 
results. After the slides were screened using the fluorescence microscope, they were washed 
with Dako wash buffer for 3 minutes. The sections were covered with peroxide block for 5 
minutes then washed twice in the wash buffer. The slides were then covered with CISH 
antibody for 30 minutes and washed twice in wash buffer. Red chromogen was added to the 
sections, incubated for 10 minutes at room temperature then washed twice in wash buffer. 
This was followed by blue chromogen for 10 minutes and then the slides were washed twice 
in wash buffer. The slides were left to air dry before applying thin Aquaperm mounting 
medium. Slides were then cover slipped. 
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2.3.8 Polymerase chain reaction (PCR) 
PCR-based techniques involve amplification of specific target sequence of DNA. They 
remain the most widely used first-line strategy for molecular diagnosis of lymphomas that are 
not diagnosed by immunomorphologic approach 
399
. 
2.3.8.1 DNA extraction from formalin fixed paraffin embedded (FFPE) tissue:  
2.3.8.1.1 Procedure  
DNA was extracted from FFPE tissues using a commercially available kit (DNeasy Blood & 
Tissue Kit, Qiagen, Crawley - West Sussex, UK). Briefly, two 15 µm sections were cut using 
a rotatory microtome (Olympus Cut 4060 microtome) and were placed in 1.5 ml Eppendorf 
tubes. Blades were changed in between the samples to avoid cross contamination. Sections 
were deparaffinised then incubated with proteinase K and lysis buffer according to the 
QIAGEN protocol in a shaking water bath (Shaker bath SBS30, Stuart Scientific, UK) at 
55ºC overnight. The remaining steps were according to the provided protocol. The elution 
step, however, was repeated twice using 60 µl and 50 µl Tris/EDTA (TE) buffer (provided) 
for maximum elution of DNA.  
2.3.8.1.2 Measuring DNA 
The concentration and quality (260:280 ratio) of the eluted DNA were measured on a 
Nanodrop 1000 spectrophotometer (Thermo Biosciences). The DNA stock was kept at -80ºC 
and a small aliquot of it was made to 100 ng concentrations and kept at -20ºC. 
2.3.8.1.3 Assessment of DNA integrity for amplification 
A multiplex PCR for control genes was performed to ascertain the integrity of the DNA using 
BIOMED primers (Invitrogen, Paisley UK) 
401
. Figure 2-2.  
 
 
 
 
 
  
75 
 
 
 
Figure 2-2 Multiplex PCR for 5 control genes in representative PTLD samples: 
M100-100 bp ladder; lanes 1-7- PTLD samples; N- negative control; samples 2 & 5 
yielded 5 PCR products; samples 4 & 7 yielded 100, 200, 300 and 400 bp PCR products; 
sample 3 yielded 200 bp products;  sample 6 yielded only the 100 bp product; sample 1 
did not yield any products (was excluded from further analysis); Polyacrylamide gel 
(10%). 
 
2.3.8.2  PCR for clonality assessment 
2.3.8.2.1 Procedure 
PCR was carried out to assess the clonality using BIOMED-2 primers 
401
(Invitrogen). All the 
reagents used were purchased from (Invitrogen). All the primer sequences and amplicon sizes 
are shown in Appendix B. Ten cases of DLBCL in immunocompetent patients and 10 cases 
of reactive hyperplasia of the lymph nodes were used as a control. Cases with amplicons 
>200 bp in size were considered adequate and used for subsequent assessment of clonality. 
DNA was used in two different concentrations, 50 and 100ng and better results were obtained 
with 100 ng. Master mix was prepared as described in Appendix A.  
All cases were investigated for T-cell receptor gene rearrangements (TCRβ, TCRγ, and TCRδ) 
and for B-cell receptor gene rearrangements (IGH, IGκ and IGג). The BIOMED-2 PCR 
protocol was followed with minor modifications 
402
. The test was performed in duplicate. For 
every run, a positive control (DNA from a known positive case which had earlier 
demonstrated a clear monoclonal PCR product), a negative DNA control and a no-DNA 
negative control (master mix with no DNA) were used. The Perkin Elmer GeneAmp PCR 
system 2400 thermal cycler was used to carry out all PCR reactions. The PCR protocol 
consisted of initial denaturation at 95ºC for 10 min then 35 cycles as follows: primer 
annealing (30 sec at 64ºC), elongation (45 sec at 72ºC) and primer disassociation (45 sec at 
95 ºC). The PCR was terminated with a final extension at 72 ºC for 10 min. All PCR products 
M100             1               2               3                4                 5                 6                7      N  
400 bp
200 bp
100 bp
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were subjected to electrophoresis in a 2% agarose gel, run for for 45-60 minutes at 100V and 
visualised by staining with Sybersafe DNA stain (Invitrogen) then imaged using an ultra 
violet gel imager (Alpha Innotech, UK). Agarose gel was prepared as described in Appendix 
C.  
2.3.8.2.2 Heteroduplex analysis 
Once the presence of PCR products had been confirmed, heteroduplex analysis was carried 
out according to the standardized protocol of BIOMED-2. Briefly, PCR products were 
denatured at 95ºC for 5 min then re-annealed at 4ºC for 60 min. Seven µl of each product was 
mixed with 2 µl non-denaturing Blue/Orange loading dye, 6X (Promega) and then subjected 
to electrophoresis in a 10% polyacrylamide Novex TBE Precast gel loaded into an XCell 
SureLock™ Mini-Cell with TBE running buffer (all Invitrogen) for 1 h at 100 V. The 
products were visualized by staining with Sybersafe DNA stain (Invitrogen). After 
electrophoresis, the gels were washed twice in TBE buffer and then imaged using an ultra 
violet gel imager (Alpha Innotech, UK).  An illustration of heteroduplex analysis technique is 
shown in Figure 2-3& Figure 2-4. 
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Figure 2-3 Diagram of the principle of heteroduplex analysis technique. 
In samples composed only of monoclonal lymphoid cells, the PCR products of rearranged Ig 
of TCR genes will form homoduplexes after denaturation and renaturation (left panel). On the 
other hand, samples which contain only polyclonal lymphoid cells, the PCR products will 
form heteroduplexes upon renaturation (right panel). In samples containing both polyclonal 
and monoclonal lymphoid proliferations, however, both hetero and homoduplexes will form 
(middle panel). On electrophoresis, homoduplexes with perfectly matching junctional regions 
will migrate more rapidly than molecules with less perfectly matching junctional region 
(adapted from Langerak et al 
403
). 
 
 
 
 
Monoclonal cells
Monoclonal cells in 
polyclonal background
Polyclonal cells
Denaturation /  Renaturation
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Figure 2-4 Gel images of PCR products before and after heteroduplex   
 
Gel, A represents amplicons before heteroduplex analysis: lane 1 is a case of T-cell 
lymphoma showing a clear band; lane 2 is a case of reactive hyperplasia of lymph node; lane 
3 is a case of suspected T-cell lymphoma before heterodulplex analysis. Gel, B represents 
amplicons after heteroduplex (denaturation then rapid renaturation) analysis: sample 1 shows 
a clear band with a background of smear (monoclonal), whereas samples 2 and 3 showed 
only smears (polyclonal). N-negative control  
 
2.3.8.2.3 Analysis of the clonality results 
The results were analysed as being: monoclonal when 1-2 dominant bands within the 
expected size range were identified, either alone or with a background of multiple weaker 
bands or a smear. They were considered to be oligoclonal when there were three or more 
bands which may be superimposed on a polyclonal background and polyclonal when there 
was either a ladder of bands or a smear over the expected size-range. A “no signal” 
designation was made when there was no product or only weak bands outside the expected 
size range were identified 
404
. 
 
2.3.8.3 Methylation-specific PCR 
It is one of the methods used to detect the aberrant hypermethylation status of the CpG 
islands of different genes. The principle of methylation-specific PCR is illustrated in Figure 
2-5.      
                                          
1                2    3                 N
A
B
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2.3.8.3.1 DNA Bisulphite conversion 
The DNA was modified according to the manufacturer protocol using MethylCode Bisulphite 
conversion kit (Invitrogen). Briefly, ~750ng was brought to a volume of 20μl using RNase-
free water. Then, 130 μl of CT Conversion reagent were added to the 20 μl of DNA sample in 
a PCR tube and mixed by pipetting up and down. The tube was placed in a thermal cycler for 
10 min at 98ºC (DNA denaturation) followed by 2.5 hours at 64ºC (Bisulphite conversion).  
600 μl of binding buffer was added to a spin column in a collection tube and was followed by 
the addition of 150 μl, obtained from the previous step. The two solutions were mixed and 
centrifuged at full speed for 30 sec and the flow-through was discarded. This was followed by 
addition of 100 μl of wash buffer to the column and centrifugation at full speed for 30 sec and 
the flow-through was discarded. Then 200 μl of desulphonation buffer were added to the 
column and let at room temperature for 15 minutes and centrifuged at full speed for 30 sec 
and the flow-through was discarded. The last step was repeated one more time and the spin 
column was then transferred to a new clean microcentrifuge tube where 10 μl of Elution 
buffer were added directly to the column matrix and centrifuged at full speed for 30 sec. The 
flow-through (bisulphite converted DNA) was collected and stored at -20C˚ till use.  
2.3.8.3.2 DNA amplification 
All PCR reagents for both unmethylated and methylated reactions were purchased from 
(Invitrogen) unless otherwise specified. 
Two (2) μl of the modified DNA were used in a PCR volume of 25 μl for both unmethylated 
and methylated PCR reactions. Hot start Platinum taq DNA polymerase was used in a 25 μl 
final volume. Master mix was prepared as described in Appendix A. The experiment was 
performed in duplicate. For the methylated reaction, (DNA from a known positive case which 
had earlier demonstrated a clear band with primers to identify methylated DNA) and DNA 
from normal peripheral blood lymphocytes were used as positive and negative control 
respectively. For unmethylated reactions, DNA from peripheral blood lymphocytes and water 
were used as positive and negative controls respectively.   
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Figure 2-5: An illustration showing the principle of methylation-specific PCR. 
 
 
DNA from peripheral blood lymphocytes of eight different individuals was used as negative 
controls. The samples were initially denatured at 95ºC for 15 min followed by 40 cycles of 
amplification for 45 sec at 95 ºC, 30 sec at the required annealing temperature (variable 
temperatures according to each primer pair) Appendix B and for 45 sec at 72ºC. The 
programme was then ended with final extension at 72 ºC for 10 min. All PCR products were 
subjected to electrophoresis in 10% polyacrylamide Novex TBE Precast gel and visualised 
using an ultra violet gel imager (Alpha Innotech, UK).  
2.3.8.3.3 Interpretation of the results: 
The cases were interpreted as positive when a clearly visible band of the expected size was 
detected with the primers specific for methylated reaction.  
 
 
 
DNA 
Chemical modification 
Unmethylated Cytosine changes to 
Uracil
Methylated Cytosine remains 
unchanged
Amplification product
Primers for UR Primers for MRPCR
Amplification product
DNA was originally methylatedDNA was originally unmethylated
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2.3.8.4 PCR for EBV genotyping  
2.3.8.4.1 Procedure 
100 ng of DNA was used in a 25 µl volume of master mix, in duplicate to verify the results, 
(Invitrogen) for PCR analysis using primers for EBNA3C Appendix B.   
The reaction was performed with an initial denaturation at 95 °C for 10 minutes followed by 
35 cycles of amplification (95 °C for 30 sec, 58 °C for 45 seconds and 72 °C for 45 seconds) 
and a 20 minutes extension at 72 °C in a thermal cycler. The PCR products were 
electrophoresed on agarose gel 2% and stained with Sybersafe (Invitrogen). In case the 
products were too weak to be visualized on agarose gel, 10% polyacrylamide gel was used. 
EBV strains A and B yielded an amplification product of size 153 bp and 246 bp fragment 
length respectively. DNA from a lymphoblastoid cell line infected with type-B-EBV was 
used as a positive control. PCR products of 5 samples were sequenced to confirm the 
sequence. For each run of PCR, tests without DNA and DNA from reactive lymph node 
negative for EBV were used as negative controls. 
2.3.8.4.2 Direct sequencing of PCR products 
After visualisation of PCR products on agarose gels, the primers and dNTP‟s were removed 
prior to sequencing through diluting the PCR product in distilled water at the ratio of 1:25 to 
1:50. The sequencing reaction was then performed using a BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems). The reaction mix was prepared as described in 
Appendix A.  An ABI 3130 thermal cycler (Applied Biosystems) was used to carry out the 
cycle sequencing reaction. The samples were initially denatured at 94ºC for 1 min followed 
by 25 cycles of amplification for 10 sec at 96 ºC,5 sec at  50 ºC and for 4 min at 60ºC. DNA 
from the cycle sequencing reaction was precipitated by adding 50μl of ice-cold 100% 
ethanol, 2 μl of 3M Sodium acetate and 2 μl l of 125mM EDTA to each well, followed by 
centrifugation at 3400rpm for 30 minutes. The precipitation step was repeated. The alcohol 
was then removed by brief centrifugation and the precipitated DNA was resuspended in 10 μl 
Hi-Di Formamide. Capillary electrophoresis was then performed on an ABI3700 DNA 
Analyzer. 
  
  
82 
 
Chapter 3 
DISEASE CLASSIFICATION, MORPHOLOGY AND IMMUNOPHENOTYPE. 
3.1 Disease classification, morphology and immunophenotype 
The sixty-six cases of B-PTLD consisted of: one case of plasma cell hyperplasia with 
inappropriate excess of kappa-light chain positive
 
cells, 4 IM-like lesions, 19 cases of 
polymorphous PTLD and 42 cases of monomorphic B-PTLD (30 diffuse large B-cell 
lymphoma (DLBCL), 2 plasmacytoma-like and 1 lymphoplasmacytic lymphoma, 6 
plasmablastic lymphoma (PL), and 3 Burkitt lymphoma (BL)).  
The case of plasma cell hyperplasia with inappropriate excess of kappa-light chain positive
 
cells showed preserved nodal architecture with moderately hyperplastic follicles and a 
markedly expanded plasma cell population with a kappa:lambda light chain ratio of about 
10:1 (in-situ hybridisation). The cases of IM-like lesions showed preserved architecture of 
affected tissues. The infiltrate was composed of numerous immunoblasts in a background of 
T cells and plasma cells. The cases of polymorphous PTLD showed effacement of the tissue 
architecture and replacement by sheets of medium-sized cells with plasmacytoid features. 
Most of the cells lacked prominent nucleoli. Foci of geographic necrosis were seen. Islands of 
larger cells resembling immunoblasts and mononuclear variants of Reed-Sternberg cells (RS) 
were also seen within the infiltrate. The cells in the majority of cases showed kappa light 
chain restriction whilst 3 cases showed lambda light chain restriction Figure 3-1.  
The two cases of monomorphic B-PTLD with plasmacytoma-like features showed a diffuse 
infiltrate of atypical and pleomorphic plasma cells displaying prominent nucleoli and kappa 
light chain restriction. The immunophenotype also suggested a plasma cell stage of 
differentiation because of the absence of PAX5 expression and the expression of MUM1 and 
CD138 in these two cases. The two cases lacked EBV- association.  
The case of monomorphic B-PTLD (lymphoplasmacytic lymphoma) was diagnosed on bone 
marrow trephine. The case showed infiltration by a kappa light chain restricted neoplastic 
infiltrate, composed of small lymphocytes, lymphoplasmacytoid cells and plasma cells. 
The cases of monomorphic B-PTLD with features of a diffuse large B-cell lymphoma 
showed a diffuse proliferation of large cells with vesicular nuclei, prominent central nucleoli 
and occasional multinucleate giant cells in some cases.  
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The cases of monomorphic B-PTLD with features of BL showed a diffuse proliferation of 
monomorphous medium-sized cells, with scant cytoplasm and round nuclei displaying 
multiple nucleoli. Scattered macrophages giving a prominent starry-sky pattern were noted. 
All cases had the following phenotype (CD20
+
/CD10
+ 
/BCL6
+
/BCL2-/MUM1
-
/CD138
-
). All 
expressed EBER, but were negative for EBV-LMP-1. The cases of monomorphic B-PTLD, 
plasmablastic subtype showed a diffuse monomorphic infiltrate of medium-sized to large 
lymphoid cells with multiple nucleoli, moderate amount of cytoplasm and subtle to 
prominent plasmacytoid features. The immunophenotype was CD20
-
, CD10
-
, BCL6
-
, Pax5
-/+
, 
MUM1
+
, CD138
+
 and on ISH the cells were EBER
+
. In majority of cases the cells showed κ 
light chain restriction Figure 3-2. 
The HIV-associated NHL cases included: 8 BL, 13 DLBCL, 3 PL, and 2 PTLD-like lesions 
(an IM-like lesion and a polymorphic PTLD-like lesion, one case each). The HIV-DLBCL 
cases showed sheets of large atypical cells with large vesicular nuclei and prominent nucleoli. 
Among the HIV-DLBCL cases, two represented extracavitary forms of primary effusion 
lymphoma (PEL). They were positive for CD45, CD20
+/-
, PAX5, MUM1, CD138, EBER and 
HHV8-LANA-1 but were negative for CD10, BCL6 and EBV-LMP-1 Figure 3-3. The HIV-
PTLD-like lesions showed similar features to those seen in IM-like lesions and pPTLD. 
The HIV-BL cases showed a diffuse proliferation of monomorphous medium-sized cells, 
with scant cytoplasm and round nuclei displaying multiple nucleoli. Scattered macrophages 
giving a prominent starry-sky pattern were noted. Six cases diagnosed as BL had morphology 
or immunophenotype that was not characteristic of classical BL. Two cases had atypical 
morphology; one was composed of small cells without the typical nuclear appearance and 
other composed of larger cells; however, the immunophenotype was typical. Two of the HIV-
BL cases expressed BCL2. One case had classic morphology of BL but the cells expressed 
MUM1 in addition to CD10 and BCL6. One case showed a diffuse infiltrate of smaller 
lymphoid cells with plasmacytoid features and expressed CD45, CD20, MUM1 and CD138 
but lacked PAX5, CD10 and BCL6 expression.  
 
3.2 Expression of markers in relationship to GC / non-GC phenotype:  
All polymorphic PTLDs and 22/30 (73%) PT-DLBCLs had a non-GC phenotype. 7 of 30 
(23%) PT-DLBCLs were classified as having a GC phenotype. Only 1/30 (3%) PT-DLBCL 
had an AGC phenotype.  
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With regard to HIV-DLBCLs, 5 cases had a GC phenotype, two had an activated-GC 
phenotype, and the other 6 cases had a non-GC phenotype. In addition, the case of 
polymorphic PTLD-like lesion had a non GC phenotype. 
 
Of 58 cases iDLBCLs examined, 15, 13 and 30 cases had GC phenotype, activated-GC 
phenotype and non-GC phenotypes respectively. 
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Figure 3-1 A typical case of polymorphic PTLD. 
H&E A) Composed of a mixture of plasma cells, small lymphocytes, and large cells with 
prominent nucleoli, positive for CD20 (B) CD30 (C), MUM1 (D) EBV–EBER-in-situ 
hybridization (E) and EBV-LMP-1 (F). The cells were kappa light chain restricted 
(image not shown). B-D) x100; A) & E- F) x200. 
 
 
 
 
 
EBER EBV-LMP-1
CD30 MUM1
CD20
A B
C D
E F
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Figure 3-2 A case of monomorphic B-PTLD, DLBCL (plasmablastic subtype), 
H&E A), diffuse infiltrate of atypical cells with plasmablastic appearance with prominent 
nucleoli, positive for MUM1 (B), CD138 (C), EBV–EBER-in-situ hybridization (D), Kappa 
light chain (E) and negative for Labmda light chain (F). A-F) x 400 
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Figure 3-3 A case of HIV-DLBCL (primary effusion lymphoma (PEL) 
H&E A)x600: a diffuse infiltrate of large atypical cells with prominent nucleoli, negative for  
PAX5 (B), positive for MUM1 (C), CD138 (D), EBV–EBER-in-situ hybridization (E), and 
HHV8-LANA-1 (F) (B-F )X400). 
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Chapter 4 
Epstein-Barr virus (EBV) AND HHV-8 VIRAL ASSOCIATION 
4.1 EBV association 
Among PTLD, EBV association (positivity of EBER on ISH in most tumour cells) was seen 
in 3/4 (75%) early lesions, 17/19 (89.5%) pPTLD and 30/40 (75%) monomorphic B-PTLD. 
Within the monomorphic DLBCLs cases, 5/7 (71%) of GC, 1/1 (100%) of AGC and 17/22 
(74%) of non-GC showed EBV association. All PT-BLs cases and 4/5 (80%) of PT-PL cases 
were EBV-associated. While in HIV-BCL, 6/8 (75%) BL, 5/6 (83.3%) of DLBCL of non-GC 
phenotype, 2/5 (40%) DLBCL of GC phenotype, all HIV-PL and the two cases of PTLD-like 
lesions were positive for EBER.  In addition, 3/29 (10.3%) of iDLBCL of non-GC phenotype 
and 1/14 (7.1%) of iDLBCL of GC phenotype were EBV-associated. Among the EBV-
positive cases, EBV-LMP-1 was not expressed in 3 pPTLD, 13 monomorphic B-PTLD (4 
DLBCL, GC phenotype, 3 cases DLBCL, non-GC, 3 PL, and all BL cases). All HIV-BL, 2 
cases of HIV-DLBCL of GC phenotype, a case of DLBCL of non-GC phenotype, all HIV-PL 
cases and a case of PTLD-like lesion lacked EBV-LMP1 expression. Three cases of iDLBCL 
were EBV-positive (2 non-GC phenotype and 1 GC phenotype). One of these (age - 67 years) 
with a non-GC phenotype expressed EBV-LMP1, and the other two were negative. All HIV-
DLBCLs and iDLBCL of AGC phenotype were not associated with EBV. Table 4-1  
 
4.2 HHV-8 association 
Two cases of HIV-DLBCL (PEL) were positive for HHV-8, while all other cases investigated 
were negative. 
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Table 4-1 Viral association among different subsets 
Diagnosis EBER-1 (N), 
(%) 
EBV-LMP-1 
(N), (%) 
HHV8-
LANA-1 (N), 
(%) 
I) PTLD     
1)Early lesions (4) 3 (75%) 3 (75%) 0 (0%) 
2) Polymorphic lesions (19) 17 (89.5%) 14 (73.7%) 0 (0%) 
3) Monomorphic lesions  
a) DLBCL (30) 
i. GC (7) 
ii. AGC (1) 
iii. Non-GC (22) 
b) Plasmacytoma-like (2) 
c) Plasmablastic (PL) (5) 
d) Burkitt lymphoma (BL) (3) 
 
5 (71%) 1 (14%) 0 (0%) 
1 (100%) 1 (100%) 0 (0%) 
17 (74%) 14 (63.6%) 0 (0%) 
0 (0%) 0 (0%) 0 (0%) 
4 (80%) 1 (20%) 0 (0%) 
3 (100%) 0 (0%) 0 (0%) 
II) HIV-BCL  
1) HIV-BL (8) 6 (66.7%) 0 (0%) 0 (0%) 
2) HIV-DLBCL  
a) GC (5) 
b) AGC (2) 
c) Non-GC (6) 
3) Plasmablastic (PL)(3)  
   
2 (40%) 0 (0%) 0 (0%) 
0 (0%) 0 (0%) 0 (0%) 
5 (83.3%) 4 (66.7%) 2* (33.3%) 
3 (100%) 0 (0%) 0 (0%) 
4) PTLD-like lesions (2)♦  2 (100%) 1(50%) 0 (0%) 
III) iDLBCL 
a) GC (15) 
b) AGC (13) 
c) Non-GC (30) 
 
1 (7.1%) 0 (0%) 0 (0%) 
0 (0%) 0 (0%) 0 (0%) 
3 (10.3%) 1#(3.7%) 0 (0%) 
(*) Both cases are tissue form of primary effusion lymphoma 
(#) The case was classified as DLBCL of the elderly. 
♦ One of PTLD-like lesions was excluded from further analysis due to core loss.  
 
 
 
 
  
90 
 
4.3 EBV GENOTYPES IN B-PTLD AND HIV-B-CELL LYMPHOMAS (HIV-BCL) 
4.3.1 Introduction:   
Several EBV genes have genetic polymorphism. Two subtypes of EBV, “type-A” and “type-
B” are distinguishable based on polymorphism in the nuclear antigens (EBNA). EBNA 2, 
EBNA 3A, EBNA 3B and EBNA 3C genes differ in the amino acid sequence between types 
A and B by 47%, 16%, 20% and 28%, respectively 
405
. Among the two strains, type-A-EBV 
is thought to be more efficient at transforming and immortalizing B lymphocytes in-vitro 
406
. 
There is geographical variation in the prevalence of the two strains, with type-A being 
predominant in Germany, France, USA, Turkey, North Africa, and Asia, whilst type-B-EBV 
is more common in Central Africa, La Reunion and New Guinea 
407-410
. In the USA, one 
study has shown that both types are equally prevalent 
411
. 
 
Since type-B-EBV is thought to be less 'oncogenic', it is possible that this strain may only be 
capable of causing clonal B-cell expansion when immune suppression is qualitatively or 
quantitatively more profound. Previous studies have suggested that PTLDs  are more 
frequently associated with the type-A-strain, as are iDLBCL, whilst the type-A and type-B 
strains occur equally commonly in HIV-BCL 
412-414
. However, in most of these studies, the 
B-PTLD and HIV-BCL were not from the same geographical region, and therefore they do 
not adequately address the issue of whether there is a relationship between the EBV strain 
seen in the lymphoma cells and the type of background immune suppression. These issues 
need to be addressed with knowledge of patient ethnicity.   
 
We therefore investigated the prevalence of different EBV genotypes amongst B-PTLD and 
HIV-BCL samples from patients diagnosed in England. 
 
4.3.2 Material & Methods:  
We analysed tumour samples from 26 EBV-associated B-PTLDs and 15 EBV-associated 
systemic HIV-BCL for EBV genotype. For patients with HIV-BCL, we also documented 
ethnicity, duration of HIV positivity before the lymphoma diagnosis, and CD4 cell count and 
plasma HIV viral load at time of lymphoma diagnosis. 
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Methods for TMA construction, immunohistochemistry, in-situ hybridization and EBV 
genotyping (PCR and sequencing) are described in the Methods chapter. 
Statistical correlations were performed using Spearman's Rho analysis, Mann Whitney U 
Test using SPSS 16.0 software. 
4.3.3 Results of EBV genotyping:  
The clinicopathological details of the 41 patient samples studied are shown in Table 4-2.  
EBV genotypes: Among the B-PTLDs, 24 were of EBV-type-A (92%) and 2 were of type-B. 
Of the two cases with type-B-EBV, one was a monomorphic B-PTLD and the other was a 
polymorphic B-PTLD. Among the HIV-BCLs, 8 were of EBV-type-A (53%) and 7 were of 
type-B (Figure 4-1). The EBV genotype did not correlate with tumour histology in patients 
with HIV-BCL. Tumour samples from patients with HIV-BCL were significantly more 
frequently associated with type-B-EBV than samples from patients with PTLD (p=0.003) 
Figure 4-2. The ethnicity of the 15 patients with HIV-BCL was white Caucasian (11), black 
African/Carribean (3) and Hispanic (1). There was no correlation between EBV genotype and 
ethnicity among the HIV-BCL (p=0.89). The two patients of PTLD with type-B-EBV were 
also white Caucasian patients. We also investigated two samples of EBV-associated diffuse 
large B-cell lymphoma (DLBL) in immune competent patients for EBV genotype, and both 
cases were of type-A (data not included). None of the cases examined was positive for both 
types of EBV. 
 
Among the HIV-BCL, the EBV strain did not correlate with either the CD4 cell count or HIV 
viral load at the time of lymphoma diagnosis; however, cases associated with type-B-EBV 
had been HIV positive for a significantly longer period of time compared to those associated 
with type-A (p=0.037) Figure 4-3 & Table 4-3. 
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Figure 4-1:  PCR for EBV-EBNA3C gene among HIV-DLBCL samples.   
M50 - 50 bp ladder; P- positive control; N1- negative control; N2- non-DNA control. Lanes 
1, 4 (weak band) & 5 represent samples showing type A EBV (153 bp). Lanes 3, 6-8 
represent samples showing type B EBV (246 bp). Lane 2 is blank. Agarose gel (1.8%). 
 
 
 
 
 
 
Figure 4-2: EBV genotypes among B-PTLD and HIV-BCL 
 
 
 
 
 
 
M50      P      N1      1          N2     2         3       4          5          6         7         8 
350 bp
150 bp
B-PTLD                HIV-BCL
P=0.003
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Figure 4-3: Box plot showing correlation of Median (IQR) length of HIV positivity 
(months) and EBV-genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.037 
EBV-type A                              EBV-type B 
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Table 4-2 Clinicopathological details and EBV genotype analysis of the samples 
 Male 
(%) 
Median age 
(range) 
Histology (%) EBV genotypes* 
Type A Type B 
B-PTLD 
(n=  26) 
19 
(73%) 
42 years  
(2-73) 
14 (54%) Monomorphic B-
PTLD or DLBL-like 
9 (35%) Polymorphic B-
PTLD 
3 (12%) IM like B-PTLD 
24 (92%) 2 (7.7%) 
HIV-
BCL 
(n=  15) 
13 
(87%) 
41 years 
(31-62) 
7 (47%) DLBL 
6 (40%) Burkitt lymphoma 
2 (13%) PTLD-like 
8 (53%) 7 (46.7%) 
*Spearman's Rho analysis; p=0.003  
Abbreviations: DLBL = Diffuse large B-cell lymphoma, IM = infectious mononucleosis 
 
 
 
Table 4-3 Correlation of EBV genotype with ethnicity, length of HIV positivity, and CD4 counts 
and HIV viral load at the time of lymphoma diagnosis 
 EBV genotype A EBV genotype B Significance* 
Median (IQR) CD4 count 
(cells/mm
3
) 
212 (54-289) 56 (40-235) 0.355 
Median (IQR) plasma HIV viral 
load (viral copy numbers/mm
3
) 
500 (181-87000) 252 (49-37012) 0.252 
Median (IQR) length of HIV 
positivity (months) 
7 (0.75-47) 105 (12-174) 0.037 
*Mann Whitney U Test 
Abbreviations: IQR = Interquartile range 
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4.3.4 Discussion:  
We found that in an overwhelming majority (92%) of cases of EBV-positive PTLD, the 
associated virus is type-A-EBV. These results are similar to the published literature, where 
the investigators initially related this finding to the higher prevalence of type-A virus in the 
background population 
413
. There are however reports of the presence of type-B-EBV among 
a minority of PTLD 
414;415
 . Though we were unable to correlate EBV types and ethnicity 
among all the cases of EBV-positive PTLD, both our cases associated with EBV-type-B, 
were white Caucasian patients.  
 
We also show that both EBV genotypes are equally prevalent in HIV-BCL in England and 
this finding is similar to the reports from other groups who have shown that both EBV 
genotypes types are found in lymphoma samples from patients with HIV 
416;417
. Similarly, 
both EBV genotypes have been detected in throat washings from patients with HIV infection 
411
.  Among HIV-BCL, there was a significant correlation between the EBV genotype and the 
duration of HIV positivity before the diagnosis of lymphoma. Cases associated with type-B-
EBV had been HIV positive for a significantly longer duration compared to those with type-
A. This finding concurs with the previously held view that the type-B-EBV is oncogenically 
less efficient than type-A. Type-B-EBV appears to be lymphomagenic only in the 
background of prolonged HIV-associated immune suppression. Additional studies are 
essential to clearly understand the basis of this finding.  
 
Overall, our results suggest that both EBV types are likely to be prevalent in the background 
population in England. We speculate that the degree and type of immune deficiency and not 
the patient ethnicity may be associated with the EBV genotype present within the expanded 
clone of B-cells in immunodeficiency associated lymphoproliferative disorders. Since type-
B-EBV is less 'oncogenic' it is possible that this strain may be more efficient in causing 
clonal B-cell expansion in context of prolonged immune suppression caused by HIV 
infection. This hypothesis is supported by the frequent finding of type-B-EBV in the 
peripheral blood of cardiac transplant recipients who are iatrogenically immunosuppressed 
but the relative scarcity of EBV-type-B associated PTLD in the allograft recipient population 
44;418
. Moreover, EBV-associated PTLDs are more common in early-onset cases (time to 
transplant less than 5 years) whilst most late-onset PTLDs are EBV-negative.  
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In summary, there is a significant difference in the distribution of the two genotypes of EBV 
among EBV-positive PTLD and EBV-positive HIV-BCL. While an overwhelming majority 
of PTLD is associated with type-A-EBV, nearly one-half of HIV-BCL is associated with 
type-B virus. This difference cannot be explained by patient ethnicity. This leads us conclude 
that a biological basis in terms of a variable oncogenicity of the two EBV types with respect 
to the length of immune suppression may be an underlying mechanism that needs further 
exploration. 
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Chapter 5 
A COMPARISON OF THE OCCURRENCE OF COMMON LYMPHOMA-
ASSOCIATED GENE REARRANGEMENTS AMONG B-POST TRANSPLANT 
LYMPHOPROLIFERATIVE DISORDERS (B-PTLD), B-CELL HIV-LYMPHOMAS 
AND DIFFUSE LARGE B-CELL LYMPHOMA IN IMMUNE COMPETENT. 
 
5.1 Introduction:  
Lymphoproliferative disorders in immune deficient states are a group of diseases that range 
from benign polyclonal to malignant monoclonal lymphoid proliferations 
1
. 
PTLDs and HIV-related lymphomas are well-known examples of immunodeficiency 
lymphoproliferative disorders (IDLDs). Epstein Barr virus (EBV) is known to be associated 
with the majority of these disorders. Though EBV plays an important role in driving the 
proliferation, it is widely perceived that it is not solely responsible for the „neoplastic‟ state. 
Accumulation of different genetic and epigenetic aberrations in proto-oncogenes and tumour-
suppressor genes is an integral part of the pathogenesis 
72
.  EBV has been reported to be 
present in a proportion of HIV- related Burkitt lymphoma (HIV-BL), HIV-DLBCL, in 
approximately 90% AIDS-PELs and all cases of HIV-PCNSL 
161
.  
 
In non-Hodgkin lymphomas (NHL), chromosomal translocations result in two distinctive 
types of genetic lesions : 1) Juxtaposition of an intact oncogene with another gene which in 
most cases is an antigen receptor gene, and 2) Juxtaposition of parts of two disrupted genes 
resulting in a new fusion gene, chimeric mRNA, and a novel protein 
419
. There are a 
relatively large number of studies investigating the cytogenetic and molecular alterations 
among a variety of immunocompetent B-NHL 
420-424
. However, there are only a few case 
reports and a relatively limited number of publications documenting different chromosomal 
alterations among PTLD and HIV-associated lymphomas 
29;41;103;111;120;123;151;169;425-427
. 
 
It has been reported that 12-40% of iDLBCL and HIV-DLBCL harbour a BCL6 
rearrangement, which in contrast is very rarely seen in PTLD 
29;188;424
. However, all post-
transplant Burkitt lymphomas (PT-BL), similar to HIV-BL and Burkitt lymphoma developing 
in immunocompetent patients (iBL), display chromosomal breaks at 8q24 involving the c-
MYC oncogene 
29;41;72;109
. More recently, t(8;14) has been the first cytogenetic abnormality 
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documented in an HIV-related plasmablastic lymphoma (HIV-PL) and t(8;22) has been 
described in a case of post transplant PEL with plasmablastic features 
218;219;428;429
. The 
t(14;18) involving the BCL2 gene is seen in 15-30% of iDLBCL, whilst it is very rarely 
observed in PTLDs 
29;430;431
. Seven to 15 % of iDLBCL of germinal centre (GC) phenotype 
have been shown to have c-MYC gene rearrangement 
432-434
. As the literature available on 
genetic alterations among immunodeficiency-related lymphomas is relatively limited, in this 
report we document and compare the occurrence of common lymphoma-associated gene 
rearrangements among B-PTLD, HIV-B-cell-lymphomas (HIV-BCL) and iDLBCL.  
 
5.2 Materials and methods: 
We analysed tumour samples from 54 B-PTLD, 25 HIV-BCL (13 DLBCL, 8BL, 3PL, and 1 
PTLD-like lesion), and 58 iDLBCL.  
Methods for tissue array construction, immunohistochemistry, in-situ hybridization and 
flourescence in-situ hybridization are described in the Methods chapter. 
Statistical analysis: Presence of rearrangements was compared between various categories 
using the Chi-square analysis, and p-values <0.05 were considered significant.  
 
5.3 Results 
5.3.1 Clinical characteristics 
Among B-PTLD 35 out of 54 (65%) were males. The age ranged from 2 to 80 years with a 
median age of 42 years. Among HIV-BCL 23 out of 25 (92%) were males. The age ranged 
from 26 to 66 years with a median age of 41 years. While in iDLBCL 33 of 58 (56.8%) were 
males and the age ranged from 18 to 86 years with a median age 48 years.   
 
5.3.2 Morphology and phenotype 
All cases were classified according to the current WHO classification 
38;159;435
. Disease 
classification and age & sex distribution are shown in Table 5-1 
Among iDLBCL, 15, 13 and 30 were of GC, AGC and non-GC phenotypes respectively. 
Among PTLD samples, 2 were early lesions (infectious mononucleosis-like (IM-like) lesion 
and plasmacytic hyperplasia), 14 were polymorphic lesions, and 39 were monomorphic 
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lesions (3 PT-BL, 30 PT-DLBCL, and 6 PT-PL). Seven PT-DLBCL and all PT-BL had a GC 
phenotype. On the other hand, all polymorphic-PTLD lesions and 22 cases PT-DLBCL had a 
non-GC phenotype.  Only one case of PT-DLBCL had an AGC phenotype. 
Among HIV-BCL, 8 were BL, 13 were DLBCL (5GC, 2 AGC and 6 non-GC), 3 PL and a 
case was a polymorphic PTLD-like lesion. Among HIV-BL, 3/8 (37.5%) expressed MUM1 
and had an AGC-like phenotype. 
BCL2 expression: BCL2 protein expression was noted in 38 of 52 (73%) B-PTLD, 15 of 25 
(60%) HIV-BCL and 30/50 (60%) iDLBCL. The 15 cases of HIV-BCL expressing BCL2 
included 3/8 (37.5%) BL, 8 of 13 (61.5%) DLBCL, 3 cases PL, and one case HIV-PTLD-like 
lesion.  
 
Table 5-1 Disease classification and age & sex distribution 
 Male (%) Median age 
(range) 
Histology (%) 
B-PTLD 
(n=  55) 
35 (65%) 42 years  
(2-80) 
mPTLD (DLBCL) - 30 (54.5%) 
mPTLD (PL) - 6 (11%) 
mPTLD (BL) - 3 (5.5%) 
 pPTLD - 14 (25.5%) 
Early lesions - 2 (3.6%) 
HIV-BCL 
(n=  25) 
23 (56%) 41 years 
(26-66) 
HIV-DLBCL - 13 (52%)                                                
HIV-BL - 8 (32%) 
HIV-PL – 3 (12%) 
PTLD-like – 1 (4%) 
iDLBCL 
(n= 58) 
33 (51%) 48 years 
(18-86) 
 
5.3.3 FISH & CISH analysis  
Overall, PTLDs and HIV-BCLs revealed no evidence of rearrangement of BCL2, BCL3, 
BCL6, PAX5 or MALT1 genes. iDLBCLs revealed no evidence of rearrangement of the PAX5 
or MALT1 genes. Only a case of iDLBCLs of AGC phenotype (2%) had a dual hit–involving 
c-MYC and BCL6 genes Table 5-2. Gene rearrangements among DLBCLs in different 
categories are shown in Figure 5-1.  
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Figure 5-1 Gene rearrangements among DLBCLs in different categories. 
 
 
 
 
 
5.3.3.1 Diffuse large B-cell lymphoma (DLBCL) 
5.3.3.1.1 iDLBCL 
Seven of 47 iDLBCL (14.9%) showed evidence of rearrangement of BCL2, all of which had 
concomitant IGH rearrangement. Among these 5 and 2 cases were of GC and AGC 
phenotypes respectively. Sixteen of 47 iDLBCL (34%) were positive for BCL6 
rearrangement. Fourteen of these were positive for IGH rearrangement as well. The 
c-MYC  
31%
None 69%
PT-DLBCL  (30 cases) 
c-MYC 8%
None 92%
HIV-DLBCL  (25 cases) 
iDLBCL (58 cases) 
BCL6 33%
BCL2 15%
c-MYC 4%
BCL3 2%
IGH only 2%
Double hit 
3%
None 41%
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remaining two cases could not be investigated for IGK and IGL rearrangements due to 
paucity of the available tissue. Among the sixteen cases of iDLBCL with BCL6 
rearrangement, one, five and ten cases showed GC, activated-GC and non-GC phenotype 
respectively.  
 
Only 2 of 52 iDLBCL (3.8%) showed rearrangement of c-MYC (both IGH rearrangement-
positive); one of the cases had a GC phenotype and a Ki67 index of 90% while the other had 
an AGC phenotype and a Ki67 index of 90%. The latter case also showed rearrangement of 
BCL6, a so-called double-hit lesion. Only one of 51 iDLBCL (2%) was positive for both 
BCL3 and IGH rearrangements. All detected oncogene rearrangements were mutually 
exclusive apart from the single case of iDLBCL with BCL6 and c-MYC rearrangement; this 
case had an AGC phenotype. There was no evidence of rearrangement of PAX5 and 
MALT1in any of the iDLBCL cases. Two of IGH rearrangement-positive iDLBCLs lacked 
rearrangements of other oncogenes tested. 
5.3.3.1.2 PT-DLBCL 
Three out of twenty nine (10.3%) cases representing 1 case each of GC, AGC and non-GC 
subtypes showed c-MYC gene rearrangement. These cases lacked rearrangement of the IGH 
gene, and rearrangement of IGL genes was observed in the case of GC phenotype. The results 
were not assessable in one and FISH was not done for the third case due to paucity of the 
available tissue.  
5.3.3.1.3 HIV-DLBCL:  
Four out of thirteen (31%) of HIV-DLBCLs representing 3 cases and 1 case of GC and non-
GC subtypes respectively showed c-MYC rearrangement. 3 of the cases were concomitantly 
associated with IGH rearrangement, and the other case had rearrangement of the IGL locus. A 
case of DLBCL non-GC phenotype was positive for IGH gene rearrangement and lacked 
rearrangement in the oncogenes investigated. 
 
5.3.3.2 Burkitt lymphoma (BL) 
5.3.3.2.1 PT-BL:  
Two out of three cases (67%) showed rearrangements involving c-MYC and IGH genes. 
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5.3.3.2.2 HIV-BL:  
Seven out of eight cases (87.5%) showed rearrangement of c-MYC gene and 6 of them had 
concomitant rearrangement of the IGH gene. The case lacking IGH rearrangement could not 
be investigated for IGK and IGL rearrangements due to paucity of the available tissue. 
 
5.3.3.3 Plasmablastic lymphoma (PL) 
5.3.3.3.1 PT-PL:  
Two out of six (33%) showed rearrangement of c-MYC gene and 1 of them had concomitant 
rearrangement of the IGH gene Figure 5-2. The case lacking IGH rearrangement could not 
be investigated for IGK or IGL rearrangements due to paucity of the available tissue. 
5.3.3.3.2 HIV-PL:  
One out of two cases (50%) showed rearrangements involving c-MYC and IGH genes. 
 
5.3.3.4 Polymorphic PTLD:  
One out of fourteen cases (7%) showed rearrangement of IGH gene without any concomitant 
rearrangement of other oncogenes tested. 
Two early lesions (PTLD) and one PTLD-like lesion in the HIV setting lacked 
rearrangements of oncogens tested. 
 
5.3.3.5  Comparison of rearrangements between entities: 
Rearrangement of BCL2 was completely absent among PTLD and HIV-BCL cases, while it 
was noted in 14.6 % of iDLBCL (p=0.039).  Similarly rearrangement of BCL6 was 
completely absent among PTLD and HIV-BCL cases, whilst it was noted in 33.3% of 
iDLBCLs (respectively p <0.001). While c-MYC rearrangement was seen in 4/13 (30.8 %) of 
HIV-DLBCL, it was seen in only 2/53 (3.8%) of iDLBCL (one of them being a double-hit 
lymphoma) and 10.3% of PT-DLBCL (p=0.012).  
 
Within iDLBCL, while (5/15) 33.3% of the GC subtype were associated with BCL2 
rearrangement, only 17% of AGC and none of non-GC subtypes were associated with BCL2 
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rearrangement (p=0.020). Similarly, while 45.5% and 40% of AGC and non-GC subtypes 
respectively were associated with BCL6 rearrangement, only 8.3% of the GC subtype 
harboured BCL6 rearrangement. However, there was no significant difference (p=0.100). The 
values were validated on a larger cohort and reached statistical significance (p=0.047) (not 
included in the thesis). Rearrangement of different genes among iDLBCL subsets are 
illustrated in Figure 5-3 
 
 
 
 
 
Figure 5-2 FISH analysis for rearrangement of c-MYC and IGH genes. 
A& B) c-MYC and IGH rearrangements respectively using dual-colour break-apart 
probes. Several nuclei in the images show a split signal (with separate green and red 
signals) in addition to co-localized signals. C & D) represent Chromogen in-situ 
hybridization 
 
 
 
 
A B
C D
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Figure 5-3 Rearrangement of different genes among iDLBCL subsets. 
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Table 5-2  Gene rearrangements among different lymphoma subsets 
Category/number of cases (n) BCL-2 BCL-3 BCL-6 c-MYC IGH 
1) B-PTLD (64) 0% 0% 0% 7 (11%) 4 (6%) 
Early lesions (2) 0% 0% 0% 0% 0% 
Polymorphic PTLD (14) 0% 0% 0% 0% 1 (7% ) 
Monomorphic PTLD  - 
DLBCL (30) 
0% 0% 0% 3 (8%) 0% 
   PT-DLBCL-GC (7) 0% 0% 0% 1 (11%) 0% 
   PT-DLBCL-AGC (1) 0% 0% 0% 1 (50%) 0% 
   PT-DLBCL-non-GC (22) 0% 0% 0% 1 (4%) 0% 
Monomorphic PTLD -PL (6) 0% 0% 0% 2 (33%) 1 (17%) 
Monomorphic PTLD  - BL 
(3) 
0% 0% 0% 2 (67% ) 2 (67% ) 
2) HIV-BCL (25) 0% 0% 0 (0%) 12 
(50%) 
11 (50%) 
Burkitt lymphoma (8) 0% 0% 0% 7 
(87.5%) 
6 (75%) 
DLBCL (13) 0% 0% 0 4 (31%) 4(36.4%) 
   HIV-DLBCL-GC (5) 0% 0% 0 3 (60%) 2 (40%) 
   HIV-DLBCL-AGC (2) 0% 0% 0 0 (0%) 0 (0%) 
   HIV-DLBCL-non-GC (6) 0% 0% 0 1 (17%) 2 (40%) 
Plasmablastic lymphoma (3) 0% 0% 0% 1  
(50%) * 
1  
(50%) * 
PTLD-like (1) 0% 0% 0% 0% 0% 
3) iDLBCL (58) 7 (15%) 1 (2%) 16 
(33%) 
2 (3.8%) 24(43%) 
iDLBCL-GC (15) 5 (33%) 0% 1 (8.3) 1 (7%) 6 (40%) 
iDLBCL-AGC (13) 2(17%) 0% 5 
(45.5%)# 
1 (7.7%) 6 (50%) 
iDLBCL-non-GC (30) 0 1 (3.7%) 10 (40%) 0 12 (41%)♦ 
* Rearrangement was noted in one of two cases and FISH was not done in the other. 
# One case with BCL6 rearrangement was „double-hit‟ cases that also carried c-MYC 
rearrangement. 
♦ One case was positive for IGH rearrangement only. 
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5.3.4 EBV-association among different histological subtypes and its association with 
different oncogene rearrangements 
EBV-association among different histological subtypes and its association with different 
oncogene rearrangements are shown in Table 5-3 
 
5.3.4.1 Diffuse large B-cell lymphoma (DLBCL) 
5.3.4.1.1 iDLBCL:  
One out of twelve of iDLBCL-GC (8%) cases and 0/13 iDLBCL-AGC and 2/27 (7%) 
iDLBCL-non-GC were EBER positive. EBV-LMP-1 was positive in only one of the EBER 
positive cases of iDLBCL-non-GC. None of the EBV-positive cases had rearrangements of 
oncogenes tested. 
5.3.4.1.2 PT-DLBCL:  
Two out of seven (29%) of PT-DLBCL-GC were EBV-associated (positive for both EBER 
and EBV-LMP-1) and none of the EBV-positive cases had rearrangements of oncogenes. The 
single case of PT-DLBCL-AGC was positive for EBER, negative for EBV-LMP-1 and 
showed rearrangement of c-MYC. 17/22 (77%) of PT-DLBCL-non-GC showed expression of 
EBER and 15 of them also expressed EBV-LMP-1; only one of these cases showed 
rearrangement of c-MYC.  
5.3.4.1.3 HIV-DLBCL:  
Two out of five (40%) of HIV-DLBCL-GC were positive for EBER, but negative for EBV-
LMP-1; both cases showed rearrangement of c-MYC. Both cases of HIV-DLBCL-AGC did 
not show EBV-association. 5/6 (83%) of HIV-DLBCL-non-GC showed expression of EBER 
and 3 of them also expressed EBV-LMP-1; none of the EBV-positive cases had 
rearrangements of oncogenes. 
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5.3.4.2 Burkitt lymphoma (BL) 
5.3.4.2.1 PT-BL:  
All the three cases (100%) of PT-BL were EBER positive, but EBV-LMP-1 negative. Two of 
these cases showed rearrangement of c-MYC.  
5.3.4.2.2 HIV-BL:  
Five out of eight (62%) of HIV-BL were EBER positive, but EBV-LMP-1 negative. Four of 
these cases showed rearrangement of c-MYC.  
5.3.4.3 Plasmablastic lymphoma (PL) 
5.3.4.3.1 PT-PL:  
Five out of six (83%) of PT-PL were EBER positive, and one of them was EBV-LMP-1 
positive. The case expressing both EBER and EBV-LMP-1 showed rearrangement of c-MYC.  
5.3.4.3.2 HIV-PL:  
All three (100%) cases of HIV-PL were positive for EBER; but none expressed EBV-LMP-1. 
One of the cases showed rearrangement of c-MYC.  
5.3.4.4 Polymorphic PTLD:  
All 14 (100%) cases were positive for EBER, and 12 of them also expressed EBV-LMP-1. 
None of the EBV-positive cases had rearrangements of oncogenes. 
Both early lesions (PTLD) were negative for EBER and EBV-LMP1. The single case of 
PTLD-like lesion in the HIV expressed EBER and EBV-LMP-1 and was negative for 
rearrangements of oncogenes. 
 
5.3.5 Comparison of rearrangements and EBV-association:  
Overall, none of the cases with either BCL2 or BCL6 rearrangement showed EBV-association 
(p=0.031 & p<0.001 respectively). On the other hand there was no correlation between EBV 
association and c-MYC or IGH rearrangement.   
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Table 5-3 EBV association among different lymphoma subsets and rearrangements of c-
MYC, BCL2 and BCL6 genes among the EBV-positive cases 
Category/number of cases (n) Number of cases 
positive for EBER 
(number of cases 
with 
rearrangements of 
c-MYC / BCL2 / 
BCL6) 
Number of cases 
positive for EBV-
LMP1 (number of 
cases with 
rearrangements of 
c-MYC / BCL2 / 
BCL6) 
1) B-PTLD (55)   
Early lesions (2) 0 0 
Polymorphic PTLD (14) 14 (none) 12 (none) 
Monomorphic PTLD  - 
DLBCL (PT-DLBCL)(30) 
20 (2 - c-MYC) 17 (1 - c-MYC) 
     PT- DLBCL-GC (7) 2 (none) 2 (none) 
     PT- DLBCL-AGC (1) 1 (1 - c-MYC) 0 
     PT- DLBCL-non-GC (22) 17 (1 - c-MYC) 15 (1 - c-MYC) 
 PT- PL(6) 5 (1 - c-MYC) 1 (1 - c-MYC) 
 PT- BL (3) 3 (2 - c-MYC) 0 
2) HIV-BCL (25)   
BL (8) 5 (4 - c-MYC) 0 
HIV-DLBCL (13) 7 (2 - c-MYC) 0 
HIV-DLBCL-GC (5) 2 (2 - c-MYC) 0 
HIV-DLBCL-AGC (2) 0 0 
HIV-DLBCL-non-GC (6) 5 (none) 3 (none) 
HIV-PL (3) 3 (1 - c-MYC) 0 
HIV-PTLD-like (1) 1 (none) 1 (none) 
3) iDLBCL (52)   
iDLBCL-GC (12) 1 (none) 0 
iDLBCL-AGC (13) 0 0 
iDLBCL-non-GC (27) 2 (none) 1 (none) 
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5.3.6 Morphology and immunophenotype of c-MYC rearrangement-positive DLBCLs 
and PLs:  
The cases diagnosed as PL showed a diffuse monomorphic infiltrate of medium sized to large 
lymphoid cells with one or more nucleoli, moderate amount of cytoplasm and subtle to 
prominent plasmacytoid features. The immunophenotype was CD20
-
, CD10
-
, BCL6
-
, Pax5
-/+
, 
MUM1
+
, CD138
+
 and on ISH the cells were EBER
+/-
 and had κ light chain restriction. The 
cases of PT-DLBCL and HIV-DLBCL showed a diffuse infiltrate of large atypical lymphoid 
cells with prominent nucleoli and frequent mitoses and apoptoses. Areas of necrosis were 
also noted. Morphological features were not those of BL. Two cases of PT-DLBCL and 3 
cases of HIV-DLBCL had a GC phenotype and one case each of PT-DLBCL and HIV-
DLBCL had a non-GC phenotype. On the other hand, among iDLBCL one had a GC 
phenotype and one had an AGC phenotype. Among all cases with DLBCL morphology, Ki67 
index varied from 70 to 95% Table 5-4. 
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Table 5-4 Immunophenotype of lymphomas other than BL with c-MYC rearrangement in the absence of BCL2 or BCL6 rearrangements 
  Immunohistochemistry ISH FISH 
BCL2 Pax-5 CD20 CD10 BCL6 MUM1 CD138 Ki67 sIg κ/ג EBER c-MYC  IGH kappa lambda 
1 PT-PL - - - - - + + 85% κ + + + ND ND 
2 PT- PL  + + - - - + - 70% κ - + - + - 
3 PT-DLBCL-AGC - + + + + - - 70% ND + + - NA NA 
4 PT-DLBCL-GC - ND + + + - - 90% ND - + - - + 
5 PT-DLBCL-non-GC + + + - - + - 80% ND + + - ND ND 
6 HIV- PL  + - - - - + + 70% κ + + + ND ND 
7 HIV-DLBCL-GC - + + - + - - 90% ND + + + ND ND 
8 HIV-DLBCL-GC + + + + + - - 90% ND + + - - + 
9 HIV-DLBCL-GC - + + - + - - 95% ND - + + ND ND 
10 HIV-DLBCL-GC + ND + + + - ND >95% ND ND + + ND ND 
11 HIV-DLBCL-AGC + ND + + + + ND >99% ND ND + + ND ND 
12 HIV-DLBCL-AGC + ND + + + + ND 95% ND ND + + ND ND 
13 HIV-DLBCL-non-GC + + + - + + - 80% ND - + + ND ND 
14 iDLBCL_GC - + + + + - - 90% ND - + + ND ND 
15 iDLBCL-non-GC - ND + - + + ND >99% ND ND + + ND ND 
16 iDLBCL-non-GC + ND + - + + ND >95% ND ND + + ND ND 
17 iDLBCL-GC - ND + + + - ND >99% ND ND + + ND ND 
18 iDLBCL-GC - ND + + + - ND 90% ND ND + + ND ND 
Abbreviations: AGC= activated germinal center, GC= germinal center, FISH= Fluorescent in situ hybridization, ISH= In situ hybridization, NA = Not 
assessable, ND = not done, PT-PL=post transplant plasmablastic lymphoma. DLBCL= diffuse large B-cell lymphoma. 
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5.4 Discussion: 
Genetic alteration through chromosomal translocations is an important pathogenetic pathway 
in B-cell lymphomas. We found rearrangement of BCL2 and IGH in 15% of iDLBCLs and 
most of them (71%) had a GC phenotype, which is in keeping with the previous reports 
430;431
. We also found BCL6 rearrangements in the absence of involvement of other 
oncogenes in 15/47 (32%) of iDLBCL, which is in line with previous reports 
424;431;436
. 62.5% 
of iDLBCLs with BCL6 rearrangement had non-GC phenotype, and it has previously been 
reported that  BCL6 rearrangement occur in a higher proportion of activated B-cell like 
(ABC) or non-GC subsets of DLBCL as compared to GC-DLBCL. 
424;437-440
.  
In this series of iDLBCL, two of 52 cases (3.8%) were positive for both c-MYC and IGH 
rearrangements and one of the cases had a GC phenotype while the other had an activated-
GC phenotype. The latter case showed additional rearrangement of BCL6 (double-hit 
lymphoma).  Previous reports on DLBCL suggest the frequency of c-MYC rearrangement to 
be higher, in the range of 7% to 15% of DLBCL, and such cases have mostly been of the GC 
subtype 
432-434
. The frequency of  c-MYC rearrangement among paediatric lymph nodal 
DLBCL is nearly 35% 
441;442
.  Among cases of B-cell lymphoma, unclassifiable with features 
overlapping between DLBCL and BL (DLBCL/BL), 35-50% have c-MYC rearrangement and 
many of these cases have non-IG genes partnering the c-MYC gene. Furthermore, ~15% of 
cases of DLBCL/BL have concurrent IGH/BCL2 and c-MYC rearrangements 
197;198;443;444
. In 
the current study, only a case (2%) of iDLBCL had involvement of more than one oncogene 
(c-MYC gene and BCL6).  
Among B-PTLD, rearrangement of the c-MYC oncogene, seen in 7/54(13%) was the only 
common-lymphoma-associated rearrangement observed. The seven cases included 3 PT- 
DLBCL, 2 PT-PL and 2 PT-BL. Absence of translocations involving BCL2 and MALT1 
genes has been previously reported 
29;41
.  Although there are occasional cases of B-PTLD 
reported to be positive for BCL6 and for PAX5 rearrangements, none of the cases investigated 
by us showed rearrangement of either of these genes 
29;113;114
. We documented presence of c-
MYC rearrangement in 8% of PT-DLBCLs, which has not been previously reported. 
 
Similar to B-PTLD, HIV-BCLs also lacked BCL2 rearrangements, this has been previously 
documented 
445
. On this background, the presence of BCL2 over-expression in the majority 
of B-PTLD and HIV-BCL points to mechanisms other than BCL2 rearrangement or 
amplification as the basis for the protein over-expression. This feature of B-PTLD and HIV-
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BCL is analogous to that of iDLBCL in which BCL2 protein over-expression is found in 22-
80% of cases; markedly higher than the frequency of t(14;18) in this subgroup 
446-448
. 
Four of thirteen (31%) HIV-DLBCLs showed c-MYC rearrangement and 3 of them had 
concurrent IGH rearrangement. Our observation of presence of c-MYC rearrangement in 
nearly 31% of HIV-DLBCLs is higher than the previous reports 
169;171;172;189
.  Diebold et 
al,
449
however, previously suggested that 30-40% of HIV-DLBCLs have c-MYC 
rearrangement. These observations raise the issue of the overlap between BL and DLBCL 
and the possibility that some of them could represent B-cell lymphoma, unclassifiable with 
features overlapping between DLBCL and BL (DLBCL/BL) 
197;450
. Although there are 
occasional cases of B-PTLD reported to be positive for BCL6 and for PAX5 rearrangements, 
none of the cases investigated by us showed rearrangement of either of these genes 
29;113;114
. 
Similarly, but in contrast to previous reports, all HIV-DLBCLs investigated in our study were 
negative for rearrangements involving the BCL6 locus 
188;189
. Our finding is in keeping with 
the notion that mutations involving BCL6 5‟ non-coding region and not BCL6 gene 
rearrangement are the most common genetic alterations in AIDS-related lymphomas and it 
also supports the view that iDLBCL and HIV-DLBCL have different pathogenetic 
mechanisms 
151;160
. 
Two of three cases of PT-BL had rearrangements involving c-MYC and IGH genes, which is 
in agreement with published reports 
41;47
. Similarly, 87.5% of HIV-BL had c-MYC 
rearrangement, and all of them except one showed concurrent IGH rearrangement and this is 
in agreement with data reported in the literature and confirming the role of c-MYC 
rearrangement in the pathogenesis of HIV-BL 
161
. 
We identified two cases of PT-PL with c-MYC rearrangement, one of which had a 
concomitant IGH rearrangement, and an additional case of HIV-PL showing rearrangement 
of c-MYC and IGH loci. There are recent reports of HIV-PL with c-MYC/IgH translocation 
218;219;451
. However, there are no reports of c-MYC gene rearrangement in PT-PL.   
In the current study, none of the cases with either BCL2 or BCL6 rearrangement showed 
EBV-association. On the other hand, there was no significant correlation between EBV-
association and c-MYC or IGH rearrangement.  Using comparative genomic hybridization 
(CGH), Poirel et al,
111
 have reported that EBV-negative PTLD tended to have more complex 
CGH imbalances than EBV-positive PTLD. It has also been reported that EBV-positive PT-
DLBCL had less recurrent genetic lesions than EBV-negative PT-DLBCL 
120
.  Vakiani et 
al,
29
 however, reported the lack of difference in the cytogenetic complexity between EBV-
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negative and EBV-positive PTLDs. Among HIV-DLBCL, EBV-positive cases have been 
shown to display lower genomic complexity than EBV-negative cases and this could be 
attributed to a direct EBV-transforming effect that can be alternative to the additional genetic 
aberrations or the genomic complexity required for EBV-negative cases of similar 
histological subtypes 
123;208;209
. 
 
Although gene rearrangements involving critical genes are well-known mechanisms of 
lymphomagenesis in immunocompetent patients, gene rearrangements, apart from c-MYC-
IGH (characteristically seen in BL and PL), appear to be very rare in immunodeficiency-
related lymphomas, both HIV-BCL and B-PTLD. In addition, HIV-DLBCL and 
monomorphic B-PTLD (DLBCL) are more frequently associated with c-MYC rearrangement 
than iDLBCL. We also noted that BCL6 rearrangement is frequently seen in iDLBCL of 
AGC and non-GC subtypes. We hypothesize that the pathogenesis of IDLDs is likely to be 
related to rearrangements other than those investigated in this study; cytogenetic 
abnormalities that are better investigated using a global approach, aberrant somatic 
hypermutation, or aberrant hypermethylation of critical genes. 
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Chapter 6 
ABERRANT HYPERMETHYLATION OF DAP-KINASE GENE OCCURS EARLY 
IN THE EVOLUTION OF B-CELL POST TRANSPLANT 
LYMPHOPROLIFERATIVE DISORDERS (B-PTLD) 
 
6.1 Introduction  
In the previous chapter we showed that gene rearrangements, apart from c-MYC-IGH 
(characteristically seen in BL and PL), appear to be very rare in immunodeficiency-related 
lymphomas, both HIV-BCL and B-PTLD. We therefore intended to investigate mechanisms 
of the pathogenesis other than gene rearrangements that could lead to lymphomagenesis. In 
this chapter we will discuss the role of DAP-k methylation in the pathogenesis of these 
disorders. 
 
Within the regulatory regions of many genes there are CpG islands that typically display a 
low level of methylation. The activity of tumour suppressor genes can be inhibited as a result 
of hypermethylation of cytosine residues in these islands. The hypermethylation is an 
epigenetic phenomenon that alters the gene activity without changing its base sequences and 
is accomplished through DNA methyl transferase enzyme 
131;452-455
.  
 
Aberrant hypermethylation (AH) is a mechanism for tumour suppressor gene silencing that is 
an alternative to deletion and/or mutation. Aberrant hypermethylation (AH) of the promoter 
regions of a number of lymphoma-related suppressor genes has been implicated in the 
pathogenesis of lymphoproliferative disorders in the post-transplant setting 
132
. It has been 
suggested that AH might be due to increased activity of methyltransferase 
456;457
. According 
to in-vitro experimental models, the hypermethylation-associated silencing of tumour 
suppressor genes, in contrast to genetic aberration, is a reversible event 
458
. There are several 
clinical trials which have shown that some drugs have therapeutic efficacy and can prevent 
methylation 
459;460
. This finding points to the possibility of using these drugs for prevention 
and treatment of EBV-driven lymphoproliferative disorders which display AH of the relevant 
genes 
455
.  
DAP-kinase (DAP-k), a serine-threonine kinase, plays an important role in apoptosis that is 
triggered by TNFα, INFγ and FAS ligand and is inhibited as a result of hypermethylation of 
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the CpG islands 
133;136;461-463
. The lack of expression of DAP-k secondary to  
hypermethylation of DAP-k gene rescue the cells from INFγ-induced programmed cell death 
favouring their survival and accumulation of different genetic alterations resulting in tumour 
progression 
461;463-465
. DAP-k hypermethylation has been reported in small cell carcinomas of 
the lung, head and neck cancers as well as in B-cell lymphomas 
466-468
. DAP-k suppresses 
both tumour formation and metastasis, a finding that has been suspected through the 
observation of loss of DAP-k expression with more aggressive malignant tumours and 
increased metastatic potential 
469-472
.  
 
In EBV-driven cancers, the EBV genome undergoes epigenetic changes  which also affect the 
cellular genome of the infected cells 
473;474
. There are some reports correlating DAP-k 
methylation with EBV association in carcinomas and no significant correlation has been 
identified 
475;476
. According to Rossi et al, 
132
, AH of DAP-k is the most frequent epigenetic 
change encountered in immunodeficiency-associated NHL being present in 75% polymorphic 
PTLD, 84% monomorphic PTLDs, 86% of HIV-DLBCL and 86% HIV-BL. It has also been 
reported in 65-76% of iDLBCL.  
As the previous reports investigating DAP-k hypermethylation in immunodeficiency-related 
lymphoma are relatively limited, we investigated whether B-PTLDs and HIV- BCL 
significantly differ from iDLBCL with regard to AH of DAP-k kinase gene and to find out if 
it is an early event in the pathogenesis. We further correlated AH with EBV association. 
 
6.2 Materials and methods 
We analysed tumour samples from 29 B-PTLDs, a case of reactive hyperplasia of a lymph 
node in a post transplant patient, 25 HIV-BCL, and 18 samples of iDLBCL for the EBV-
association and methylation status of DAP-k. Ten samples of peripheral blood lymphocytes 
of post bone marrow transplant patients were also used. DNA from 10 samples of normal 
peripheral blood lymphocytes was used as a negative control. 
Methods for tissue array construction, in-situ hybridization and methylation-specific PCR are 
described in the Methods chapter. 
The cases considered positive for methylated DAP-k showed a clearly visible band of the 
expected size (98bp) with the primers specific for methylated reaction. The unmethylated 
reaction yielded a 106 bp product. 
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Statistical analysis: Chi-square analysis was performed to assess the association between AH 
and histological subsets, and between EBV-association and AH within different histological 
subsets, and p-values <0.05 were considered significant. 
 
6.3 Results 
6.3.1 Clinical characteristics 
All PTLD samples are classified according to the current WHO classification 
38
 
Among 29 cases B-PTLD, 21(72.4%) were male and eight were female. Age ranged from 2-
73 years (median age: 43 years). HIV-BCL cases included 22(88%) males and three females. 
Age ranged from 26-66 years (median age: 41 years). In iDLBCL  12/18(66.7%) were males 
and 6 were females. Age ranged from 18-69 (median age: 37).   
6.3.2 Morphology and phenotype 
B-PTLD cases included 16 monomorphic B-PTLD (DLBCL), 11 polymorphic B-PTLD and 
2 early lesions (1 infectious mononucleosis-like lesion and 1 plasmacytic hyperplasia), 
whilst, HIV-BCL included 14 HIV-DLBCL, 9 HIV-BL and two PTLD-like lesions Table 
6-1.   
6.3.3 Results of methylation-specific PCR for DAP-kinase gene 
Among B-PTLD, the 2 cases of early lesions as well as the case post transplant reactive 
hyperplasia of the lymph node showed DAP-k hypermethylation. Eight out of eleven (72.7%) 
and 13/16 (81.3%) polymorphic and monomorphic B-PTLD cases respectively were positive 
for DAP-k hypermethylation respectively Figure 6-1. However, we did not find a significant 
difference in the methylation status among different subsets of B-PTLD investigated 
(p=0.541). Among HIV-BCL, 8/9 (88.9%) BL, 9/14 (64.3%) DLBCL, and 1/2 (50%) PTLD-
like lesions showed DAP-k methylation. HIV-BL and HIV-DLBCL did not significantly 
differ with regards to DAP-k methylation (p= 0.171). 
 
With regards to iDLBCL, 14/18 (77.8%) were positive for DAP-k methylation. However, 
there was no significant difference in the proportion of cases that showed AH between PT-
DLBL, HIV-DLBCL and iDLBCL (p=0.54). DAP-k methylation among different subsets is 
shown in Table 6-1. While all normal peripheral blood samples were negative for DAP-k 
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hypermethylation, 4/10 (40%) of peripheral blood lymphocytes from transplant patients were 
positive for AH of DAP-k. 
 
Among the samples positive for DAP-k methylation, 9 B-PTLD (5 polymorphic and 4 
monomorphic lesions), 6 HIV-BCL (1BL, 5 DLBCL) and 3 iDLBCL showed complete 
methylation of the DNA as there were no bands in the unmethylated reactions.   
 
6.3.4 Correlation of AH of DAP-kinase with EBV association: 
Among B-PTLD samples, AH of the DAP-k gene was noted in 79 % of the cases and EBV-
association was noted in 83% cases. 75% of cases positive for EBER and 100 % of cases 
negative for EBER showed AH. However, this did not reach statistical significance 
(P=0.108).  
Among HIV-BCL, AH of the DAP-k was noted in 72% of the cases and EBV association was 
noted in 60% cases.  73% of cases positive for EBER and 70% of cases negative for EBER 
showed AH (p= 0.856).  
On the other hand, among iDLBCL 11.1% were EBV-positive and 77.8% were positive for 
DAP-k methylation. None of the EBER positive cases and 87.5% of EBER-negative cases 
showed AH (p= 0.008). DAP-k methylation and viral association among different categories 
are shown in Figure 6-2.  
 
6.3.5 Correlation of DAP-k methylation with different translocations: 
Overall, 5/15 (33%) cases that lacked AH and 12/50 (24%) cases with AH showed 
rearrangement of the genes tested (p=0.471). Among iDLBCL, 2/4 (50%) cases that lacked 
AH and 3/12 (25%) cases with AH showed rearrangement of the genes tested (p=0.350). 
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Figure 6-1: Methylation-specific PCR of DAP-kinase gene among representative 
samples of PTLD.  
Lanes 1-3, 6, 8-10 & 12-13 are samples positive for methylation as they shows clear band in 
the methylated reaction (M). Lanes 5 &7 are samples negative for methylation as they show a 
clear band in the unmethylated reaction only (U). Samples 9, 12, &13 showed complete 
methylation of the DNA (no products in unmethylated reaction. Samples 4 & 11 did not show 
any products in either U&M and were excluded from the analysis. P- positive control; N- 
negative control, polyacrylamide gel (10%) 
 
 
 
 
Figure 6-2: DAP-k methylation and EBV association among different categories. 
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Table 6-1 Clinicopathological details, frequency of DAP-k hypermethylation and EBV 
status in different histological subtypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histology  Male sex 
(%)  
Age 
range 
(median)  
DAP-k 
methylation  
EBV 
status 
1) B-PTLD (n=29)  
 
• Early lesions (n=2)  
• pPTLD(n=11)  
• mB- PTLD(n=16)  
21(72.4%)  2-73 
43  
23(79.3%) 
 
2 (100%) 
8(72.7%) 
13(81.3%) 
24(82.8%)  
 
1(50%) 
11(100%) 
12(75%)  
2) HIV-BCL (n=25)  
 
• HIV-BL(n=9)  
• HIV-DLBCL(n=14)  
• PTLD-like lesion(n=2)  
22(88%) 26-66  
41  
18(72%)  
 
8(88.9%)  
9 (64.3%) 
1 (50%) 
15(60%)  
 
6 (66.7%) 
7 (50%) 
2 (100%) 
3) iDLBCL (n=18) 
 
12(66.7%) 18-69 
37 
14 (77.8%)  2 (11%) 
Total (n= 72)    55(76%)   41(57%)  
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6.4 Discussion 
There is a growing line of evidence that points to the role of aberrant hypermethylation of 
different genes in the pathogenesis of malignant neoplasms 
452-455
.  
DAP-k, a serine-threonine kinase, plays an important role in apoptosis and its expression is 
triggered by TNFα, INFγ and FAS ligand. Its activity is inhibited as a result of 
hypermethylation of the CpG islands 
133;136;461-463
. The lack of expression of DAP-k 
secondary to hypermethylation of DAP-k gene rescues the cells from INFγ-induced 
programmed cell death favouring their survival and subsequent accumulation of different 
genetic alterations resulting in tumour progression 
461;463-465
. 
 
DAP-k gene is frequently hypermethylated in several types of lymphomas 
468;477;478;478
. We 
found DAP-k hypermethylation in 73% polymorphic PTLD and in 81% monomorphic PTLD. 
This is in line with a study on this topic 
132
.  
Surprisingly, in our study the 2 early PTLD lesions, the case of post transplant reactive 
hyperplasia of lymph node and 40% of post-transplant peripheral blood samples were 
positive for DAP-k hypermethylation, a finding that suggests that DAP-k hypermethylation is 
likely a very early genetic event that might occur even before the establishment of a clonal B-
cell population. However, more studies on a larger series of early lesions of PTLD are 
required to confirm this finding.  
Strategies directed against prevention or reversal of hypermethylation through demethylating 
drugs would represent an additional or an alternative way to strategies used for prevention 
and treatment of EBV-driven lymphoproliferative disorders that display aberrant 
hypermethylation of DAP-k 
455
.  
In line with previous studies, we observed DAP-k hypermethylation in a high proportion of 
HIV-BCL 
132
. BL usually has deregulated c-MYC and DAP-k inactivation through 
hypermethylation may act in a synergetic way with c-MYC in HIV-BL
479
.   
 
We found DAP-k hypermethylation in about three-quarters of iDLBCL, which is in keeping 
with previous reports 
477;478
. However, there was no significant difference in the proportion of 
cases with aberrant hypermethylation of DAP-k among DLBCL in different subsets 
investigated. It is likely that AH of DAP-k is independent of immune deficiency / competent 
status of the patients. 
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Nine cases of B-PTLD, 6 HIV-BCL, and 3 iDLBCL showed complete methylation of DAP-k 
while the rest of the samples had incomplete methylation. The unmethylated alleles amplified 
in cases positive for AH of DAP-k could represent either normal tissue found within the 
tumour samples as none of the samples was microdissected or this could be due to 
heterogeneity of the aberrant hypermethylation process within the tumour itself.  
 
Among iDLBCL, there was a significant inverse relationship between AH of DAP-k and 
EBV-association. This finding refers to that AH of DAP-k might act independently of EBV in 
the pathogenesis of iDLBCL. However, there is no significant correlation between AH of the 
DAP-k gene and EBV association among B-PTLD and HIV-BCL. Additional studies on a 
larger number of cases of PTLD and HIV-BCL are mandatory to confirm this observation.  
To sum up, our results indicated that aberrant hypermethylation of DAP-k is a frequent 
finding in aggressive BCL. Moreover, it is an early event in the pathogenesis of PTLD that 
might even occur before the establishment of clonal population. Aberrant hypermethylation 
of DAP-k, might act either in conjunction with EBV and other known gene rearrangements to 
induce neoplastic transformation or it might act independent of these factors. In addition, 
demethylating drugs would represent an alternative or an additional strategy directed to 
prevent or treat different types of lymphoma including those developing in the context of 
immunosuppression.  
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Chapter 7 
METHYLATION OF SHP1 GENE AMONG IMMUNE DEFICIENCY-
ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS 
7.1 Introduction 
In the previous chapter we found that DAP-k methylation is an early lesion in the 
pathogenesis of IDLD. In this chapter we further extend the methylation assay to include the 
SHP1 gene.  
 
The SHP1 gene is located on chromosome 12p13, and it encodes SHP1 protein. SHP1 is a 68 
kDa, cytoplasmic protein tyrosine phosphatase (PTP) 
141
. It is expressed in hematopoietic 
cells and it potentiates its negative effect on cell cycle regulation by inhibiting the 
JAKs/STATs pathway. In B-lymphocytes, therefore, it inhibits proliferation and its 
deficiency through AH results in overgrowth 
142;143
.  
 
Methylation of SHP1 gene has been investigated among several haematological 
malignancies. These include: 
1) Plasma cell myeloma: It has been suggested that SHP1 methylation might play a role in 
the pathogenesis of plasma cell myeloma through activating JAK2/STAT pathway 
144
.  
2) Lymphoma: SHP1 gene silencing occurs in various lymphoma types including DLBCL 
where it is observed in 80% of cases 
138;144;480;481
.  
With regards to SHP1 methylation in IDLD, we could identify only a single abstract of a 
presentation at a scientific meeting in the literature 
145
. SHP1 methylation was frequently 
present in IDLDs being observed in 23/48 (48%) HIV-NHL cases, including 12/21 (57%) 
HIV-DLBCL, 3/17 (17.6%) HIV-BL, and 8/10 (80%) HIV-PEL. Among B-PTLD, SHP1 
methylation was also detected in 19/25 (76%) cases, including 13/17 (76.5%) PT-DLBCL), 
3/4 (75%) pPTLD, 2/3 (66%) PT-BL and 1 PT-multiple myeloma (PT-MM). 
 
We aimed to investigate the presence of SHP1 methylation in IDLD and to correlate it with 
EBV-association. 
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7.2 Materials and methods:  
The samples analysed included 6 cases of B-PTLD (1 plasmacytic hyperplasia, 5 PT-
DLBCL) and 10 cases of HIV-BCL (4HIV-BL and 6 HIV-DLBCL). DNA from normal 
peripheral blood lymphocytes of 8 samples was used as a negative control. 
Methods for tissue array construction, in-situ hybridization and methylation-specific PCR are 
described in the methods chapter. 
The cases were considered positive for SHP1 methylation when there was a clearly visible 
band of the expected size (159 bp) with the primers specific for methylated reaction. The 
unmethylated reaction yielded a 159 bp product. 
 
7.3 Results 
7.3.1 Clinical characteristics 
Among 6 cases B-PTLD, 4/6 (66.6 %) were male and 2 were female. Age ranged from 34-80 
years (median age: 46.5 years). AIDS-BCL cases included 8/10(80%) males and two females. 
Age ranged from 26-49 years (median age: 40.5 years).   
7.3.2 Morphology and phenotype 
The six cases of B-PTLD, included (1 plasmacytic hyperplasia and 5 PT-DLBCL), whilst the 
10 cases of HIV-BCL included (4HIV-BL and 6 HIV-DLBCL) Table 7-1. 
7.3.3 Results of methylation-specific PCR for SHP1 gene 
Three out of six (50%) of B-PTLD samples, including the case of plasmacytic hyperplasia, 
and 2/5 (40%) PT-DLBCL showed aberrant hypermethylation of SHP1 gene. On the other 
hand, 7/10(70%) HIV-BCL, including 3/4 (75%) of HIV-BL and 4/6 (66.7%) of HIV-
DLBCL were positive for SHP1 aberrant hypermethylation Figure 7-1. The methylation was 
incomplete in all B-PTLD samples and in 3/7 HIV-BCL. This could be either due to normal 
tissue found within the tumour samples as none of the samples was microdissected or due to 
heterogeneity of the aberrant hypermethylation within the tumour sample itself. All normal 
blood samples were negative for SHP1 hypermethylation. 
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7.3.4 Correlation of SHP1 gene methylation with EBV status 
Overall, 8/16 (50%) were EBV- associated and 10/16 (62.5%) were positive for SHP1 
hypermethylation. 50% of EBV-positive cases and 50% of EBV-negative cases showed 
SHP1 methylation (p=0.302). 
 
 
Table 7-1   Clinicopathological details, frequency of SHP1 methylation of samples analysed 
Histology Male sex 
(%) 
Age range 
(median) 
SHP1 
methylation 
EBV-
association 
1) B-PTLD (n=6)  4 (66.6 %) 
 
34-80 
( 46.5) 
 
3 (50%)  
Early lesions (n=1)  1 (100%) 0 (0%) 
B-PTLD-DLBCL (n=5) 2 (40%) 1 (20%) 
2) HIV-BCL (n=10)  8 (80%) 26-49 
(40.5) 
7 (70%)  
HIV-BL (n=4) 3 (75%) 3 (75%) 
HIV-DLBCL (n=6)  4 (66.7%) 4 (66.7%) 
 
 
 
 
 
Figure 7-1: Methylation-specific PCR of SHP1 gene among representative HIV-B-cell 
lymphoma samples.  
Lanes 1, 2 & 4-6 are samples positive for SHP1 methylation (clear bands in methylation 
reaction (M)); lane- 3- is a sample negative for SHP1 methylation (clear bands in 
unmethylated reaction only (U)).  Samples 1,5 & 6 showed complete methylation; P-positive 
control; N-negative control; Polyacrylamide gel (10%). 
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7.4 Discussion 
SHP1 gene, a tumour suppressor gene, encodes SHP1 protein which is a cytoplasmic protein 
tyrosine phosphatase (PTP)
141
. It is expressed in hematopoietic cells and it inhibits 
JAKs/STATs pathway and therefore potentiates its negative effect on cell cycle regulation. In 
B-lymphocytes, therefore, it inhibits proliferation and its deficiency through aberrant 
hypermethylation results in overgrowth 
142;143
. In support of this, SHP1 gene silencing 
through AH has been shown to frequently occur in various lymphoma types including 
DLBCL and in multiple myeloma as well 
138;144;480;481
.  
 
Among HIV-BCL, we found aberrant hypermethylation of the SHP1 gene in 70% HIV-BCL, 
which is in keeping with the findings of Cerri et al. 
145
. We found SHP1 hypermethylation in 
one-half of B-PTLD samples, including the case of plasmacytic hyperplasia. However, the 
presence of SHP1 hypermethylation in the case of plasmacytic hyperplasia suggests that it is 
likely a very early event in the pathogenesis of PTLD that might even occur much before the 
establishment of clonal B-cell population. We hypothesize that SHP1 gene repression through 
aberrant hypermethylation results in loss of negative control of SHP1 on the cell cycle with 
subsequent release of JAKs/STATs pathway from the inhibitory effect and this in turn results 
in uncontrolled proliferation of B-lymphocytes and lymphoma development. 
 
In conclusion, our results show that SHP1 aberrant hypermethylation is frequently seen in 
immunodeficiency-related lymphomas and might be a very early event in the pathogenesis of 
PTLD.  It is independent of EBV-status of the tumour samples. 
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Chapter 8 
TUMOUR-INFILTRATING PLASMACYTOID DENDRITIC CELLS IN B-CELL 
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS, HIV-
ASSOCIATED B-CELL LYMPHOMAS AND IMMUNE COMPETENT- DIFFUSE 
LARGE B-CELL LYMPHOMAS. 
 
8.1 Introduction 
PDCs are potent antigen-presenting cells that originate from hematopoietic stem cells in the 
bone marrow under the effect of certain cytokines, principally Flt3L. PDCs migrate through 
the blood to lymphoid organs, including mucosal-associated lymphoid tissue, lymph nodes, 
the spleen and the thymus. In the lymph nodes, they home into the paracortical T-cell areas 
close to the high endothelial venules 
240
. PDCs can be identified through their expression of 
CD45RA, CD123 (IL-3R), Blood dendritic cell antigen 2 (BDCA2) and BDCA-4 
238;267
. 
 
PDCs play an important role in fighting viral infections through the expression of toll-like 
receptors (TLRs) 7, 8 & 9. PDCs produce type I interferon (IFN-I), which boosts the 
cytotoxic function of CD8
+
 T cells and NK cells. IL-6 and IL-12 are also produced by PDCs. 
IL-6 and IFN-I help the terminal differentiation of memory B-cells to plasma cells, which in 
turn generates antiviral antibodies, whereas the IL-12 and IFN-I together facilitate the 
production of IFN-γ in CD4+ T cells, CD8+ T-cells and NK cells 244-247.  
 
Tumour infiltration by PDCs and their clinical impact has been studied in melanomas, breast 
cancer, squamous cell carcinoma, basal cell carcinoma and certain lymphomas 
242
. PDCs are 
reported to be markedly decreased in number and qualitatively altered in non-Hodgkin‟s 
lymphoma compared with reactive lymph nodes. However, they are reported to be present in 
increased numbers in classical Hodgkins lymphoma (cHL) 
242
. Presence of PDC clusters are 
also documented in cutaneous marginal zone B-cell lymphoma 
277
.  
 
To our knowledge, no work has previously been published to establish whether PDCs play a 
role in IDLDs. Therefore, we address this question by investigating the prevalence of PDCs 
in B-PTLD, HIV-associated B-cell lymphoma and iDLBCL. We then correlated the impact of 
EBV-association on PDC infiltration. 
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8.2 Material and methods:  
We analysed tumour samples from 62 B-PTLD, 23 HIV-BCL and 58 iDLBCL. 
Methods for tissue array construction, immunohistochemistry and in-situ hybridization are 
described in the Methods chapter. 
Primary antibodies to CD123 (7G3; BD Bioscience) in a dilution of 1:200 and BDCA-2 
primary antibody (124B3-13; Cambridge biosciences) in a dilution of 1:160 were used to 
assess the prevalence of PDCs in the tumour microenvironment. Antigen retrieval was carried 
out by microwaving in EDTA at pH 9.0 for 20 min. For every run of immunostaining, 
paraffin sections of normal human tonsil, reactive lymph node and spleen were used as 
positive control slides. As a negative control, PBS was used to replace the primary antibody. 
In addition to PDCs, CD123 was also expressed by some of the endothelial cells. The 
endothelial cell staining served as an internal positive control. The staining pattern in the 
endothelial cells was weak and diffuse and this helped differentiate the endothelial cells from 
the lymphoid cells with their crisper pattern of staining.  In contrast, expression of BDCA-2 
was restricted to PDCs. CD123- and BDCA-2-positive cells were quantified in each of the 
tissue cores and then expressed as cells per mm
2
 by using a gridded cover-slip. 
Statistical analysis: The mean values of the infiltrating CD123/BDCA-2-positive cells were 
compared between groups using One-way ANOVA and Scheffe's test.  'p' values of <0.05 
was considered significant and those <0.1 was considered a trend towards significance. 
Statistical analysis was performed using SPSS software version 17.0. 
 
8.3 Results 
8.3.1 Clinical characteristics:  
Forty-two out of the sixty-two B-PTLD patients (67.7%) were males. The age ranged from 2 
to 80 years (median 42 years). In the HIV-BCL cases, 21/23 (91.3%) were males, aged 26 to 
66 years (median 41 years). In the iDLBCL cases, 33/ 55 (60%) were males, age range 18 to 
86 years (median 48 years). 
8.3.2 Morphology and phenotype:  
All cases were classified according to the current WHO classification 
38;159;482
. Among PTLD 
samples, 5 were early lesions (4 infectious mononucleosis-like (IM-like) lesions and 1 
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plasmacytic hyperplasia), 18 were polymorphic B-PTLD, and 38 monomorphic B-PTLD (3 
PT-BL, 30 PT-DLBCL, and 5 PT-PL respectively). Among HIV-BCL, 8 were BL, 13 were 
DLBCL, 1 PL and one was a case of polymorphic PTLD-like lesion. 
8.3.3 Numbers of PDCs among different categories  
Overall, B-PTLDs had significantly greater numbers of PDCs compared with other HIV-BCL 
and iDLBCLs. 
8.3.3.1 Number of PDCs among different subsets of B-PTLD:  
Among B-PTLD, there were significant differences in the number of infiltrating PDCs 
between early and polymorphic B-PTLD and early and monomorphic B-PTLD. Within B-
PTLD, the PDC numbers were highest in early lesions, intermediate in polymorphic B-PTLD 
and lowest in monomorphic B-PTLD Table 8-1; Figure 8-1 & Figure 8-2. There were 
statistically insignificant differences in PDC numbers between polymorphic B-PTLD and 
monomorphic B-PTLD. Similarly, though PT-DLBCL had 4-5 fold higher numbers of PDCs 
compared with the other monomorphic B-PTLDs, the differences were not statistically 
significant. 
8.3.3.2 Numbers of PDCs among HIV-BCL:  
Though, the infiltrating PDC numbers were 1.2 fold higher among HIV-BL compared with 
HIV-DLBCL, these were not statistically significant. 
8.3.3.3 Numbers of PDCs among DLBCLs within different groups:  
PT-DLBCL had significantly higher numbers of PDCs than iDLBCL  Table 8-2, Figure 8-3 
& Figure 8-4. 
 
8.3.4 Correlation of PDC numbers with EBV-association among PTLD:  
Among 62 PTLDs, 48 were EBV associated (EBER
+
). Though EBV
- 
B-PTLD had >1.5 fold 
higher numbers of PDCs compared with EBV
+
 B-PTLD, this was not statistically significant. 
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Table 8-1 Numbers of plasmacytoid dendritic cells per mm
2
 of tumour tissue among different 
categories of PTLD (Values expressed as mean value ± 2 SE) 
 Early 
lesions  
(5 cases) 
P-PTLD 
(18 cases) 
M-PTLD 
(39 cases)   
Significance 
(One-way 
Anova) 
Significant 
differences 
between specific 
subsets (Scheffe 
test) 
CD123 147±116.2 56.1±32.1 26.0±14.5 <0.001 Early & 
polymorphic 
(p=0.019), early 
& monomorphic 
( p=0.001) 
BDCA2 141.7±106.3 58.9±33.5 28.85±14.2 0.001 Early & 
polymorphic 
(p=0.032), early 
& monomorphic 
(p=0.001) 
 
 
 Table 8-2 Numbers of plasmacytoid dendritic cells per mm
2
 of tumour tissue among DLBCL subsets 
in different groups (Values expressed as mean value ± 2 SE) 
 PT-DLBCL 
(30 cases) 
HIV-
DLBCL  
(13 cases) 
iDLBCL 
(53 cases) 
Significance 
(One-way 
Anova) 
Significant 
differences 
between specific 
subsets (Scheffe 
test) 
CD123 30.84±17.8 12.43±14.6 3.59±1.2 0.001 PT-DLBCL and 
iDLBCL (p=0.001) 
BDCA2 33.5±17.2 13.2±16 4.99±1.7 <0.001 PT-DLBCL and 
iDLBCL (p<0.001) 
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Figure 8-1  Increased numbers of tumour-infiltrating CD123+ and BDCA2+ PDCs in 
representative examples of early and polymorphic PTLD; immunohistochemistry 
(x200). 
. 
BDCA2
Early lesion
pPTLD
CD123
CD123 BDCA2
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Figure 8-2: Boxplots showing the density of PDCs among different categories of PTLD.  
A) There were significant differences in the density of CD123
+ 
cells between early lesions 
and polymorphic PTLD (pPTLD) (P=0.019), and early lesions and monomorphic PTLD 
(mPTLD) (P=0.001). B) Similarly, there were significant differences between the density of 
BDCA2
+ 
cells, between early lesions and pPTLD (P=0.032) and between early lesions and 
mPTLD (P=0.001). 
Early lesions      pPTLD            mPTLD
CD123
Early lesions     pPTLD            mPTLD
BDCA2
P=0.019
P=0.001
P=0.032
P=0.001
A
B
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Figure 8-3 Tumour-infiltrating BDCA2+ cells in representative post-transplant diffuse 
large B cell lymphoma (PT-DLBCL) cases, HIV-DLBCL and iDLBCL.  
PT-DLBCL show a higher density of PDCs compared with iDLBCL; immunohistochemistry 
(x400). 
BDCA2
PT-DLBCL
HIV-DLBCL
iDLBCL
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Figure 8-4  Boxplots showing the numbers of PDCs among different categories of DLBCL.  
A) There were significant differences in the density of CD123
+ 
cells between post-transplant 
DLBCLs (PT-DLBCL) and DLBCLs in immune-competent patients (iDLBCL) (p=0.001). B) 
Similarly, there were significant differences in the density of BDCA2
+ 
cells between early 
lesions and polymorphic PT-DLBCL and iDLBCL (p<0.001). 
PT-DLBCL     HIV-DLBCL       iDLBCL
CD123
BDCA2
PT-DLBCL     HIV-DLBCL     iDLBCL
P=0.001
P<0.001
A
B
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8.4 Discussion 
Immune deficiency lymphoproliferative disorders (IDLD) develop as a consequence of 
immunosuppression. Immunodeficiency settings may be of congenital, infectious or 
therapeutic origin. PTLD and HIV-lymphomas are well-known examples and are similar in 
some aspects: most are derived from B-cells with preferential presentation as NHL as 
opposed to Hodgkin lymphoma. They originate usually in extranodal sites, they rarely affect 
skin, they behave aggressively and frequently harbour the EBV genome 
1
. A smaller 
proportion of lymphomas are either of T-cell or NK-cell lineages 
2;3
. Although IDLDs have 
been studied in great depth, to our knowledge, this study is the first to investigate the 
prevalence of PDCs in the microenvironment of IDLDs. 
 
Our results show that early lesions of PTLD harbour higher but not statistically significant 
numbers of PDCs than polymorphic PTLD and significantly higher numbers than 
monomorphic PTLD. It is currently difficult to say whether the large numbers of PDCs in 
early lesions have suppressive or co-operative influence on the expanding clones of PTLD. It 
is possible that early lesions remain „early‟ due to suppressive influence of PDCs on virally 
infected oligoclonal or polyclonal lymphoid populations. As PTLD evolves, and the 
neoplastic clones accumulate additional genetic lesions, they become relatively more 
independent of PDCs. Furthermore, it is likely that the EBV
- 
PTLDs are driven by, as yet, 
unidentified infective agents, because they also harbour larger numbers of PDCs compared 
with EBV
+
 PTLD. Although PDC numbers decrease as the disease progresses, from early to 
polymorphic and from polymorphic to monomorphic lesions, monomorphic PT-DLBCLs 
have significantly higher numbers of PDCs compared with iDLBCL. 
 
We speculate that the paradoxical finding of reduced numbers of circulating blood PDC 
precursors, demonstrated in renal and cardiac transplant recipients 
278
 might be attributable to 
the redistribution of PDCs from peripheral blood to the microenvironment of the lymphoid 
organs (i.e. the site of infected lymphoid cells). However, as our study did not include 
circulating PDCs, it is difficult to speculate whether the relative distribution of the PDCs 
between blood and tissues varies with disease progression in PTLD.   
In HIV-BCL, there was no significant difference in PDC numbers between BL and DLBCL. 
However, HIV-DLBCL samples had higher numbers of PDCs as compared to iDLBCL. It 
has been suggested that, in HIV infection, PDCs are activated peripherally, and then are 
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redistributed to the lymph nodes in a manner similar to that seen in patients with systemic 
lupus erythematosus, where PDCs are recruited from the peripheral blood to the skin  
253
. In 
chronically HIV-infected individuals, PDCs are also redistributed to the spleen 
248
. 
 
To conclude, the presence of significantly higher numbers of PDCs in early lesions of PTLD 
compared with more established PTLD and in PT-DLBCL compared with iDLBCL, and 
finally in HIV-DLBCL compared with iDLBCL, strongly suggests that PDCs play a 
pathogenetically relevant role in immunodeficiency lymphoproliferative disorders. 
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Chapter 9 
REGULATORY T-CELLS, NK CELLS AND T-CELL SUBSETS IN B-CELL POST-
TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS, HIV-ASSOCIATED B-
CELL LYMPHOMAS AND IMMUNE COMPETENT DIFFUSE LARGE B-CELL 
LYMPHOMAS. 
9.1 Introduction  
In the previous chapter we investigated resident PDCs in the microenvironment of IDLD. In 
this chapter we will discuss the role of non-tumoural infiltrating lymphoid cells in the 
pathogenesis of IDLD.   
 
Over the past decade, Treg cells have come under intense investigation in human diseases
330
. 
The identification of large numbers of Treg cells in the peripheral blood of cancer patients, 
within the tumour microenvironment or in lymph nodes draining tumours indicates a possible 
role in cancer-induced immunosuppression 
331-334
. These cells became the focus of interest 
after the identification of population of CD4
+
 T lymphocytes with high levels of CD25 
expression which could prevent autoimmunity in mice 
335
.  Several types of Treg cells have 
been identified. Among these are naturally occurring Treg cells and induced Treg cells. 
Naturally occurring Treg cells develop in the thymus and are exported in a fully-functional 
state 
347
. Induced T reg cells include; Treg1, Th3, and CD8 expressing Treg cells. Treg1 cells 
are derived, under the influence of IL-10, from CD4
+
 T-lymphocytes and are chronically 
active in both mice and humans. This subset produces high levels of IL-10, low level of IL-2 
and no IL-4 and can suppress the proliferation of CD4
+
 T-lymphocytes in response to 
antigens. Th3 cells can be generated in vivo after oral administration of antigen and produce 
TGF-β as well as IL-4 and IL-10 348-350. There is a small population of Treg cells which 
express CD8 and not CD4 
351
.  
 
The intratumoural Treg cells have been shown to have an inhibitory effect on production and 
release of perforin and granzyme B, which are necessary for the effector function of CD8+ 
cells and CTC-mediated lysis of tumour cells 
355;356
. Treg cells are also known to have a 
direct effect on B-lymphocytes, and inhibit the production of immunoglobulins 
363
.  
Treg cells can suppress the growth of some tumours in addition to its role in suppression of 
the anti-tumour immune response 
483
. Higher numbers of Treg cells have been described to be 
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predictors of improved survival in follicular lymphoma and to predict response to therapy  
345
. Treg cells are seen in higher numbers in tissue samples of B-cell lymphomas as compared 
to reactive lymph nodes or tonsils and this is thought to be due to attraction of Treg cells to 
the tumour microenvironment through CCL22 secreted by the lymphoma cells 
345;365
. 
CD57 positive cells account for 10-25% of the peripheral blood cells, which include CD8
+
 T-
cells and CD16
+
/CD56
+
 NK cells. Normal CD8
+
 CD57
+
 T-cells suppress generation of CTC 
cells in response to EBV-transformed lymphoblastoid cells. These cells preferentially 
mediate lectin dependent cytotoxicity 
377;378
. Within lymphoid tissues CD4
+ 
CD57
+
 T-cells 
specifically identify follicular T- helper cells (TFH), which also expresses BCL6, CD10 and 
PD-1 and secrete the chemokine CXCL13. These cells present in normal germinal centres are 
also the normal lymphoid cell counterpart of neoplastic cells in angioimmunoblastic T-cell 
lymphoma 
379;380
. They form an important component of the microenvironment of follicular 
lymphoma and nodular lymphocytic predominant Hodgkin lymphoma 
384;385
. 
 
Lymphoproliferative disorders in immune deficient states are distinctive from other 
lymphomas in that an infective agent, often a virus (e.g. Epstein Barr virus (EBV) and 
Human Herpes virus 8 (HHV8)) plays a central role in the proliferation. In many cases, the 
neoplastic cells harbour the virus. Despite the knowledge that viral infections lead to 
significant immune responses, literature on the immune-microenvironment in these disorders 
are rather scanty 
312;484;485
. We, therefore, intended to study the prevalence of different T cell 
subsets including Treg cells and NK cells in the microenvironment of these disorders and to 
find out whether there is a significant difference when compared to iDLBCL. We further 
correlated the impact of EBV-association on the infiltration of these T-cell subsets and NK 
cells. 
 
9.2 Materials and methods:  
We analysed tumour samples from 61 B-PTLD, 23 HIV- BCL and 55 iDLBCL.  
Methods for tissue array construction, immunohistochemistry including double-
immunostaining, in-situ hybridization and combined immunohistochemistry and in-situ 
hybridization are described in the Methods chapter. 
Primary antibodies to FOXP3 (236A/E7; eBioscience) in a dilution of 1:200 were used. 
Antigen retrieval was carried out by microwaving in citrate buffer at pH 6.0 for 20 min. For 
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every run of immunostaining, paraffin sections of normal human tonsil, reactive lymph node 
and spleen were used as positive control slides. As a negative control, PBS was used to 
replace the primary antibody. Immunotaining procedures for rest of the antibodies FOXP3, 
CD3, CD4, CD8, CD56, CD57, and granzyme B positive cells were quantified in each of the 
tissue cores and then expressed as cells per mm
2
 by using a gridded cover-slip. 
The mean values of the non-tumoural infiltrating FOXP3, CD3, CD4, CD8, CD56, CD57, 
and granzyme B positive cells were compared between groups using One-way ANOVA and 
Scheffe's test. The correlation between the tumour infiltrating FOXP3+ and CD8+ or 
granzyme among different categories of DLBCL was investigated by bivariate analysis and 
Pearson correlation. 'p' values of <0.05 were considered significant and those <0.1 was 
considered a trend towards significance. Statistical analysis was performed using SPSS 
software version 17.0.  
 
9.3 Results: 
9.3.1 Clinical characteristics:  
Among B-PTLD, 42 of 61 (67.7%) were males. The age ranged from 2 to 80 years with a 
median age of 42 years. Among HIV-B-cell-lymphomas, 21 of 23 (91.3%) were males. The 
age ranged from 26 to 66 years with a median age of 41 years. While in iDLBCL, 30/55 
(54.5%) were males and the age ranged from 18 to 86 years with a median age 48 years. 
9.3.2 Morphology and phenotype:  
Among PTLD samples, 5 were early lesions, 19 were classified as polymorphic PTLDs, and 
37 as monomorphic PTLDs (3 PT-BL, 29 PT-DLBCL, and 5 PT-PL respectively). Among 
HIV-NHL, 8, 13, 1 and 1 were classified as BL, DLBCL, PL and polymorphic PTLD-like 
lesion respectively. Fifty five cases were iDLBCL. 
9.3.3 Numbers of FOXP3, CD3, CD4, CD8, CD56, CD57, and granzyme B-positive cells 
among B-PTLD, HIV-BCL and iDLBCL (values expressed as mean value ± 2 SE):    
The mean values for CD3, CD4, CD8, CD56, CD57, granzyme B, and FOXP3-positive
 
cells 
are listed in Table 9-1 . Among iDLBCL, there was variable loss of tissue cores among 
different TMAs, and 37-48 analyzable samples were available for each of the different 
antibodies evaluated. 
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9.3.3.1 Comparison of PTLD subsets:  
With regard to FOXP3
+ 
cells, there was a trend towards significant difference between early 
lesions & polymorphic PTLD (166+55 vs. 79+30 cells per mm
2
; p=0.091) and early lesions 
& monomorphic PTLD (166+55 vs. 74+27 cells per mm
2
; p=0.051) Figure 9-1 & Figure 
9-2. Similarly, CD4+ cells showed a trend toward significant difference between early lesions 
& polymorphic PTLD (876+576 vs. 289+145 cells per mm
2
; p=0.052) and early lesions & 
monomorphic PTLD (876+576 vs. 391+168 cells per mm
2
; p=0.099). There were no 
significant differences in the infiltration of other lymphoid cell subsets investigated. We also 
did not find any significant difference in the infiltration between different categories of 
monomorphic PTLD.  
9.3.3.2 Comparison of HIV-BCL subsets:  
Compared with HIV-BL, HIV-DLBCL had significantly higher numbers of CD4+ cells 
(48.7+27.7 vs 184.9+89.9; p=0.032) and FOXP3
+
 lymphoid cells (50+23 vs. 7+4 cells per 
mm
2
; p=0.011). There were no significant differences in the infiltration of other lymphoid 
cell subsets investigated Figure 9-1& Figure 9-3. 
9.3.3.3 Comparison of PT-BL and HIV-BL:  
Compared with PT-BL, HIV-BL had significantly higher numbers of CD56
+
 cells (6 vs. 1+1 
cells per mm
2
; p=0.017), and showed a trend towards higher numbers of granzyme B
+
 cells 
(41+23 vs. 2+4 cells per mm
2
; p=0.077), There were no significant differences in the 
infiltration of other lymphoid cell subsets investigated Figure 9-4.  
9.3.3.4 Comparison of PT-DLBCL, HIV-DLBCL and iDLBCL:  
There were significant differences in the numbers of tumour infiltrating lymphoid cells 
between the three subsets. Generally, they were highest in PT-DLBCL, intermediate in HIV-
DLBCL and lowest in iDLBCL. The values and the significance levels are shown Table 9-2. 
Figure 9-5, Figure 9-6, Figure 9-7, Figure 9-8 & Figure 9-11 
9.3.3.5 Correlation between FOXP3 and CD8 or Granzyme B in PT-DLBCL, HIV-DLBCL 
and in iDLBCL:  
In PT-DLBCL there was a direct correlation between FOXP3+ cells and CD8+ cells 
(p=0.006) but no significant correlation was reached between FOXP3+ cells and Granzyme 
B+ cells. With regard to HIV-DLBCL, there was a direct correlation between FOXP3 and 
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CD8+ cells (p=0.001) and between FOXP3 and Granzyme B+ cells (p=0.038). There was no 
correlation between FOXP3 and CD8/granzyme-B positive cells in iDLBCL Figure 9-9. 
9.3.4 Correlation between the numbers of non-tumoural infiltrating lymphocytes and 
EBV-association:  
Among B-PTLD samples, EBV-negative cases as compared to EBV-positive cases had 
significantly higher numbers of CD4
+
 cells (709+374 vs. 314+121 cells per mm
2
; p=0.011) 
and FOXP3
+
 cells (135+63 vs. 70+20 cells per mm
2
; p=0.014). There was a trend towards 
presence of higher numbers of CD56
+
 cells in EBV-negative cases as compared to EBV-
positive cases (22+13 vs. 12+4 cells per mm
2
; p=0.064). There were no significant 
differences in the infiltration of other lymphoid cell subsets investigated. 
Among HIV-BCLs, EBV-positive cases compared with EBV-negative cases had significantly 
higher numbers of granzyme B
+
 cells (87+28 vs. 34+31 cells per mm
2
; p=0.019) Figure 9-10. 
There were no significant differences in the infiltration of other lymphoid cell subsets 
investigated. 
Among the EBV-positive PTLD, EBV-LMP1 expression did not have any impact on the 
density of infiltrating CD4
+
, CD56
+
 or FOXP3
+
 cells. Similarly, among HIV-BCL EBV-
LMP1 expression did not have any impact on the density of infiltrating Granzyme B
+
 cells. 
 
 
9.3.5 Results of double immunostains:  
On FOXP3/CD4 double-stain, not all FOXP3
+
 cells expressed CD4; on FOXP3/CD25 
double-stain, nearly all FOXP3
+
 cells expressed CD25; and on FOXP3/CD20 double-stain, 
none of FOXP3
+
 cells expressed CD20 Figure 9-11. 
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Table 9-1 Numbers of FOXP3, CD3, CD4, CD8, CD56, CD57, and granzyme B-positive cells 
among categories (Values expressed as mean cells/mm
2
 ± 2 SE) 
 PTLD HIV-BCL iDLBCL Significance 
CD3 887±225 452.208±131.8 259±52 B-PTLD vs HIV-BCL 
(p=0.017) 
B-PTLD vs iDLBCL 
(p=<0.001) 
CD4 403.1±127 148.85±60.0 188±36 B-PTLD vs HIV-BCL 
(p=0.013) 
B-PTLD vs iDLBCL 
(p=0.016) 
CD8 483.52±130 299.94±75.6 78±20 B-PTLD vs iDLBCL 
(p=<0.001). 
HIV-BCL vs  
iDLBCL(0.057) 
CD56 14.994±4.8 4.383±3.7 2±1 B-PTLD vs HIV-BCL 
(p=0.005) 
B-PTLD vs iDLBCL 
(p=<0.001) 
CD57 48.61±10.1 34.65±13.3 18±5 B-PTLD vs iDLBCL 
(p=<0.001) 
FOXP3 84.79±20.7 37.71±16 40±7 B-PTLD vs HIV-BCL 
(p=0.005) 
B-PTLD vs iDLBCL 
(p=0.001) 
Granzyme B 76.49±17.3 67.1±21.1 13±4 B-PTLD vs iDLBCL 
(p=<0.001) 
HIV-BCL vs iDLBCL 
(p=<0.001) 
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Table 9-2 Numbers of FOXP3, CD3, CD4, CD8, CD56, CD57, and granzyme B-positive cells 
among DLBCL of different immune groups (Values expressed as mean cells/mm
2
 ± 2 SE) 
 PT-DLBCL HIV-
DLBCL 
iDLBCL Significance 
CD3 988±368 511±194 259±52 PT-DLBCL vs. iDLBCL 
(p=<0.001)  
PT-DLBCL vs. HIV-
DLBCL (p=0.079) 
CD4 457±202 185±90 188±36 PT-DLBCL vs. iDLBCL 
(p=0.008) 
PT-DLBCL vs. HIV-
DLBCL (p=0.060) 
CD8 559±229 316±108 78±20 PT-DLBCL vs. iDLBCL 
(p=<0.001)  
CD56 13±6 6±6 2±1 PT-DLBCL vs. iDLBCL 
(p=0.001) 
CD57 45±13 42±21 18±5 PT-DLBCL vs. iDLBCL 
(p=0.001) 
HIV-DLBCL vs. iDLBCL 
(p=0.042) 
FOXP3 84±32 50±23 40±7 PT-DLBCL vs. iDLBCL 
(p=0.008) 
Granzyme B 85±28 79±33 13±4 PT-DLBCL vs. iDLBCL 
(p=<0.001)  
HIV-DLBCL vs. iDLBCL 
(p=<0.001) 
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Figure 9-1 Tumour-infiltrating FOXP3+ cells in representative samples of PTLD, HIV-BCL 
and iDLBCL.  
The images show increased tumour-infiltrating FOXP3+ cells in an early lesion as compared 
to pPTLD and mPTLD cases (x200), and in HIV-DLBCL as compared to iDLBCL (x400) 
and HIV-BL (x200); on immunohistochemistry  
 
 
 
 
 
Early lesion
pPTLD
mPTLD
HIV-BL
HIV-DLBCL
iDLBCL
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Figure 9-2 Boxplots showing the numbers of FOXP3+ cells in different subsets of PTLD 
(early, pPTLD and mPTLD).  
The numbers are highest in early lesions, intermediate in pPTLD and lowest in mPTLD. 
 
 
 
 
 
 
 
 
p=0.052
early lesions        pPTLD           mPTLDA
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Figure 9-3 Boxplots showing the numbers of FOXP3+ and CD4+ cells in HIV-Burkitt 
lymphoma and HIV-DLBCL.  
A) There were significant differences in the density of FOXP3+
 
cells between HIV-BL and 
HIV-DLBCL (P=0.011), and B) in CD4+ cells between HIV-BL and HIV-DLBCL 
(p=0.032). 
p=0.032
p=0.011
HIV-BL                   HIV-DLBCL
HIV-BL                     HIV-DLBCL
A
B
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Figure 9-4 Boxplots showing the numbers of CD56+, Granzyme B+ cell in PT-BL and 
HIV-BL.  
A)  HIV-BL tended to have higher numbers of granzyme B+ cells than PT-BL (p=0.077). B) PT-BL 
had significantly higher numbers of CD56+ cells than HIV-BL (P=0.017). 
p=0.017
p=0.077
PT-BL                       HIV-BL
PT-BL                         HIV-BL
A
B
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Figure 9-5 Tumour-infiltrating CD4+ and CD8+ lymphoid cells in representative 
samples from different categories of DLBCL.  
The numbers of CD4+ cells were higher in PT-DLBCL, intermediate in iDLBCL and lowest 
in HIV-DLBCL. The numbers of CD8+ cells were highest in PTLD, intermediate in HIV-
DLBCL and lowest in iDLBCL; on immunohistochemistry (x400). 
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Figure 9-6 Tumour-infiltrating CD57+ (A-C) and granzyme B+ (D-F) cells in 
representative samples from different categories of DLBCL.  
The numbers were highest in PT-DLBCL, intermediate in HIV-DLBCL and lowest in 
iDLBCL; on immunohistochemistry (x200). 
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Figure 9-7 Boxplots showing the density of CD56+ and CD57+ cell in different 
categories of DLBCL.   
A) PT-DLBCL had significantly higher numbers of CD56+ cells compared with iDLBCL 
(p=0.001). B) There were significant differences in the density of CD57+ cells between PT-
DLBCL and iDLBCL (P=0.001) and between HIV-DLBCL and iDLBCL (P=0.042). 
p=0.001
p=0.001
p=0.042
PT-DLBCL     HIV-DLBCL       iDLBCL                          
PT-DLBCL      HIV-DLBCL       iDLBCL                          
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Figure 9-8 Boxplots showing the density of FOXP3+, Granzyme B+ cell in different 
categories of DLBCL.  
A) PT-DLBCL had significantly higher numbers of FOXP3
+ 
cells compared with iDLBCL 
(P=0.008). B) Significantly higher numbers of granzyme B+ cells were seen in PT-DLBCL 
compared with iDLBCL (P=<0.001) and in HIV-DLBCL compared with iDLBCL 
(P=<0.001). 
P=0.008
P =<0.001
P =<0.001
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Figure 9-9 Correlation graph of FOXP3+ cells and CD8+ cells/granzyme B+ cells.  
There was a direct correlation between CD8+ and FOXP3+ cells in PT-DLBCL (p=0.006) 
(A) and in HIV-DLBCL (p=0.001) (B). There was a direct correlation between granzyme B+ 
and FOXP3+ cells in HIV-DLBCL (p=0.038)(C). 
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Figure 9-10 Boxplots showing the numbers of granzyme B+ cells in EBV-negative and 
EBV-positive HIV-BCL.  
EBV-positive cases had significantly higher numbers of granzyme B+ cells compared with 
EBV-negative cases (p=0.011). 
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Figure 9-11 the density of CD56+ cells in a representative sample of PT-DLBCL and 
double immunohistochemistry for FOXP3 and CD20/CD4/CD25.  
A) The density of tumour-infiltrating CD56+ cells in PT-DLBCL; on 
immunohistochemistry(x200). Expression of FOXP3 and CD20 is mutually exclusive 
(B)(x400) and not all FOXP3+ cells express CD4 (C), nearly all FOXP3+ cells expressed 
CD25 (D) (x200) . B-D) (double immunostaining of FOXP3 (red) and CD20, CD4 or CD25 
(brown).  
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9.4 Discussion 
This study draws attention to the importance of the immune cells in the microenvironment of 
lymphoproliferative disorders, particularly in the setting of immune deficiency. Immune 
deficiency lymphoproliferative disorders (IDLD) develop as a consequence of 
immunosuppression. Immunodeficiency may be congenital, infectious or therapeutic in 
origin. PTLDs and HIV-lymphomas are well-known examples and are similar in some 
aspects: most are derived from B-cells with preferential presentation as non-Hodgkin 
lymphoma as compared to Hodgkin lymphoma; they originate usually in extranodal sites; 
they rarely affect skin; they behave aggressively; and frequently harbour the EBV genome 
1;108
. Though IDLDs have been studied in a great depth, studies addressing NK cells, CTCs, 
Treg cells, and other T cell subsets in the microenvironment are extremely limited. We 
therefore, intended to study the prevalence of different T cell subsets including Treg cells and 
NK cells in the microenvironment of these disorders and to find out whether there are 
significant differences in comparison to immunocompetent-DLBCL (iDLBCL). We further 
correlated the impact of EBV-association on the infiltration of these T-cell subsets and NK 
cells. 
 
Among PTLD, we found that early lesions harboured higher numbers of FOXP3
+ 
cells and 
CD4+ cells as compared to polymorphic and monomorphic PTLD. Furthermore, PT-DLBCL 
harboured higher numbers of FOXP3
+
 cells and CD4
+
 cells as compared to HIV-DLBCL and 
iDLBCL. In a previous study, Perera et al, reported the presence of fewer T cells in 
monomorphic B-PTLDs as compared to polymorphic PTLDs 
484
. These aspects lead us to 
infer that Treg cells play a critical role in the pathogenesis of PTLDs, and possibly they are 
even more relevant in the earlier stages of PTLD-evolution. In the current study, not all 
FOXP3
+
 cells expressed CD4, though nearly all FOXP3
+
 cells expressed CD25. This might 
be in support of the finding that a small proportion of FOXP3+ expresses CD8 
351
. 
Unfortunately, due to technical issues, we could not perform double immunostains for CD8 
and FOXP3.  
Previous studies have shown that B-cell lymphomas harbour higher numbers of Treg cells as 
compared to reactive lymph nodes or tonsil 
365
. Treg cells may have a positive effect on the 
tumour by suppressing anti-tumour immune responses 
483
. Intratumoural Treg cells are 
known to inhibit the proliferation of CD8
+
 T cells and the production and release of perforin 
  
155 
 
and granzyme B which are necessary for the effector function of CD8
+
 cells and CTC-
mediated lysis of B-cell lymphoma cells 
355;356
. This relationship between Treg cells and 
CTCs is further substantiated by the reported inverse correlation between the number of Treg 
cells and CD8
+
 T cells. Contrary to these observations, in our study, we noted a direct 
correlation between FOXP3+ cells and CD8+ cells in PT-DLBCLs and in HIV-DLBCLs, and  
between FOXP3+ cells and Granzyme B + cells in HIV-DLBCL. The apparent discordance 
of our findings with those of Yang et al,
355
 is most likely because only 2 of the 28 B-cell 
lymphoma cases studied by Yang et al were DLBCLs, and also because the patient cohort in 
the Yang et al study did not represent immune suppressed patients.  
 
Among B-PTLDs, EBV-negative cases had higher numbers of CD4
+
 cells, FOXP3
+
 cells and 
CD56+ cells as compared to EBV-positive cases. Among HIV-BCL, we found significantly 
higher numbers of Granzyme B+ cells in EBV-positive as compared to the EBV-negative 
cases.  These differences were, however, independent of EBV-LMP-1 protein expression. In 
contrast to B-PTLD and HIV-BCLs, EBV-LMP-1 has been shown to induce the influx of 
Treg cells into the tumour microenvironment in classical Hodgkin lymphoma 
375
. It is 
possible that in EBV-negative PTLD, as yet unidentified infective agents induce a stronger 
influx of Treg cells as compared to EBV-positive cases.  
It has been previously shown that in recipients of solid organ transplants who are on multiple 
immunosuppressive drugs, the levels FOXP3
+
 Treg cells reduce in the peripheral blood, 
possibly due to redistribution into tissues and lymphoid organs. The higher numbers of Treg 
cells seen in the microenvironment of PTLD tissue samples in the current study, is likely to 
be a reflection of this phenomenon. Despite the likely role of Treg cells in the pathogenesis of 
PTLDs, the numbers of Treg cells in the tumour microenvironment have not been shown to 
impact on patient survival in a previous study 
312;366
.  
 
In our study, the CD4+ cells in the microenvironment were lowest among HIV-BCL, and this 
is likely to reflect the low CD4 count in the peripheral blood in HIV-infected individuals. We 
found that PT-DLBCLs had significantly higher numbers of CD4
+
 cells as compared to HIV-
DLBCL and iDLBCL. These CD4+ cells in PT-DLBCL could represent either FOXP3 
positive or negative cells. CD4+ cells have been shown to play a role in initiating and 
maintaining CTC numbers and function, and also have the ability to exert a direct effector 
activity 
317;318;486
. We also observed that HIV-DLBCLs had significantly higher numbers of 
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CD4- and FOXP3-positive cells than HIV-BL. This might be attributed to the suppressive 
effect of microenvironment-resident macrophages in Burkitt lymphoma 
487
. 
 
In our study, we found that PT-DLBCLs harbour significantly higher numbers of CD8+ cells 
and CD56+ cells as compared to iDLBCLs. Both CD8+ CTCs and NK cells play a crucial 
role in mediating the anti-tumour response through release of IFN-γ and directly killing target 
cells 
296
.  In a previous study, it has been shown that activated CD8+ T cells (that expressed 
TIA-1) were present in all HIV-NHL samples, whereas CD4+ T-cells were noted in only 2/20 
samples 
485
. It has been shown that HIV stimulates a potent antiviral CD8+ T-cell response, 
and that a high frequency of circulating CD8+ T cells are HIV-specific 
488;489
. CD8+ T-cells 
are thought to play a central role in host defence against primary and chronic phases of HIV 
infection. We also documented significantly higher numbers of granzyme B+ cells in EBV-
positive-HIV-BCL as compared to EBV-negative-HIV-BCL. It has been reported that 
granzyme B+ cells are targeted mainly to EBV-infected cells and HIV-1 infected cells 
490
. 
We also found significantly higher numbers of CD56+ cells and Granzyme B+ cells in HIV-
BL as compared to PT-BL. However, this finding needs to be confirmed on a larger series of 
PT-BL and HIV-BL. 
 
In the current study, PT-DLBCLs and HIV-DLBCLs had higher numbers of CD57+ cells 
when compared to iDLBCLs. It has been previously shown that the numbers of CD8
+
 & 
CD57
+
 cells rises in some infectious diseases, which are dominantly associated with immune 
dysfunction; for instance, AIDS, tuberculosis, and CMV infection, and in some non-
infectious diseases such as autoimmune lymphoproliferation, rheumatoid arthritis, multiple 
myeloma, common variable immunodeficiency and following hematopoietic stem cell 
transplantation 
386
. In follicular lymphomas, the presence of higher numbers of CD57+ cells 
in the tumour microenvironment is associated with poor prognosis 
384
. The relevance and the 
impact of the presence of higher numbers of CD57+ cells in the microenvironment of IDLDs 
needs further exploration.  
 
It has been shown however that that NK cells play a major role in fighting virally infected 
cells and tumour cells via various mechanisms 
387-389
. Wendel et al, using in- vitro 
experimental models, showed that the accumulation of NK cells within the microenvironment 
of tumours is dependent on availability of IFN-γ and on the expression of CXCR3 by the NK 
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cells 
393
. In the current study, we found that EBV-negative PTLD tended to harbour higher 
numbers of CD56+ cells than EBV-positive PTLDs. A better understanding of the 
aetiopathogenesis of EBV-negative PTLD and investigating the cytokine milieu of EBV-
negative PTLD may throw light on this observation. 
 
In conclusion, the microenvironment-resident T-cell subsets and NK-cells seem to play an 
important role in the pathogenesis of IDLDs, both PTLDs and HIV-BCLs. The presence of 
higher numbers of FOXP3
+
 cells and CD4+ cells in early lesions of B-PTLDs compared with 
more established monomorphic B-PTLDs, and also of their presence in higher numbers in 
PT-DLBCLs as compared with HIV-DLBCL and iDLBCL strongly suggests that Treg cells 
(and CD4+ cells that are not Treg cells) play a pathogenetically relevant role in IDLDs. 
Similarly, the presence of significantly higher numbers of CD8+ cells and CD56+ cells in 
PT-DLBCLs compared with iDLBCLs and the presence of significantly higher numbers of 
CD57+ cells in PT-DLBCLs and HIV-DLBCLs compared with iDLBCLs draw the attention 
to a possible role in the pathogenesis of these disorders. 
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Chapter 10 
PRESENCE OF MONOCLONAL T-CELL POPULATIONS IN B-CELL POST 
TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (B-PTLD) 
10.1 Introduction  
In the previous chapter we found that the numbers of infiltrating T-cells were highest in B-
PTLDs, intermediate in HIV-BCLs and lowest in iDLBCLs. In this chapter we intend to 
evaluate whether the prominent T-cell infiltrates represent clonally expanded T-cell lymphoid 
populations.  
Distinguishing benign from malignant lymphoid proliferations can be challenging and 
consequently 5-10% of cases require confirmation by clonality assessment. Clonality 
assessment is based on the fact that all malignant tumour cells share a common clonal origin 
401
. 
 
10.2 Immunoglobulin (IG) and T-cell receptor (TCR) gene rearrangements 
Lymphocytes express antigen receptors on their surface: B-cells express surface 
immunoglobulins (IG) and T cells express T-cell receptors (TCRs) 
491
. The IG and TCR gene 
loci are composed of many different variable (V), diversity (D), and joining (J) segments, 
which are discontinuous during embryonic configuration Figure 10-1 & Figure 10-3. They 
undergo rearrangement during early lymphoid differentiation in the bone marrow, resulting in 
the formation of a continuous segment of (V(D)J) DNA resulting in the production of Ig and 
TCRs in B-cells and T-cells respectively 
492-494
 . The wide diversity of epitopes that the 
antigen receptors recognise is mainly driven by the random rearrangement of these 
discontinuous segments 
491
. This diversity can be further expanded in the population of 
mature B-cell lymphocytes in germinal centres upon antigen recognition by somatic 
hypermutation, a process that takes place in the germinal centres mainly occurring via the V 
(D) J exon of both heavy and light chain genes 
61
. The rearrangement process is mediated by 
a recombinase enzyme and begins with a D to J rearrangement followed by a V to D-J 
rearrangement in the case of the Ig heavy chain (IGH), TCR beta (TCRβ), and TCR delta 
(TCRδ) genes Figure 10-2 & Figure 10-4.  In the case of IG kappa (IGκ), IG lambda (IGג), 
TCR alpha (TCRα), and TCR gamma (TCRγ) genes, however, direct V to J rearrangements 
occur 
401
. The sequences between the rearranged gene segments are removed in the form of 
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B-cell receptor or TCR receptor excision circles. Rearrangement does not occur between the 
continuous VJ or VDJ segments and the C region. At the time of transcription into VDJC 
messenger RNA (mRNA) the message encoded by the C region is integrated into the IG or 
TCR molecule and is translated into protein 
491
.  
 
During early lymphoid differentiation the IG and TCR genes rearrangements happen in a 
specific order. In B-cell differentiation, the IG genes rearrange sequentially such that the IGH 
gene rearranges first, then IGK, resulting in IGH/k expression. Alternatively the IGH gene 
rearranges first followed by IGκ deletion and IGL rearrangement, resulting in IGH/ג 
expression 
401
. During T cell differentiation, the TCRδ gene rearranges first, then the TCRγ 
gene, resulting in TCRγδ expression. Alternatively the TCRδ gene rearranges first followed 
by further TCRβ gene rearrangement and TCRδ deletion with subsequent TCRα 
rearrangement, resulting TCRαβ expression495;496. 
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Figure 10-1 Germline (embryonic) configuration of immunoglobulin heavy (IGH), IGκ 
and IGג light-chain genes.  
Each gene is composed of variable (V), joining (J), and constant (C) regions.  The IgH gene 
also has diversity (D) region. Adapted from  Medeiros & Carr  
491
. 
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Figure 10-2  An illustration of IGH gene rearrangement.  
Diversity-joining (D-J) joining occurs initially, followed by V-DJ joining. During the process 
of transcription, VDJ RNA is joined with constant (C) region RNA. Adapted from Medeiros 
& Carr 
491
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Figure 10-3 Germline (embryonic) configuration of TCR α/δ-, β-, and γ-chain genes.  
Each gene is composed of variable (V), variable (V), joining (J), and constant (C) regions.  
The TCRδ and TCRβ genes also have diversity (D) regions. Adapted from Medeiros & Carr 
491
 
 
 
 
 
 
Figure 10-4  An illustration of TCRβ gene rearrangement.  
Diversity-joining (D-J) joining occurs initially, followed by V-DJ joining. Adapted from 
Medeiros & Carr 
491
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In reactive lymphoid proliferations each B and T cell carries its own unique gene 
rearrangement, whilst, in malignant lymphoid proliferations all the neoplastic cells carry an 
identical IG or TCR gene rearrangement, a phenomenon known as monoclonal rearrangement 
491;492
. 
 
Monotypic IG light chains could be used as indirect evidence of clonality. As only a single 
type of IG light chain or TCR molecule is expressed by a lymphoid clone or a lymphocyte, 
the clonally rearranged genes of mature lymphoid malignancies could be identified at the 
protein level. The detection of either IGκ or IGג light chain restriction has been used to 
distinguish reactive (polyclonal) B-lymphocytes from (malignant) clonal B-lymphocytes. In 
reactive lymphoid proliferations the IGκ-to-IGג ratio ranges between 0.8-2.2, although in rare 
occasions it can be 0.3-7.0 
497. On the other hand,  Igκ-to-Igג ratios of > 4.0 or < 0.5 have 
been cited in some studies as indicators of the presence of a clonal B-cell population 
498-500
. 
Although > 90% of mature B cell lymphomas show light chain restriction which supports the 
clonal origin of malignancy, in tissue sections, reliable detection of Ig light chain expression 
is sometimes difficult to interpret.  
 
The occurrence of IG gene rearrangements in T-cell lymphomas and TCR gene 
rearrangements in B-cell lymphomas is defined as lineage promiscuity or infidelity; a 
common phenomenon in precursor B and T cell neoplasms but a rare one in neoplasms of 
mature lymphoid cells 
492;501
. 
 
The co-existence of monoclonal IGH and TCR gene rearrangement (dual genotyping) in the 
same lesion is seen in either a condition referred to as true bigenotypic lymphoma (where 
both IGH and TCR monoclonal rearrangements are present in the same lymphoma cells) or in 
a lymphoproliferative lesion with two distinct B and T –cell monoclonal proliferation 502-504.  
 
Southern blot analysis is a highly reliable method for detecting clonality. However, it has 
been replaced by PCR because of its various drawbacks: it is technically demanding, time-
consuming, requires fresh tissue, uses radioactive material, has poorer sensitivity and requires 
more DNA than PCR 
401
. On the other hand, PCR analysis has the following advantages: 
rapid turn-around time, requires only minimal amounts of medium quality DNA, can be used 
on fixed archival material, and has overall good sensitivity  - being 1-5% in most cases and ‹ 
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1% in some lymphomas 
402;505;506
. However, despite the use of PCR, there are other factors 
that can prejudice the correct interpretation of clonality results, as detailed below.  
 
1) Clonality does not equate to malignancy. The presence of clonal expansion in a given 
sample does not necessarily mean malignancy. There are various settings where clinically 
benign lymphoproliferations show a clonal origin, e.g. benign monoclonal gammopathy, 
early lesions of EBV
+
 lymphoproliferative disorders in immune suppressed patients, and 
benign cutaneous T-cell proliferations such as lymphomatoid papulosis. This finding 
emphasizes the importance of interpreting the results of clonality in conjunction with close 
clinical, morphological and immunophenotypic correlation 
399
. 
2) Limited sensitivity: It has been demonstrated that a normal polyclonal background 
lymphoid population might affect the identification of small clonal cell populations with 
presence of less than 5-10% clonal lymphoid cells 
399
. 
3) IG and TCR gene rearrangements are not absolute markers for lineage:  The occurrence of 
IG gene rearrangements in T-cell lymphomas and TCR gene rearrangements in B-cell 
lymphomas is defined as lineage promiscuity or infidelity. The phenomenon is common in 
precursor B and T cell neoplasms but is rare in neoplasms of mature lymphoid cells 
401
 .  
4) Pseudoclonality and oligoclonality: PCR, being highly sensitive, enables the amplification 
of IG or TCR gene rearrangements derived from a small number of B or T-cells in tissue 
samples. Examples include B-NHL with a high tumour load, and the few reactive T cells 
in a small needle biopsy.  Great caution should be used when interpreting of the clonality 
results in such cases 
401
.  
5) False-positive results:  False-positive results are rare in southern blot analysis but are 
potentially a serious problem in PCR analysis. However, they can be minimised by the 
careful analysis of PCR products and by distinguishing monoclonal, polyclonal and 
oligoclonal PCR products. Such a distinction could be achieved through GeneScanning, 
single-stranded conformational polymorphism analysis, denaturing gradient gel 
electrophoresis, or heteroduplex analysis. The latter technique is simple, fast, inexpensive 
and has been used in our study to assess the T cell and B cell clonality 
401
. Heteroduplex 
analysis involves the denaturation of PCR products at high temperature followed by rapid 
renaturation at a lower temperature. This results in heteroduplex formation with different 
migration speeds for a polyclonal population and homoduplex formation in case of 
monoclonal populations. Heteroduplexes appear as a smear at a higher position, whilst 
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homoduplexes appear as a single band within the expected size range  
403
 Figure 2-3 & 
Figure 2-4. 
6) False-negative results: False-negative results by PCR are caused by the presence of primer 
mismatches which prevent the primers from annealing correctly to the rearranged gene. 
They result from three main causes: a) somatic hypermutation (a phenomenon that affects 
lymphomas of germinal center or postgerminal center origin 
507
 and b) chromosomal 
translocations to the IGH locus might hinder the detection of clonal populations by making 
one allele inappropriate for VDJ amplification 
508
. The need for multiple primers, capable 
of annealing to all potential gene segments, which is not practically possible, also 
contributes to false-negative results. 
     
The sensitivity and specificity values for the combined BIOMED-2 PCR assay for B-cell 
clonality in formalin-fixed paraffin embedded samples are 96% and 100% respectively and 
98% and 93% for the T cell clonality assay 
402
. 
 
10.3 Hypothesis and aim 
As has been previously shown, the lack of immune surveillance plays a major role in the 
proliferation of unchecked EBV-infected B-cells in the pathogenesis of PTLD with 
subsequent development of B-cell lymphoproliferation 
509
. We hypothesised that the lack of 
immune surveillance should possibly also affect T-cells, and this should lead to subsequent 
emergence of T-cell clones. From the published literature, it appears that PTLDs which 
demonstrate both B-cell and T-cell clones are a rare phenomenon, and there are only a few 
cases reported in the literature 
7;510-516
 Table 10-1. To test whether this is in fact a more 
frequent phenomenon than is generally thought, we systematically evaluated a relatively large 
cohort of B-cell PTLD for the presence of expanded T-cell clones. We compared B-PTLD 
with HIV-associated aggressive B-cell lymphomas (HIV-BCLs) and diffuse large B-cell 
lymphomas in immune-competent individuals (iDLBCLs).  We also attempted to characterise 
the clonal T-cells present in the B-PTLD and to evaluate the impact of EBV association with 
the presence or absence of T-cell clones. 
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Table 10-1 Summary of literature of PTLD cases harbouring both T and B cell clones 
Cases harbouring both T and B cell clones Reference  
Metachronus T and B cell PTLD  
7;515
 
Concurrent T-cell and B-cell PTLDs at different sites 
514
 
Simultaneous presence EBV-positive B-PTLD and 
T-PTLD in the same patient 
510
 
Cutaneous EBV-driven B-PTLD with concomitant 
peripheral blood T-cell clones 
512
 
Both B-cell and T-cell clones in the same lesion Case 
reports 
511;513
 
Both B-cell and T-cell clonal populations in a 
polymorphic PTLD 
516
 
 
 
10.4 Materials and methods:  
We analysed tumour samples from 26 B-PTLD, 23 HIV-BCL, and 10 iDLBCL for B- and T-
cell clonality. Ten samples of reactive lymph nodes and ten samples of DNA from normal 
peripheral blood mononuclear cells were also tested. 
Methods for tissue array construction, polymerase chain reaction and heteroduplex analysis 
for assessment of clonal IG and TCR gene rearrangements, immunohistochemistry, in-situ 
hybridization and combined immunohistochemistry and in-situ hybridization are described in 
the Methods chapter. 
Statistical correlations were performed using Chi-Square Tests to evaluate the differences 
between cases with presence or absence of T-cell clones and EBV-association, and between 
presence or absence of T-cell clones and cases having a CD4:CD8 ratio of <0.4 or >0.4, using 
SPSS 17.0 software. All tests were two-sided and a P value less than 0.05 was considered 
significant. 
 
10.5 Results 
10.5.1 Clinical characteristics 
All B-PTLD samples were classified according to the current WHO classification 
38
. 
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Among B-PTLDs, 17 (66%) were males. The age ranged from 2 to 80 years (median 48 
years). Among HIV-BCLs, 22 (92%) were males. The age ranged from 26 to 66 years 
(median 41 years). Five (50%) of the iDLBCL cases were males. The age ranged from 27 to 
83 years (median 43 years).  
 
10.5.2 Morphology and phenotype  
Among B-cell PTLD samples, one was classified as an early lesion (plasmacytic 
hyperplasia), nine as polymorphic PTLDs and sixteen were monomorphic B-cell PTLD. 
Among HIV-BCLs, nine were Burkitt lymphoma, fourteen were DLBCLs and one was a 
polymorphic PTLD-like lesion. 
 
10.5.3 B-cell clonality testing by investigating IGH, IgKappa and IgLambda gene 
rearrangements 
Among B-cell PTLD, 22/26 (84.6%) showed monoclonal B-cell expansion (15/16 
monomorphic B-PTLD and 7/9 polymorphic PTLDs) Figure 10-5. The plasmacytic 
hyperplasia and 2/9 polymorphic lesions showed polyclonal B-cell expansion. The case of 
monomorphic B-PTLD that did not show evidence of monoclonal B-cell expansion by 
polymerase chain reaction was κ-light chain restricted on in-situ hybridization. This was used 
as a surrogate for the presence of clonal B-cell expansion. All HIV-associated BCL samples, 
apart from the polymorphic PTLD-like lesion, and all iDLBCLs showed monoclonal B-cell 
expansion.  
 
10.5.4 T-cell clonality assessment by investigating TCRβ, TCRγ, and TCRδ gene 
rearrangements 
 Among B-cell PTLDs, 13 out of 26 (50%) showed evidence of monoclonal T-cell expansion 
Figure 10-6. They included 2 cases of polymorphic PTLD (both with monoclonal B-cell 
population) and 10 cases of monomorphic B-PTLD. One out of the 26 B-cell PTLD and one 
of the 10 iDLBCL samples showed the presence of a dominant amplicon in the background 
of polyclonal/oligoclonal T-cell expansion, suggesting a minor T-cell clone. Two of 26 B-cell 
PTLD showed oligoclonal T cell population. The other B-cell PTLD samples, all of the HIV-
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BCLs, nine of the iDLBCLs, the ten cases of reactive lymph nodes, and all the normal 
peripheral blood mononuclear cell samples did not show evidence of monoclonal T-cell 
expansion.   
Table 10-2 summarizes PCR reactions demonstrating the presence of clonal B-cell and T-cell 
populations amongst B-PTLD. 
 
10.5.5 Correlation between the monoclonal T-cell populations in B-PTLD with 
CD4:CD8 ratio and other T-cell characteristics 
All of the cases of B-cell PTLD with a monoclonal T-cell population showed dominance of 
CD8
+ 
cells. Whilst 9/13 (69%) of the B-cell PTLD with the monoclonal T-cell population 
(not including oligoclonal cases) had a CD4:CD8 ratio of ≤ 0.4, none of the cases without 
monoclonal T-cell expansion had a ratio <0.4 (P=0.002) Figure 10-7, Figure 10-9 & Table 
10-3. The morphology of the T-cell population in the B-cell PTLD with clonal T-cell 
expansion was revisited. A proportion of the CD3
+ 
T-cells were large and atypical in one case 
of monomorphic B-PTLD Figure 10-8. Histological examination of a second case found 
features that were compatible with a co-existing T-cell PTLD of small cell type. It showed 
effacement of the nodal architecture and replacement by a diffuse infiltrate composed of 
scattered small and large blastic lymphoid cells. The large cells were CD20
+
 and EBER
+
, and 
showed lambda light chain restriction. The small cells were positive for both CD3 and CD8.  
Overall, in only 6 of 26 B-PTLD samples CD4
+
 cells were seen in excess of CD8
+
  cells, and 
1 of these 6 cases was EBV-positive. 
 
10.5.6 Correlation of presence of monoclonal T-cell populations in B-PTLD with EBV-
association 
EBV association was present in 20/26 (77%) of the B-PTLD. Whilst 13/15 (86.7%) B-PTLDs 
which harboured a T-cell clone (including both oligo and monoclonal) were EBV-associated, 
7/11 (63.6%) samples lacking T-cell clones showed EBV association. This, however, was not 
statistically significant (p= 0.618). Seven out of the 13 (53.8%) EBV
+ 
B-PTLDs with 
associated monoclonal T-cell expansion were analysable by “immunoISH”, using combined 
immunohistochemistry and in-situ hybridization (with CD3 antibody and EBER probe): none 
of the CD3
+ 
T-cell population showed EBV-positivity Figure 10-9. Morphologies, EBV-
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association and CD4:CD8 ratios of cases associated with monoclonal and oligoclonal T cell 
populations are shown in Table 10-3. 
 
 
 
 
Figure 10-5 Heteroduplex-PCR for Igκ gene rearrangement in representative B-
PTLD samples (120-160 bp or 190-210 bp).  
M100-100 bp ladder; P-positive control; samples 3, 4 (weak), 5 & 7 shows clonal 
bands; N- negative control; polyacrylamide gel(10%); sample 1-no clone; sample 6- 
polyclonal. 
 
 
 
 
 
 
Figure 10-6 Heteroduplex-PCR for TCR gene rearrangement in representative 
PTLD samples (145-255bp). 
M100-100 bp ladder; P-positive control; samples 1-3 & 5-7- B-BTLD samples; samples 
1, 6 & 7- dominant bands suggesting monoclonal expansion; samples 2, 3 & 5- 
polyclonal population; Sample 4- monoclonal (a case of monomorphic T-cell PTLD); 
N-negative control. 
 
200 bp
100 bp
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Figure 10-7  Boxplot showing correlation between the monoclonal T-cell populations in 
B-PTLD with CD4:CD8 ratio.  
69% of the B-cell PTLD within the monoclonal T-cell population (not including oligoclonal 
cases) had a CD4:CD8 ratio of ≤ 0.4, none of the cases without monoclonal T-cell expansion 
had a ratio <0.4 (P=0.002). 
 
 
 
Oligo/monoclonal expansion    polyclonal expansion
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Figure 10-8  A case of monomorphic PTLD (H&E- A) positive for CD20 (B) and EBER (C).  
Infiltrating T-cells are demonstrated by CD3 immunostaining (D). Occasional cells are larger 
than the rest of the T-cells (all images x100). 
 
 
 
 
 
 
 
 
 
 
 
A B
DC
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Figure 10-9 Immunostaining for CD3, CD4 and CD8 and immune-ISH with CD3 and 
EBER riboprobe.  
CD3 highlights infiltrating T-cells in the PTLD sample (A), including occasional larger and 
atypical cells. Most of the T-cells are CD4
-
 (B) and CD8
+
 (C). Immuno-ISH with CD3 
antibody (red) and EBER riboprobe (brown) demonstrates that the positive cells are mutually 
exclusive (all images X400).
A B
DC
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Table 10-2  PCR reactions demonstrating the presence of clonal B-cell and T-cell populations amongst B-PTLD  
Abbreviations: DLBCL – Diffuse large B-cell lymphoma; DOC – dominant band in an oligoclonal background; mPTLD – Monomorphic post transplant lymphoproliferative disorder; pPTLD -
polymorphic post transplant lymphoproliferative disorder; MC – monoclonal; NC-no amplification products; OC – oligoclonal; PC – polyclonal; TCRG(A and B) –T cell receptor Gamma tube 
(A) and tube B, TCRB (A, B &C) – T-cell receptor Beta tube (A, B &C) ; TCRD –T-cell receptor Delta; W – weak band (-) not done as monoclonality was established with other primer pairs. 
Note: Primer sequence and notations mentioned in the table(including grouping of A,B and C) were as per the BIOMED-2 protocol 402. (*) The case showed IgK restriction on ISH 
  
 
B-cell clonality – primer pairs T-cell clonality – primer pairs 
 
Clonality 
Max size 
among 
house 
keeping 
genes cases Diagnosis 
FR1 / 
JHC  
FR2 
/ 
JHC  
FR3 / 
JHC  
DH 1-6 
/ JHC  
DH7 / 
JHC  
Vκ1/6-
7/Jκ1-
4&5  
IGL  
 
TCRG 
(A)  
TCRG 
(B) 
TCRB 
(A) 
TCRB 
(B) 
TCRB  
( C ) 
 
TCRD 
 
 
B cell  
 
T cell  
1 pPTLD - - - MC MC PC PC MC(W) PC - - - - MC MC 300 
2 Early lesion PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC 600 
3 mPTLD(Plasmacytoma-like) MC (W) - - OC - MC - PC PC PC PC PC PC MC PC 300 
4 mPTLD(lymphoplasmacytic) PC PC PC PC - MC - MC(W) PC - - - - MC MC 300 
5 mPTLD(DLBCL) - - - PC - MC - MC(W) PC - - - - MC MC 600 
6 mPTLD(DLBCL) - PC PC - - MC - MC PC - - - - MC MC 300 
7 mPTLD(DLBCL) - PC PC - - MC - MC - - - - - MC MC 200 
8 mPTLD (Plasmablastic) PC PC PC PC PC PC PC MC PC - - - - PC* MC 200 
9 mPTLD(DLBCL) - PC PC - PC MC - PC MC - - - - MC MC 300 
10 pPTLD PC PC PC PC PC PC PC NC PC PC PC PC PC PC PC 200 
11 pPTLD - PC MC - - OC - DOC PC PC PC PC PC MC DOC  300 
12 pPTLD - - PC NC PC PC - PC PC PC PC PC PC PC PC 400 
13 mPTLD(DLBCL) - PC PC PC - MC - PC MC - - - - MC MC 200 
14 mPTLD(DLBCL) - PC MC PC - PC PC PC PC PC PC MC - MC MC 300 
15 mPTLD(DLBCL) - PC PC PC PC PC MC OC PC PC PC PC PC MC OC 200 
16 pPTLD - PC MC - - PC MC PC OC PC PC PC PC MC OC 300 
17 mPTLD(DLBCL) - PC MC PC PC - PC PC PC PC PC PC PC MC PC 200 
18 pPTLD - MC - - PC PC PC PC PC PC PC PC PC MC PC 200 
19 mPTLD(DLBCL) - PC PC PC MC PC PC NC PC MC PC - - MC MC 300 
20 mPTLD(DLBCL) - - MC - MC - - PC MC - - - - MC MC 400 
21 mPTLD(DLBCL) - PC PC - - MC - PC PC PC PC PC PC MC PC 200 
22 mPTLD(DLBCL) - - PC MC - - - PC PC PC PC PC PC MC PC 200 
23 pPTLD - - PC PC MC - - MC PC - - - - MC MC 300 
24 pPTLD - PC MC - - PC - PC PC PC PC PC PC MC PC 200 
25 mPTLD(DLBCL) - - PC - - MC - PC PC PC PC PC PC MC PC 300 
26 pPTLD - PC MC  MC - - PC PC PC PC PC PC MC PC 200 
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Table 10-3 Morphologies, EBV-association and CD4:CD8 ratios of cases associated with 
monoclonal and oligoclonal T cell populations. 
 
Abbreviations: pPTLD- polymorphic PTLD; mPTLD - monomorphic PTLD; DLBCL – Diffuse large B-
cell lymphoma; PC - polyclonal; OC – oligoclonal; DOC** - dominant band in an oligoclonal 
background (minor clone), MC – monoclonal.  
* The case showed IgK restriction on ISH 
 
 
 
  Morphology 
CD4 : CD8 
ratio 
EBV 
(EBER) 
Clonality 
B-cell T-cell 
1) pPTLD 0.2 Positive MC MC (weak) 
2) mPTLD (Lymphoplasmacytic) 0.2 Positive MC MC (weak) 
3) mPTLD (DLBCL) 0.2 Positive MC MC (weak) 
4) mPTLD (DLBCL) 0.4 Negative MC MC 
5) mPTLD (DLBCL) 1.6 Negative MC MC 
6) mPTLD (Plasmablastic lymphoma) 0.2 Positive PC* MC 
7) mPTLD (Plasmacytoma-like) 1.7 Positive MC MC 
8) pPTLD 1.2 Positive MC DOC** 
9) mPTLD (DLBCL) 0.1 Positive MC MC 
10) mPTLD (DLBCL) 0.9 Positive MC MC 
11) mPTLD (DLBCL) 0.3 Positive MC OC 
12) pPTLD 0.9 Positive MC OC 
13) mPTLD (DLBCL) 0.2 Positive MC MC 
14) mPTLD (DLBCL) 0.4 Positive MC MC 
15) pPTLD 0.4 Positive MC MC 
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10.6 Discussion: 
This study, to the best of our knowledge, constitutes the largest series of B-cell PTLD in which 
both B-cell and T-cell clonality has been investigated. Our results demonstrate that B-cell PTLD 
harbour secondary clonal populations in addition to the preponderant clonal population that is 
perceived as being „neoplastic‟. Among the B-PTLD that we investigated in our study, 88% had 
a monoclonal B-cell population (100% of mB-PTLD and 78% of pPTLD). This finding is in line 
with published literature 
29;44
. Half of the B-PTLD, all incorporating documented monoclonal B-
cell populations showed evidence of monoclonal T-cell expansion. The clonal T-cell expansion 
in two cases was associated with morphological features that could imply co-existence of 
neoplastic T-cell PTLD, or of an early evolution of T-cell PTLD. The coexistence of both B-cell 
and T-cell clones in the same lesion has been previously documented in PTLDs, but only as case 
reports 
511;513
. The reports concerning co-existing B-cell and T-cell clones include two reports 
with metachronous B-PTLD and T-cell PTLDs, presence of concurrent T-cell and B-PTLD at 
different sites, simultaneous presence  of EBV-positive B-PTLD and T-cell PTLDs, and a case of 
cutaneous EBV-driven B-cell PTLD with concomitant peripheral blood T-cell clones 
7;510;512;514;515
. Two cases of EBV-negative
 
cutaneous anaplastic large cell lymphoma with dual T-
cell and B cell receptor gene rearrangements have also been reported 
517
. 
 
Whether the emergence of T-cell clones is triggered by B-cell clones (EBV-infected or 
otherwise) or whether it is secondary to the lack of immune surveillance similar to its impact on 
EBV-infected B-cells is not clear and needs to be elucidated. The lack of immune surveillance 
secondary to reduced EBV-specific CTC consequent to the use  of immunosuppressive drugs, is 
said to play a major role in promoting the development of uncontrolled proliferation of EBV-
infected B-cells, resulting in the development of B-PTLDs 
509
. We speculate that a similar lack 
of immune surveillance might also be responsible for the emergence of T-cell clones.   
All of the cases of B-PTLDs with a monoclonal T-cell population showed a significant 
predominance of CD8
+ 
cells. This finding needs to be experimentally reinforced using laser 
capture microdissection. In this way, the clonality of isolated CD8
+ 
cells in cases with T-cell 
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clonal expansion can be assessed. If fresh tissue is available, T-cell subpopulations could also be 
examined. Whether an agent directly infecting the T-cells plays a role is difficult to substantiate. 
Amongst our cases, we found that the majority of B-cell PTLD (77%) contained more CD8
+ 
T-
cells than CD4
+ 
T-cells. Literature pertaining to this aspect of PTLD is scarce. In a small study in 
1998,  CD4
+
 cells predominated over CD8
+
 cells in 8/11 PTLD samples 
484
.  
 
There has been a report linking the existence of oligoclonal cytotoxic T-cell populations with 
tumour regression in PTLDs 
518
. More recently, higher numbers of tumour-infiltrating T-cells 
and TIA-1
‏+
 (T-cell intracellular antigen-1) CTC have been reported to be predictive of 
favourable outcome in PTLD patients, thereby indicating that antitumor immune responses in 
these patients is maintained 
312
.   
 
We excluded the possibility that EBV infects and drives the T-cells. EBV has been found to 
infect a subset of T-cells that express the viral receptor CD21 
6
. High levels of uncontrolled viral 
replication are thought to facilitate the entrance of EBV into T-cells 
7
. Despite previous reports 
showing that EBV can infect T cells, in our study none of the seven assessable cases showed 
evidence of EBV-infection in the T-cell population.  
In the first five years of transplantation, EBV-positive PTLDs predominate over EBV-negative 
B-PTLDs. Furthermore, a greater proportion of late-onset B-PTLD are EBV-negative, and most 
T-cell PTLD are late-onset 
46-48;517
. Therfore, in the post-transplant setting, EBV-infected B-cells 
appear to have a proliferative advantage.  
 
The presence of „benign‟ clonally expanded T-cells, or T-cells demonstrating a skewed T-cell 
receptor repertoire in the peripheral blood are known to be present in post-transplant patients. 
Among patients who have had allogenic stem cell transplantation, these T-cells are of donor 
origin and are likely to be induced by EBV-infected B-cells 
519
. On the other hand, in patients 
with solid organ transplants (such as renal transplants), the T-cells are of patient/recipient origin 
and represent allo-reactive T-cells against the transplanted organ. The presence of expanded T-
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cell clones in the peripheral blood has been shown to negatively impact on long-term graft 
function, such as survival of the transplanted kidney 
520
. 
 
Contrary to what we found in the PTLDs, we did not encounter a single case of HIV-associated 
aggressive B-cell lymphomas with the presence of T-cell clones. During the early course of HIV-
1 infection, CD8
+
 T cells show a moderate rise which is transient in most cases; then they decline 
in parallel with the depletion of CD4
+
 T-cells 
298
. However, the persistent elevation of circulating 
CD8
+
 T cells with visceral involvement, mainly in the salivary glands and lung, in response to 
HIV-1 infection, has been described in certain groups of patients 
299
.  These are manifested as 
clonally expanded T-cell populations in the peripheral blood and in the viscera. The clonal 
expansions can be large and may persist with specific clones dominating 
302;303;305;306
.  
 
To summarize, our results show that monoclonal expansion of T-cell population occurs 
frequently in B-PTLDs, and that these clonal T-cell populations co-exist with monoclonal B-cell 
population in B-PTLDs. The T-cell clones seem to arise mainly from CD8
+ 
T-cells. Whether 
EBV plays a pivotal role in the emergence of T-cell clones is unclear. It is intuitive to think that 
EBV and other infective agents possibly play a role in the clonal expansion of CD8
+ 
T-cells. 
Although the monoclonal T-cell population is usually cytomorphologically occult, rare cases 
with morphological atypia may suggest a propensity for progression. In such cases follow up and 
clinical correlation could be recommended. More studies are required to validate these findings. 
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Chapter 11 
CONCLUDING DISCUSSION 
Immune deficiency associated lymphoproliferative disorders (IDLDs) are a group of diseases 
that range from benign polyclonal to malignant monoclonal lymphoid proliferations. They 
develop in a wide variety of immunodeficiency settings which may be of congenital, infectious 
or therapeutic origin. Post transplant lymphoproliferative disorders (PTLDs) and HIV-related 
lymphomas are the best-studied examples of these disorders 
1
.  
 
The pathogenesis of IDLDs seems to be multifactorial. Among possible infective aetiologies, the 
role of EBV has been studied in depth, and the virus is thought to play a central role in the 
driving the proliferation of EBV-infected B cells that leads to subsequent development of the 
lymphoproliferative disorder 
72
. It is apparent, however, that EBV is not solely responsible for 
the „neoplastic‟ state. Accumulated genetic alterations of oncogenes and tumour suppressor 
genes (deletion, mutations, rearrangements, and amplifications) and epigenetic changes (aberrant 
hypermethylation) that involve tumour suppressor genes are an integral part to the pathogenesis 
72;120;123
. Antigenic stimulation plays an evident role in the pathogenesis of HIV-NHL and PTLD 
11;72
. We are aware that PDCs are critical to fight viral infections and hence, would be a critical 
component of host defence against virally-infected neoplastic/pre-neoplastic cells. Similarly, 
Treg cells, which are modulators of immune reactions once incited, should have an important 
role in disorders where antigenic stimulation is key for the pathogenesis.  
Despite the presence of a relatively large number of publications on the IDLDs, some aspects of 
the pathogenesis of these disorders are still poorly understood. In this study we aimed to: classify 
disease groups according to the current WHO classification of lymphoid neoplasm; investigate 
EBV and HHV-8 viral association; study the frequency of EBV-genotypes among EBV-positive 
cases; study chromosomal gene rearrangements involving different lymphoma-related 
oncogenes; evaluate the methylation status of DAP-k and SHP1 genes; evaluate the numbers of 
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PDCs, Treg cells, other T cell subsets and NK-cells in the microenvironment in these diseases; 
and finally to define clonal populations with respect to their lineages within IDLDs.   
 
All the cases were classified according to the current WHO classification of lymphoid 
neoplasms. With regard to viral associations, HHV-8 was absent in all but two cases of HIV-
PEL. EBV-association (positivity of EBER on ISH in most tumour cells), however, was 
frequently present among IDLDs (in 47/59 cases (80%) of B-PTLD and 18/26 (69%) of HIV-
BCL cases), as compared to only 4/58 (6%) among iDLBCL cases. It is likely that other 
viruses/infective aetiologies are involved in the pathogenesis of IDLDs among cases negative for 
both EBV & HHV-8. Further studies to identify novel infective agents in EBV- and HHV-8- 
negative cases are required. Of the two EBV genotypes, type-A-EBV was noted in 92% of EBV-
positive PTLD - a finding similar to the published literature 
413
. The two cases associated with 
EBV-type-B, were white Caucasian patients. In HIV-BCL, however, both EBV genotypes were 
equally prevalent in England and this finding is similar to the reports from other groups who 
have shown that both EBV genotypes types are found in lymphoma samples from patients with 
HIV 
416;417
. The interesting finding was that cases associated with type-B-EBV had been HIV 
positive for a significantly longer duration compared to those with type-A. This reinforces the 
notion that the type-B-EBV is oncogenically less efficient than type-A, and type-B-EBV appears 
to be lymphomagenic only in the background of prolonged HIV-associated immune suppression. 
Overall, our results suggest that both EBV types are likely to be prevalent in the background 
population in England. We speculate that the degree and type of immune deficiency, and not the 
patient ethnicity, is associated with the EBV genotype present within the expanded clone of B-
cells in IDLDs.  
 
In morphological and immunophenotypic terms, only a small subset of 
lymphomas/lymphoproliferative disorders occurring in immune deficient states has distinctive 
features. The question as to whether lymphomas of similar morphology occurring in immune 
competent or in various immune deficient states, are biologically distinct needs to be critically 
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addressed.  Contrary to DLBCLs in immune competent patients (iDLBCL), a recent study 
published as an abstract suggested that among HIV-DLBCL, cases of non-GC phenotype have a 
better 3-year survival as compared to those of GC phenotype. Furthermore, EBV-association was 
stronger among non-GC DLBCLs as compared to the GC subset in this study  
521
. The 
underlying biological reasons for such differences between iDLBCLs and HIV-DLBCLs need to 
be explored. A recent study from the National Cancer Institute, USA, has documented 
significantly better survival rates for the GC-subset of HIV-DLBCLs on treatment with 
Etoposide-based regimens in combination with anthracyclines and rituximab (SC-EPOCH-
RR)
522
. Some aspects of our study potentially provide insights to explore differences between 
apparently similar lymphomas occurring on the background of immune competent or immune 
deficient states. The need for different treatment strategies for PT-DLBCLs as compared to 
iDLBCL is well-documented 
523
. 
 
The obvious aspect for investigation of possible differences between lymphomas of similar 
histology, but occurring in different immune competent/deficient settings would be the 
rearrangement of common lymphoma-associated genes. In lymphomas, chromosomal 
translocations result in two distinctive types of genetic lesions: 1) Juxtaposition of an intact 
oncogene with another gene, which in most cases is an antigen receptor gene, and 2) 
Juxtaposition of parts of two disrupted genes resulting in a new fusion gene, chimeric mRNA, 
and a novel protein 
419
. Rearrangement of c-MYC oncogene was the only common lymphoma-
associated rearrangement observed among B-PTLD cases (seen in 7/54 (13%) cases). The seven 
cases included 3 PT-DLBCL, 2 PT-PL and 2 PT-BL. The presence of c-MYC rearrangement in 
8% of PT-DLBCLs has not been previously reported.  
 
We found c-MYC rearrangement in 31% of HIV-DLBCLs, which is higher than the previous 
reports 
169;171;172;189
. Diebold et al,
449
, however, previously suggested that 30-40% of HIV-
DLBCLs have c-MYC rearrangement. In marked contrast to our finding of c-MYC rearrangement 
in 31% of HIV-DLBCLs, only two out of 52 (3.8%) of iDLBCLs had rearrangements of this 
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gene. We, therefore, speculate that HIV-DLBCLs is biologically distinct from iDLBCLs. The 
issue of the overlap between BL and DLBCL, and the possibility that some of the cases 
classified as HIV-DLBCL could represent B-cell lymphoma, unclassifiable with features 
overlapping between DLBCL and BL (DLBCL/BL), was given due consideration during the re-
classification process 
197;450
.  
 
We identified two cases of PT-PL with c-MYC rearrangement, one of which had a concomitant 
IGH gene rearrangement. There was a further case of HIV-PL showing rearrangement of c-MYC 
and IGH loci. There are recent reports of HIV-PL with c-MYC/IgH translocation 
218;219;524
. 
However, there are no previous reports of c-MYC gene rearrangement in PT-PL. 
 
Similar to B-PTLD in our study, but in contrast to previous reports, all HIV-DLBCLs 
investigated in our study were negative for rearrangements involving the BCL6 locus 
188;189
. Our 
finding reinforces the notion that mutations involving BCL6 5‟ non-coding region and not BCL6 
gene rearrangement are the most common genetic alterations in AIDS-related lymphomas. It also 
further supports the view that iDLBCLs and HIV-DLBCLs have different pathogenetic 
mechanisms 
151;160
. In addition, all B-PTLD and HIV-DLBCL lacked BCL2 gene rearrangement 
which was present in iDLBCL-GC phenotype. 
 
The differences among DLBCL of different categories could be summarised as follows: a) Gene 
rearrangement involving common lymphoma associated oncogenes is rare in PT-DLBCLs; b) c-
MYC rearrangement is a relatively frequent finding among the HIV-DLBCL-GC subtype in 
contrast to iDLBCL-GC subtype; c) BCL2 rearrangement is not associated with HIV-DLBCL-
GC subtype in contrast to iDLBCL-GC subtype; d) BCL6 rearrangement is not associated with 
HIV-DLBCL-non-GC subtype in contrast to iDLBCL-non-GC subtype; e) A significant 
proportion of HIV-DLBCL-non-GC subtype are EBV-associated as compared to iDLBCL-non-
GC subtype; f) EBV-association is a frequent finding in PT-DLBCL. 
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We therefore envisaged that pathogenetic mechanisms other than the rearrangement of 
oncogenes commonly associated with lymphomas could be critical to development of IDLDs.  
 
We therefore, intended to assess the methylation status of DAP-k and SHP1 genes among 
IDLDs. DAP-k is a serine-threonine kinase and plays an important role in apoptosis and its 
expression is triggered by TNFα, INFγ and FAS ligand. Its activity is inhibited as a result of 
hypermethylation of the CpG islands 
133;136;461-463
. DAP-k hypermethylation was a frequent 
finding in B-PTLDs (both pPTLD and mPTLD), HIV-BCLs and iDLBCLs. It is likely that AH 
of DAP-k is independent of the immune deficiency / competent status of the patients. The most 
important observation we found with this line of investigation was the identification of the 
presence of AH of DAP-k in the early PTLD lesions, in the case of post-transplant reactive 
hyperplasia of the lymph node and in 40% of post-transplant peripheral blood samples. This 
suggests that DAP-k hypermethylation is likely to be a very early epigenetic event that might 
occur even before the establishment of the clonal B-cell population. Performing analysis of AH 
of DAP-k on peripheral blood mononuclear cells might provide a useful tool for identification of 
patients at risk of developing PTLD. In addition, such patients may benefit from strategies 
directed against prevention or reversal of hypermethylation through demethylating drugs 
455
. The 
significant negative correlation observed in our study between AH of DAP-k and EBV-
association among iDLBCLs suggests that they are independent pathogenetic pathways.  
 
SHP1 gene, a tumour suppressor gene, encodes SHP1 which is a cytoplasmic protein tyrosine 
phosphatase (PTP) 
141
. It is expressed in hematopoietic cells and it inhibits JAKs/STATs 
pathway and hence it potentiates its negative effect on cell cycle regulation 
142;143
. Among HIV-
BCL, we found aberrant hypermethylation of SHP1 gene in 70% of the cases, which is in 
keeping with a previous study 
145
. We found SHP1 hypermethylation in one-half of B-PTLD 
samples, including the single case of plasmacytic hyperplasia. Similar to DAP-k, the presence of 
SHP1 hypermethylation in the case of plasmacytic hyperplasia suggests that it is likely a very 
early event in the pathogenesis of PTLD. Overall, all B-PTLD samples and 86% of HIV-BCL 
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samples showed concomitant DAP-k and SHP1 gene methylation. AH of multiple genes seems to 
be a common finding in IDLDs which needs further exploration using a global approach.  
 
We later followed our investigations to dissect the differences in the microenvironment between 
different subsets of IDLDs, and between IDLDs and iDLBCL. We particularly focussed our 
investigations on plasmacytoid dendritic cells (PDCs) and Treg cells. Our interest in PDCs was 
propelled by the importance of PDCs in countering viral infections and by the fact that EBV is a 
critical factor in the pathogenesis of IDLDs. Similarly, as both the infecting virus and the 
transplant itself act as immunogens, we wanted to understand the role of Treg cells which have 
been identified as key players in modulating the immune reaction. In the process of studying 
Treg cells, we also evaluated several other immune cells.  
 
Tumour infiltration by PDCs and their clinical impact has been studied in various malignant 
neoplasms, including lymphomas 
242;277
. PDCs are reported to be markedly decreased in number 
and qualitatively altered in non-Hodgkin‟s lymphoma compared with reactive lymph nodes 242. 
However, PDCs are reported to be present in increased numbers in classical Hodgkin lymphoma 
(cHL) 
242
. In our study, the finding of significantly higher numbers of PDCs in early lesions of 
PTLD as compared to more established PTLDs may denote that that early lesions remain „early‟ 
due to suppressive influence of PDCs on virally infected oligoclonal or polyclonal lymphoid 
populations. As PTLD evolves, and the neoplastic clones accumulate additional 
genetic/epigenetic lesions, they become relatively more independent of PDCs. Furthermore, it is 
likely that the EBV-negative
 
PTLDs are driven by, as yet, unidentified infective agents, because 
they also harbour larger numbers of PDCs. Further studies investigating the cytokines secreted 
by PDCs, however, are required to substantiate and further clarify the precise role of PDC in the 
pathogenesis of PTLD. Further studies investigating novel viruses and other infective agents in 
the EBV-negative cases are also required. 
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Treg cells are CD4
+
 & CD25
+ 
T lymphocytes that are a subset of immune regulatory cells and 
have the ability to suppress immune responses. There is a sub-population of Treg cells which 
express CD8 and not CD4 
351
. When Treg cells undergo activation via their TCR, they inhibit the 
proliferation of CD4
+
 and CD8
+
 T-lymphocytes, through the release of cytokines such as IL-10 
and TGF-β 352;354. The intra-tumoural Treg cells have been shown to have an inhibitory effect on 
the production and release of perforin and granzyme B, which are necessary for the effector 
functions of CD8+ cells and CTC-mediated lysis of tumour cells 
356
. Treg cells are also known to 
have a direct effect on B-lymphocytes, and inhibit the production of immunoglobulins 
363
.  
Treg cells can suppress the growth of some tumours in addition to their role in suppressing the 
anti-tumour immune response 
483
. Higher numbers of Treg cells have been described as 
predictors of both improved survival in follicular lymphoma and therapeutic response 
345
. Treg 
cells are found in higher numbers in tissue samples of B-cell lymphomas as compared to reactive 
lymph nodes or tonsils. This is thought to be due to the attraction of Treg cells to the tumour 
microenvironment through CCL22 secreted by the lymphoma cells 
345;365
. 
 
The possible critical role of Treg cells in the pathogenesis of PTLD (in particular in the earlier 
stages of its evolution) stems from our finding of higher numbers of FOXP3
+ 
cells and CD4+ 
cells in early lesions of PTLD as compared to pPTLD and mPTLD, and of FOXP3
+
 cells and 
CD4
+
 cells in PT-DLBCL as compared to HIV-DLBCLs and iDLBCLs. The higher numbers of 
Treg cells seen in the PTLD tissue samples could at least in part be due to the redistribution of 
Treg cells from the peripheral blood into the microenvironment 
366
. Irrespective of whether the 
Treg cells are locally expanded or redistributed from the peripheral blood, we believe they 
represent a response to the „immune-active‟ microenvironment in PTLDs. By analogy, PTLDs 
should have a significantly stronger „immune-active‟ microenvironment as compared to HIV-
BCLs and iDLBCLs, and within the PTLDs, immune mechanisms must be stronger during early 
disease-evolution. Whether the infiltrating Treg cells in PTLDs are effective in suppressing other 
immune cells is difficult to address by our studies and would require in-vitro studies. 
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Intra-tumoural Treg cells are known to inhibit the proliferation of CD8
+
 T cells and the 
production and release of perforin and granzyme B 
355;356
. Therefore, we expected to see an 
inverse correlation between FOXP3+ cells and CD8/granzyme B positive cells. However, 
surprisingly, we observed a direct correlation between FOXP3+ cells and CD8+ cells in PT-
DLBCLs and in HIV-DLBCLs, and  between FOXP3+ cells and Granzyme B + cells in HIV-
DLBCLs. This relationship was independent of EBV-association (EBER positivity) or EBV-
LMP-1 expression. Although not easily explainable, this discrepancy between our findings and 
those in the afore-mentioned papers could in part relate to the fact that only 2 of the 28 B-cell 
lymphoma cases studied by Yang et al were DLBCLs, and that the patient cohort in the Yang et 
al’s study did not represent immune suppressed patients. In the disease course of HIV, CD8-
positive T-cell expansions (in response to HIV itself or to EBV) that could be oligoclonal and 
rarely monoclonal is well documented 
302;303;305;306
.  
 
At this juncture, we investigated whether independent expansions of T-cell populations could 
occur in PTLD samples. We hypothesized that, as in B-cell expansions occurring in the post-
transplant setting, T-cell populations could also expand – beginning as a polyclonal, then 
becoming oligoclonal and finally monoclonal. In the published literature, there were rare reports 
of PTLD where both B-cell and T-cell clones (Table 10-1). We evaluated PTLD and other 
samples for T-cell clonality and tested whether this is in fact a more frequent phenomenon than 
is generally appreciated. We documented the co-existence of clonal T-cell populations with 
monoclonal B-cell populations in one-half of B-PTLD. All of the cases of B-PTLDs with a 
monoclonal T-cell population showed a significant predominance of CD8
+ 
cells. The clonal T-
cell expansion in two cases was associated with morphological features that could imply co-
existence of neoplastic T-cell PTLD, or of an early evolution of T-cell PTLDs. Despite previous 
reports showing that EBV can infect T-cells 
6
, in our study none of the assessable cases showed 
evidence of EBV-infection in the T-cell population.   
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The monoclonal T-cell population is cytomorphologically occult in most cases; however, rare 
cases displayed morphological atypia. It is likely that the evolution of the T-cell expansion is at a 
far slower pace as compared to the B-cell proliferation; therefore, in most cases these are occult 
and clinically irrelevant. Our thinking is substantiated by the fact that T-cell PTLDs that account 
for <15% of all PTLDs present much later in comparison to B-PTLDs following transplantation.  
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Chapter 12 
LIMITATIONS OF STUDY 
Some of the limitations of this study relate to the nature of the material available:  
1) The unavailability of peripheral blood samples from the post-transplant patients who 
subsequently developed PTLD. 
 
2) The lack of fresh frozen tissue limited the kind of investigations that could be undertaken. 
 
3) The relatively low numbers of early PTLD lesions (5 cases) in comparison to pPTLD (19 
cases) and mPTLD (42 cases), and the small number of cases of PT-BL (3 cases) in 
comparison to HIV-BL cases (8 cases). The number of HIV-BCL samples was also relatively 
low (25 cases).  
 
Other limitations related to the sample-quality: 
1) DNA extracted from 23 PTLDs samples was degraded and could not be amplified. These 
samples were excluded from further PCR analysis.  
2) Thirty four PTLD samples were excluded from the FISH analysis due to either very weak or 
no signals or due to tissue core loss.  
 
These sample-quality problems were more obvious in material collected from hospitals other 
than Hammersmith and Charing Cross hospital, and likely to be related to fixation.  
 
Remaining problems were variable in nature and included: 
1) Some of the assays required more DNA than could be extracted from the tissue sections. For 
example, the amount of DNA needed for methylation specific-PCR is ~500 ng for each of the 
methylated and unmethylated reactions. This was reflected on the assay of SHP1 gene 
methylation (only 6 PTLD samples and 10 HIV samples were investigated). 
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2) There were technical problems in performing double immunohistochemistry for FOXP3 and 
CD8. 
 
3) Variable tissue-core losses from the TMA sections reduced the number of cases assessable for 
some of the antibodies used and for some FISH probes.  To ensure consistency, the numbers 
of tumour-infiltrating PDCs and lymphoid cells were counted in three cores from each sample 
and the numbers were then expressed as cell/mm
2
. Cases with only one core available were 
excluded from the study.  
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Chapter 13 
CONTRIBUTION TO SCIENTIFIC KNOWLEDGE AND FUTURE STUDIES 
13.1 Contribution to scientific knowledge 
1- The study documented the prevalence of EBV genotypes among HIV-BCL and B-PTLD in 
patients from England. 
 
2- The study documented the incidence of different rearrangements among PTLDs, HIV-related 
lymphomas and iDLBCLs. This study is also the first to find the presence of c-MYC/IGH 
gene rearrangements in PT-PL. 
 
3- Our results demonstrated that aberrant hypermethylation of DAP-k gene and SHP1 genes are 
possibly crucial for the pathogenesis of IDLDs. From the results we obtained we suspect that 
aberrant hypermethylation is a very early event in the pathogenesis of PTLDs, occurring 
before the establishment of clonal population. This will lead to novel ways of monitoring this 
group of patients (who may develop more established PTLD lesions) and possibly to 
treatments (using demethylating drugs) before they develop PTLDs.  
 
4- This study also highlighted the possible critical roles played by the microenvironment-
resident PDCs, regulatory T-cells, and other T/NK subsets in the pathogenesis of PTLDs. This 
could lead to novel therapeutic targets. This is a topic of current interest in follicular 
lymphomas, but has not been thoroughly investigated in IDLDs. The gene expression profile 
of the tumour-infiltrating benign cells will be the central question for future research.  
5- This study also documented the co-existence of clonal T-cell populations (predominantly 
CD8+ cells) with monoclonal B-cell populations in 50% of B-PTLD samples. The clonal T-
cell expansion in two cases was associated with morphological features that could imply co-
existence of neoplastic T-cell PTLD, or of an early evolution of T-cell PTLD. In such cases, 
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follow up and clinical correlation could be recommended. The study will pave the way for a 
better understanding of the early phases of T-cell PTLD. 
 
13.2 Future studies. 
The question as to whether lymphomas of similar morphology occurring in immune competent 
or in different immune deficient states are biologically distinct needs to be critically addressed. 
We found some differences (described in the concluding discussion chapter) between DLBCL in 
immune competent/deficient settings regarding gene rearrangements involving common 
lymphoma-associated genes. Our future plan in this aspect would be to investigate differences in 
array CGH profiles and microRNA expression between these disease subsets. 
 
With regards to AH of DAP-k, the most important observation we made was the identification of 
the presence of AH of DAP-k gene in the early PTLD lesions, in the case of post-transplant 
reactive hyperplasia of lymph node and in 40% of post-transplant peripheral blood samples. Our 
future plan is to expand this to a clinical study investigating the methylation patterns in PB 
lymphocyte DNA from post-transplant patients and establish whether the methylation status can 
be used as a biomarker for the likelihood of developing PTLD. Furthermore, all B-PTLD 
samples and 86% of HIV-BCL samples showed concomitant DAP-k and SHP1 genes 
methylation. AH of multiple genes seems to be a common finding in IDLDs. Our future plan 
regarding this would be to further explore methylation patterns using a global approach. 
With regards to tumour-infiltrating PDCs and Treg cells, the finding of significantly higher 
numbers of PDCs in early lesions of PTLD as compared to more established PTLDs may denote 
that that early lesions remain „early‟ due to suppressive influence of PDCs on virally infected 
oligoclonal or polyclonal lymphoid populations. As PTLD evolves, and the neoplastic clones 
accumulate additional genetic/epigenetic lesions, they become relatively more independent of 
PDCs.  Future studies to investigate would focus on the cytokines secreted by PDCs to 
substantiate and further clarify the precise role of PDCs in the pathogenesis of PTLDs. 
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The possible critical role of Treg cells in the pathogenesis of PTLD (in particular in the earlier 
stages of evolution) stems from our finding of higher numbers of FOXP3
+ 
cells and CD4+ cells 
in early lesions of PTLD as compared to pPTLD and mPTLD, and of FOXP3
+
 cells and CD4
+
 
cells in PT-DLBCL as compared to HIV-DLBCL and iDLBCL. Whether the infiltrating Treg 
cells in PTLDs are effective in suppressing other immune cells is difficult to address by our 
studies. Our future work in this respect would be to perfrom in-vitro analysis on Treg cells 
isolated from tissue samples and then to evaluate how they interact with other immune cells. 
 
HHV-8 was absent in all but two cases of HIV-PEL. EBV-association, however, was frequently 
present among IDLDs (80% of B-PTLD and 69% of HIV-BCL cases) as compared to iDLBCLs 
(6%). We also found that EBV-negative
 
PTLDs harbour larger numbers of PDCs and they are 
likely to be driven by, as yet, unidentified infective agents. We, therefore, plan to identify these 
novel infective agents in EBV- and HHV-8- negative cases using the Primer Extension and 
Enrichment Reaction (PEER). 
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Appendix A 
PREPARATION OF MASTER MIX FOR PCR REACTIONS 
Master mix for multiplex PCR (clonality assessment):  
Primers:  0.5 µl of each primer (0.2 µM final concentration) 
PCR buffe:  2.5 µl (1x final concentration) 
Mgcl2:     0.75 µl (1.5 mM final concentration) (optimized for each target) 
dNTP mix(2.5mM): 2 µl (200 µM final concentration) 
Taq polymerase enzyme: 0.2 µl (1 U). 
DNA: 1 µl (100 ng) 
Water: to 25 µl final volume. 
 
Master mix  for methylation-specific PCR (both unmethylated and methylated reactions) and PCR 
for EBV genotyping: 
Primers:   0.5 µl (0.2 µM final concentration) 
PCR buffer:  2.5 µl (1x final concentration) 
Mgcl2:    0.75 µl (1.5 mM final concentration) 
dNTP mix(2.5mM): 2 µl (200 µM final concentration) 
Platinum Taq polymerase enzyme: 0.2 µl (1 U). 
DNA: 1 µl (~ 75 ng) 
Water*:  25 µl final volume. 
(*) RNAse, DNAse-free water) 
 
Master mix for PCR for sequencing reaction 
It was prepared by mixing 1μl the purified PCR product (10 to 50ng DNA), 1μl of 8pmol/μl of 
template- specific primer, 0.5μl of BigDye Terminator ready reaction mix (containing the fluorescent 
dideoxy terminator nucleotides) and 2μl of 2.5x BigDye Terminator buffer to 5.5μl of distilled water 
in a 96-well plate.   
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Appendix B 
PRIMER SEQUENCES AND THE PRODUCT SIZES USED IN THIS STUDY 
    Primers for control genes 
 PRIMER SEQUENCE (5'-3') PRODUCT SIZE 
AF4/X3U 
AF4/X3L 
GGA GCA GCA TTC CAT CCA GC 
CAT CCA TGG GCC GGA CAT AA 
600 bp 
AF4/X11U 
AF4/X11L 
CCGCAGCAAGCAACGAACC 
GCTTTCCTCTGGCCGGCTCC 
400 bp 
PLZF/X1U 
PLZF/X1L 
TGCGATGTGGTCATCATGGTG 
CGTGTCATTGTCGTCTGAGGC 
300 bp 
RAG1/X2U 
RAG1/X2L 
TGTTGACTCGATCCACCCCA 
TGAGCTGCAAGTTTGGCTGAA 
200 bp 
TBXAS1/X9U 
TBXAS1/X9L 
GCCCGACATTCTGCAAGTCC 
GGTGTTGCCGGGAAGGGTT 
100 bp 
 
 
 
   Primers used for methylation-specific PCR . 
 PRIMER SEQUENCE (5'-3') AT PRODUCT 
SIZE 
DAP-kinase UF 
DAP-kinase UR 
GGA GGA TAG TTG GAT TGA GTT AAT GTT 
CAA ATC CCT CCC AAA CAC CAA 
66Cº 106 bp 
DAP-kinase MF 
DAP-kinase MR 
GGA TAG TCG GAT CGA TCG AGT TAA CGT C 
CCC TCC CAA ACG CCG A 
65Cº 94 bp 
SHP-1 UF 
SHP-1 UR 
GTG AAT GTT ATT ATA GTA TAG TGT TTG G 
TTC ACA CAT ACA AAC CCA AAC AAT 
65Cº 159 bp 
SHP-1 MF 
SHP-1 MR 
GAA CGT TAT TAT AGT ATA GCG TTC 
TCA CGC ATA CGA ACC CAA ACG 
64Cº 159 bp 
AT; annealing temperature, UF, unmethylated forward, UR, unmethylated reverse, MF, methylated 
forward,   MR, methylated reverse. Primers for DAP-kinase  and SHP-1 genes 
481;525
. 
 
 
 
 
 
Primers used for EBNA-3C 
 PRIMER SEQUENCE PRODUCT SIZE 
Forward primer: AGAAGGGGAGCGTGTGTTGT  Type A EBV 153bp 
Type B EBV 246bp Reverse primer: GCCGACGTCAAAAACGAGCC 
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   Primers for IGH gene rearrangement 
 PRIMER SEQUENCE PRODUCT SIZE  
IGH tube A VH1-FR1  GGCCTCAGTGAAGGTTCTCCTGCAAG 
VH2-FR1  GTCTGGTCCTACGCTGGTGAAACCC 
VH3-FR1  CTGGGGGGTCCCTGAGACTCTCCTG 
VH4-FR1  CTTCGGAGACCCTGTCCCTCACCTG 
VH5-FR1 CGGGGAGTCCTCCTGAAGATCTCCTGT 
VH6-FR1  TCGCAGACCCTCCTCACTCACCTGTG 
JHc  CTTACCTGAGGAGACGGTGACC 
310-360 bp 
IGH tube B VH1-FR2  CTGGGTGCGACAGGCCCCTGGACAA 
VH2-FR2  TGGATCCGTCAGCCCCCAGGGAAGG 
VH3-FR2  GGTCCGCCAGGCTCCAGGGAA 
VH4-FR2  TGGATCCGCCAGCCCCCAGGGAAGG 
VH5-FR2  GGTGCGCCAGATGCCCGGGAAAGG 
VH6-FR2  TGGATCAGGCAGTCCCCATCGAGAG 
VH7-FR2  TTGGGTGCGACAGGCCCCTGGACAA 
JHc            CTTACCTGAGGAGACGGTGACC 
250-295 bp 
IGH tube C VH1-FR3 TGGAGCTGAGCAGCCTGAGATCTGA 
VH2-FR3 CAATGACCAACATGGACCCTGTGGA 
VH3-FR3 TCTGCAAATGAACAGCCTGAGAGCC 
VH4-FR3 GAGCTCTGTGACCGCCGCGGACACG 
VH5-FR3 CAGCACCGCCTACCTGCAGTGGAGC 
VH6-FR3 GTTCTCCCTGCAGCTGAACTCTGTG 
VH7-FR3 CAGCACGGCATATCTGCAGATCAG 
JHc           CTTACCTGAGGAGACGGTGACC 
100-170 bp 
IGH tube D DH1 GGCGGAATGTGTGCAGGC 
DH2 GCACTGGGCTCAGAGTCCTCT 
DH3 GTGGCCCTGGGAATATAAAA 
DH4 AGATCCCCAGGACGCAGCA 
DH5 CAGGGGGACACTGTGCATGT 
DH6 TGACCCCAGCAAGGGAAGG 
JHc  CTTACCTGAGGAGACGGTGACC 
(110-290) bp 
(390-420) potential 
background band 
peak 
IGH tube E DH7 TGACCCCAGCAAGGGAAGG 
JHc  CTTACCTGAGGAGACGGTGACC 
100-130 
22-20(germline dh-jh 
band) 
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  Primers for IGκ and λ gene rearrangement 
 PRIMER SEQUENCE PRODUCT SIZE 
IGK tube A Vκ1F/6 TCAAGGTTCAGCGGCAGTGGATCTG 
Vκ2f     GGCCTCCATCTCCTGCAGGTCTAGTC 
Vκ3f     CCCAGGCTCCTCATCTATGATGCATCC 
Vκ4      CAACTGCAAGTCCAGCCAGAGTGTTTT 
Vκ5      CCTGCAAAGCCAGCCAAGACATTGAT 
Vκ7      GACCGATTTCACCCTCACAATTAATCC 
Jκ1-4    CTTACGTTTGATCTCCACCTTGGTCCC 
Jκ5       CTTACGTTTAATCTCCAGTCGTGTCCC 
120-160 bp 
190-210 bp 
260-300 bp 
IGK tube B Vκ1F/6 TCAAGGTTCAGCGGCAGTGGATCTG 
Vκ2f     GGCCTCCATCTCCTGCAGGTCTAGTC 
Vκ3f     CCCAGGCTCCTCATCTATGATGCATCC 
Vκ4      CAACTGCAAGTCCAGCCAGAGTGTTTT 
Vκ5      CCTGCAAAGCCAGCCAAGACATTGAT 
Vκ7      GACCGATTTCACCCTCACAATTAATCC 
Kde      CCTCAGAGGTCAGAGCAGGTTGTCCTA 
INTR    CGTGGCACCGCGAGCTGTAGAC 
210-250 bp 
270-300 bp 
350-390 bp 
IGL Vλ1/2   ATTCTCTGGCTCCAAGTCTGGC 
Vλ3      GGATCCCTGAGCGATTCTCTGG 
Jλ1/2/3 CTAGGACGGTGAGCTTGGTCCC 
140-165 bp 
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   Primers for TCRβ gene rearrangement 
 PRIMER SEQUENCE PRODUCT SIZE  
TCRB 
tube A 
Vβ2       AACTATGTTTTGGTATCGTCA 
Vβ4       CACGATGTTCTGGTACCGTCAGCA 
Vβ5/1    CAGTGTGTCCTGGTACCAACAG 
Vβ6a/11 AACCCTTTATTGGTACCGACA 
Vβ6b/25 ATCCCTTTTTTGGTACCAACAG 
Vβ6c      AACCCTTTATTGGTATCAACAG 
Vβ7        CGCTATGTATTGGTACAAGCA 
Vβ8a      CTCCCGTTTTCTGGTACAGACAGAAC 
Vβ9        CGCTATGTATTGGTATAAACAG 
Vβ10      TTATGTTTACTGGTATCGTAAGAAGC 
Vβ11      CAAAATGTACTGGTATCAACAA 
Vβ12a/3/13a/15  ATACATGTACTGGTATCGACAAGAC 
Vβ13b     GGCCATGTACTGGTATAGACAAG         
Vβ13c/12b/14 GTATATGTCCTGGTATCGACAAGA 
Vβ16        TAACCTTTATTGGTATCGACGTGT 
Vβ17        GGCCATGTACTGGTACCGACA 
Vβ18        TCATGTTTACTGGTATCGGCAG 
Vβ19        TTATGTTTATTGGTATCAACAGAATCA 
Vβ20        CAACCTATACTGGTACCGACA 
Vβ21        TACCCTTTACTGGTACCGGCAG 
Vβ22        ATACTTCTATTGGTACAGACAAATCT           
Vβ23/8b   CACGGTCTACTGGTACCAGCA 
Vβ24        CGTCATGTACTGGTACCAGCA 
Jβ1.1      CTTACCTACAACTGTGAATCTGGTG 
Jβ1.2      CTTACCTACAACGGTTAACCTGGTC 
Jβ1.3      CTTACCTACAACAGTGAGCCAACTT 
Jβ1.4      CATACCCAAGACAGAGAGCTGGGTTC 
Jβ1.5      CTTACCTAGGATGGAGAGTCGAGTC 
Jβ1.6      CATACCTGTCACAGTGAGCCTG 
Jβ2.2      CTTACCCAGTACGGTCAGCCT 
Jβ2.6      CTCGCCCAGCACGGTCAGCCT 
Jβ2.7      CTTACCTGTAACCGTGAGCCTG 
240-285 bp 
TCRB 
tube B 
Vβ2       AACTATGTTTTGGTATCGTCA 
Vβ4       CACGATGTTCTGGTACCGTCAGCA 
Vβ5/1    CAGTGTGTCCTGGTACCAACAG 
Vβ6a/11 AACCCTTTATTGGTACCGACA 
Vβ6b/25 ATCCCTTTTTTGGTACCAACAG 
Vβ6c      AACCCTTTATTGGTATCAACAG 
Vβ7        CGCTATGTATTGGTACAAGCA 
Vβ8a      CTCCCGTTTTCTGGTACAGACAGAAC 
Vβ9        CGCTATGTATTGGTATAAACAG 
Vβ10      TTATGTTTACTGGTATCGTAAGAAGC 
Vβ11      CAAAATGTACTGGTATCAACAA 
Vβ12a/3/13a/15  ATACATGTACTGGTATCGACAAGAC 
Vβ13b     GGCCATGTACTGGTATAGACAAG         
Vβ13c/12b/14 GTATATGTCCTGGTATCGACAAGA 
Vβ16        TAACCTTTATTGGTATCGACGTGT 
Vβ17        GGCCATGTACTGGTACCGACA 
Vβ18        TCATGTTTACTGGTATCGGCAG 
240-285 bp 
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Vβ19        TTATGTTTATTGGTATCAACAGAATCA 
Vβ20        CAACCTATACTGGTACCGACA 
Vβ21        TACCCTTTACTGGTACCGGCAG 
Vβ22        ATACTTCTATTGGTACAGACAAATCT           
Vβ23/8b   CACGGTCTACTGGTACCAGCA 
Vβ24        CGTCATGTACTGGTACCAGCA 
Jβ2.1    CCTTCTTACCTAGCAGGTGA 
Jβ2.3    CCCGCTTACCGAGCAACTGTCA 
Jβ2.4    CCAGCTTACCCAGCACTGAGA 
Jβ2.5    CGCGCACACCGAGCAC 
TCRB 
tube C 
Jβ1.1      CTTACCTACAACTGTGAATCTGGTG 
Jβ1.2      CTTACCTACAACGGTTAACCTGGTC 
Jβ1.3      CTTACCTACAACAGTGAGCCAACTT 
Jβ1.4      CATACCCAAGACAGAGAGCTGGGTTC 
Jβ1.5      CTTACCTAGGATGGAGAGTCGAGTC 
Jβ1.6      CATACCTGTCACAGTGAGCCTG 
Jβ2.2      CTTACCCAGTACGGTCAGCCT 
Jβ2.6      CTCGCCCAGCACGGTCAGCCT 
Jβ2.7      CTTACCTGTAACCGTGAGCCTG 
Jβ2.1      CCTTCTTACCTAGCAGGTGA 
Jβ2.3      CCCGCTTACCGAGCAACTGTCA 
Jβ2.4      CCAGCTTACCCAGCACTGAGA 
Jβ2.5      CGCGCACACCGAGCAC 
Dβ1        GCCAAACAGCCTTACAAAGAC 
Dβ2        TTTCCAAGCCCCACACAGTC 
170-210 bp 
285-325 bp 
 
 
 
 
Primers for TCRγ gene rearrangement 
 PRIMER SEQUENCE PRODUCT SIZE  
TCRG tube A Vγ1f    GGAAGGCCCCACAGCRTCTT 
Vγ10   AGCATGGGTAAGACAAGCAA 
Jγ1.1/2.1 TTACCAGGCGAAGTTACTTATGAGC 
Jγ1.3/2.3  GTGTTGTTCCACTGCCAAAGAG 
145-255 bp 
TCRG tube B Vγ9    CGGCACTGTCAGAAAGGAATC 
Vγ11  CTTCCACTTCCACTTTGAAA 
Jγ1.1/2.1 TTACCAGGCGAAGTTACTTATGAGC 
Jγ1.3/2.3  GTGTTGTTCCACTGCCAAAGAG 
80-140 bp 
160-220 bp 
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        Primers for TCRδ gene rearrangement 
 PRIMER SEQUENCE PRODUCT SIZE  
TCRD Vδ1    ATGCAAAAAGTGGTCGCTATT 
Vδ2    ATACCGAGAAAAGGACATCTATG 
Vδ3    GTACCGGATAAGGCCAGATTA 
Vδ4    ATGACCAGCAAAATGCAACAG 
Vδ5    ACCCTGCTGAAGGTCCTACAT 
Vδ6    CCCTGCATTATTGATAGCCAT 
Jδ1     GTTCCACAGTCACACGGGTTC 
Jδ2     GTTCCACGATGAGTTGTGTTC 
Jδ3     CTCACGGGGGCTCCACGAAGAG 
Jδ4     TTGTACCTCCAGATAGGTTCC 
Dδ2    AGCGGGTGGTGATGGCAAAGT 
Dδ3    TGGGACCCAGGGTGAGGATAT 
120-280 bp 
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Appendix C 
PREPARATION OF AGAROSE GEL AND TBE BUFFER 
1- Agarose (2 %): 
50 ml of 1x Tris acetic acid EDTA (TAE) buffer  
1 gr agarose 
Microwave at 850 Watt for 1 min 30sec 
Add 2 drops ethidium bromide (eth. Br dropper bottle) (0.5mg/ml final concentration) 
Let the solution cool under tap water then carefully pour in the gel tank ensuring no bubbles in gel and 
leave for 20 minutes. 
 
2- TAE buffer 
242 gm trizma base 
57.1 ml acetic acid 
100 ml 0.5M EDTA 
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